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Abstract
More than 85%of the global burden of cervical cancer occurs in developing countries, where it
is the second most common cancer among women. In Brazil alone, a total of 17,500 new cases
and 3,300 deaths of cervical cancer are expected in 2012. Despite the investments in cytology-
based screening in the country, the reduction of cervical cancer incidence has been less than
expected. The aim of this thesis was to investigate the cost-effectiveness of alternative cervical
cancer screening and HPV vaccination strategies in Brazil. This was achieved by focusing on
three specific objectives: 1) To evaluate the cost-effectiveness of cervical cancer screening
strategies for women presenting equivocal cytological results, 2) To evaluate the cost-
effectiveness of cervical cancer screening strategies for HIV-infected women, 3) To evaluate
the cost-effectiveness of HPVvaccination for pre-adolescent women. An additional objective
was to review and provide guidance on the use of model calibration methods in economic
modelling assessments,as they are particularly important in screening and vaccination studies.
The first empirical analysis found that HPV triage for women above 30 years-old presenting
equivocal cytology results was likely to be very cost-effective. The second empirical analysis
found that to screen HIV-infected women with HPVtesting followed by cytology annually was
also likely to be very cost-effective. The third empirical analysis demonstrated that adding the
quadrivalent vaccination of pre-adolescent girls to the current efforts to control cervical cancer
in Brazil was very cost-effective for most of the scenarios analyzed. The vaccine was even cost
saving when considering low coverage and cost of vaccination. This thesis presents findings
that will inform cervical cancer screening and HPV vaccination policies in middle-income
countries like Brazil and also provides guidance to help improve the standards of model
calibration approaches used in cost-effectiveness analysis.
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1 Introduction
1.2 Background
Cervical cancer is the third most common cause of cancer among women worldwide, and the
second in developing countries [1]. According to GLOBOCAN,an estimated 530,000 new cases
and 275,000 deaths occurred in 2008 [2]. More than 85% of the global burden of disease
occurs in developing countries and this figure is expected to increase to 90% by the year 2020
[2, 3]. In Latin America, an average of 72,000 new casesof cervical cancer and 33.000 deaths
occur annually, representing an economic loss of approximately US$3.3 billion per year [4]. In
Brazil, a total of 17,500 new casesand 3,300 deaths of cervical cancer are expected in 2012 [5].
This neoplasm has an especially profound societal impact because it primarily affects women
in their 30s to their 50s, a time when they are more likely to be raising and supporting families.
In Brazil as in most Latin American countries, despite the investments in cytology-based
screening, the impact in reducing cervical cancer incidence has been less than expected [6].
Cervical cancer control strategies in the region have been mostly centred on increasing the
coverage of cytology-based screening to the overall population [7]. Little has been made to
evaluate potential improvements by using new HPVvaccination and screening technologies, or
to better screen groups subjected to higher risk of pre-cancer and cancer lesions [8, 9]. For
example, women presenting equivocal results at routine screening and women infected with
HIV.
HIV-infected women are at increased risk of acquiring HPV, particularly the HPV-types with a
high risk of causing cancer [10]. HIV-mediated immunosupression appears to reduce clearance
of HPVand increase the risk of cervical cancer disease progression [11]. With the widespread
availability of highly active antiretroviral therapy (HAART)there has been a dramatic increase
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in the life expectancy of people infected with HIV [12]. Unfortunately, the incidence of cervical
cancer among HIV-infected women has not decreased [13-15].
Cervical cancer screening programmes based on cytology are difficult to implement in
resource-limited countries in the same way they have been implemented in industrialized
countries [6]. Cytology is a subjective test and in countries with limited quality control it is
difficult to attain or sustain high test performance [6]. Alternative strategies involving HPV
DNA testing (for high-risk types) have the potential to improve the current screening
standards. HPV DNA testing is more sensitive than cytology, but it is less specific and more
costly [16, 17]. Determining the optimal cervical cancer screening strategies for those women
presenting equivocal cytology results and those infected with HIV requires a formal analysis of
the costs and health outcomes of alternative strategies over a long time horizon.
Although low- and middle-income countries (LMIC) bear most of the global burden of cervical
cancer and could benefit the most of these cost-effectiveness analyses, these studies have
mainly been conducted in high income countries. In the UK, USand the Netherlands, studies
have shown that the HPV DNA test for high-risk types is a cost-effective technology for
managing women with equivocal cytological results [18-20]. For HIV-infected women, only two
studies from the US looked at the cost-effectiveness of primary and secondary screening
strategies [21, 22]. In fact, the second study is an extension of the first including HPV DNA
testing. This study concluded that HPVDNA testing followed by cytology triage would be an
effective and cost-effective modification of the screening protocol of annual cytology
screening for HIV-infected women [22].
In recent years, two HPVvaccines became available: a bivalent vaccine that prevents infections
by types 16 and 18, and a quadrivalent vaccine that besides 16 and 18 also prevents infection
by types 6 and 11 [23-25]. HPVtypes 16 and 18 are associated with 70%of cervical cancers and
types 6 and 11 are associated with 90% of anogenital warts [25, 26]. Although having the
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potential to reduce the burden of these two diseases in developing countries, neither vaccine
has been introduced in the publicly funded immunization programmes of most of these
countries.
Mathematical models offer the opportunity to synthesize the best available data and project
the impact of vaccination in order to evaluate its cost-effectiveness over a period of time
beyond those used in clinical trials. Dynamic individual-based models allow for more realistic
representation of the disease as well as a broader analysis of the benefits of the vaccine. The
bivalent vaccine has been previously evaluated for Brazil using a dynamic individual-based
model [27]; however, the quadrivalent vaccine has not yet been evaluated.
Following from literature reviews, discussions with international experts and decision makers
in Brazil, this thesis aim was to investigate the cost-effectiveness of alternative cervical cancer
screening and HPVvaccination strategies in Brazil. This broad investigation was composed by
three cost-effectiveness analyses based on three distinct mathematical models built according
to the research question. The first empirical analysis attempts to define what the most cost-
effective management for women presenting equivocal cytological results is by using a Markov
model representing the natural history of HPV. The second empirical analysis attempts to
define what the most cost-effective cervical cancer screening strategy for HIV-infected women
is by also using a Markov model that besides the HPV natural history also features the HIV-
mediated immunosupression. The third empirical analysis attempts to define whether the
inclusion of the HPVquadrivalent vaccination to the current efforts to control cervical cancer is
cost-effective using a dynamic individual-based model representing the natural history of the
four HPVtypes included in the vaccine.
Model calibration is particularly important in economic assessments looking at large
populations such as those evaluating screening and vaccination. These models tend to be
particularly complex and highly dependent on data from various sources subjected to different
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levels of certainty. Calibration is an important tool not only to estimate uncertain parameters
but also to evaluate the consistency of models. Despite its importance and growing use, the
literature on how to best calibrate models in EEis scarce. In order to shed some light on the
best practices in calibrating models, which would be useful in conducting the empirical
analyses proposed, an additional objective to review and provide guidance on these methods
was added to the thesis.
1.3 Aim and objectives
The overall aim of this thesis was to evaluate the cost-effectiveness of cervical cancer screening
and HPVvaccination strategies in Brazil.This was achieved by focusing on four specific objectives.
The first three objectives relate to the empirical examination of various HPVand cervical cancer
prevention questions. In addition, whilst reviewing the literature, particularly the calibration
methods used in screening and vaccination economic modelling assessments, I noticed the
lack of standards in calibrating these models, and how this could undermine the credibility of
economic evaluations. Therefore, a fourth objective was added to the thesis. The four
objectives of the thesis are:
1. To evaluate the cost-effectiveness of cervical cancer screening strategies for women
presenting equivocal cytological results
2. To evaluate the cost-effectiveness of cervical cancer screening strategies for HIV-infected
women
3. To evaluate the cost-effectivenessof HPVvaccination strategies for women
4. To review the current methods of calibration and provide guidance on the use of
model calibration in economic evaluation
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1.4 Thesisstructure
The remaining chapters of the thesis are structured as follows. The second chapter provides
background information on the burden of HPV-related diseases. It then presents an overview
of the natural history of HPV infection and cervical cancer as well as potential control
strategies. Finally, the tenets of economic evaluation are discussed focusing on how they can
better inform decisions in health care.
The third chapter provides a review of the literature assessing the cost-effectiveness of
cervical cancer screening strategies. It also presents a review of the literature assessing the
cost-effectiveness of HPVvaccination. The methods and results of the studies are discussed in
detail, particularly of those studies looking at research questions similar to the ones explored
in this thesis.
Chapters four to seven comprise four research papers, each prefaced with a brief preamble.
Chapter four offers a practical seven-step approach to calibrate models in economic evaluation.
Thesesevensteps are: (1)Which parameter should be varied in the calibration process?(2)Which
calibration target should be used? (3) What measure of goodness-of-fit should be used?(4)What
parameter search strategy should be used? (5) What determines acceptable goodness-of-fit
parameter sets (convergence criteria)? (6) What determines the termination of the calibration
process?(7) How should the model calibration results and economic parameters be integrated? In
each of these steps, the alternative methods that could be used were explained and
compared.
Chapter five presents an evaluation of the lifetime cost-effectiveness of alternatives strategies
to manage women presenting equivocal cytological results in Brazil in terms of cost per years
of life saved (YLS).It uses a Markov model that was populated using data from the Ludwig-
McGill cohort study and calibrated to independent observational data sets. This study analyzed
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five secondary screening strategies including repeated cytology, HPVhybrid capture II testing
and colposcopy according for different age strata.
Chapter six evaluates the lifetime cost-effectiveness of alternative strategies to screen HIV
infected women for cervical cancer in Brazil in terms of cost per YLS.This analysis uses a
Markov model that was populated using data derived from the literature and calibrated to
data from the IPEC/FIOCRUZWomen's HIV-infected cohort. This study analyzed twenty seven
primary and secondary screening strategies combining cytology, HPVHClI, and colposcopy for
different time intervals and CD4cell count strata.
The seventh chapter presents a cost-effectiveness analysis of HPV quadrivalent for pre-
adolescent women in Brazil in terms of cost per quality-adjusted life year (QALY).The model
used in this evaluation is a dynamic individual-based model representing the natural history of
the HPVtypes 6, 11, 16 and 18. The analysis focused on the impact of the HPVquadrivalent
vaccination of pre-adolescent girls to the current efforts to control cervical cancer in Brazil.
Chapter eight provides an overview of the thesis as a whole, bringing together the result of the
four research papers. The chapter also provides a balanced analysis of the strengths and
limitations of the thesis, pointing out potential areas for future research. In the conclusion of
the chapter, the implications of the findings for both analysts and decision-makers are
discussed.
1.5 Contribution of the candidate to the thesis
The candidate had the ideas for all four studies included in this thesis and also conducted most
of the investigations himself. Therefore, he is first author of the four resulting papers. Three of
which have already been published and the last one has been accepted for publication. It
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constitutes his distinct contribution to the field of economic modelling assessment in health, as
detailed below.
Research paper 1 was conceived and developed by the candidate. He conceptualized the
seven step approach, conducted the literature review, discussed the findings, and drafted the
manuscript. Jonathan Karnon contributed to the discussion of the findings and accompanying
methodological guidance. Jason Madan contributed to the section on Bayesian methods.
Richard G White and John Edmunds also contribute to the design of the study and
interpretation of results. Rosa Legood and Anna Foss collaborated in the review of the
literature, interpreting the findings, and help manage each round of comments and
suggestions from co-authors. This paper has been published in the Pharmacoeconomics
journal.
The research question for research paper 2 was conceived by the candidate while he was
writing his Master's dissertation on a similar topic. The candidate developed the mathematical
model, calibrated the model, discussed the results and drafted the manuscript. Eduardo
Franco and Luiza L Villa provided the data derived from the Ludwig-McGill cohort study to
populate the model and discussed the results. Paula Mendes Luz provided modelling and
calibration advice and helped discuss the findings. Rosa Legood and Gilberto Schwartsmann
helped the candidate to discuss the findings and to manage each round of comments and
suggestions from co-authors. This paper has been published in the International Journal of
Cancer.
Research paper 3 was linked to a research grant funded by IPEC/FIOCRUZ.The research
question for this paper was conceived by the candidate in collaboration with Paula Mendes Luz
and Beatriz Grinsztejn as part of a research grant financed by FIOCRUZ.The candidate
developed the mathematical model, calibrated the model, discussed the results and drafted
the manuscript. Paula Mendes Luz helped the candidate estimate the calibration targets,
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provided modelling advice, discussed the findings and interprets the results. Beatriz Grinsztejn,
Valdilea G Veloso and Marco Mesa-Frias also helped to discuss the findings and interpret the
results. Rosa Legood and Anna Foss helped to discuss the findings, and to manage each round
of comments and suggestions from co-authors. This paper has been published in the
International Journal of Cancer.
The candidate led in the conception of the research question for research paper 4 in
collaboration with Rosa Legood. The candidate developed the mathematical model, calibrated
the model, discussed the results and drafted the manuscript. Paula Mendes Luz provided
modelling and calibration advice, discussed the findings and interpret the results. Marco Mesa-
Frias also helped to discuss the findings and interpret the results. Rosa Legood and Anna Foss
helped to discuss the findings, interpret the results, and to manage each round of comments
from co-authors. This paper has been accepted for publication in the Vaccine journal.
2 Background
2.2 Diseaseand control
2.2.1 Burden of cervical cancer
Cervical cancer is the third most common cancer among women worldwide, and the second in
developing countries [2]. Some 85% of the cases occur in developing countries and this figure
is expected to increase to 90% by the year 2020 [1, 3]. Cervical cancer accounts for 13% of
female cancers in developing countries, with a cumulative risk before age 65 of 1.5%, while in
developed countries it accounts for only 3.6% of all female cancers, with a cumulative risk of
(ages 0-64) of 0.8% [2]. The incidence is generally higher in the developing countries of Eastern
and Western Africa (age-standardized incidence rates (ASR) 30.0 per 100,000), South-Central
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Asia (ASR24.6.3) and South America (ASR23.9) [2]. The incidence starts to rise from age 20 to
30 and is the highest between age 50 to 60 [5].
According to GLOBOCAN2008, the overall cervical cancer mortality rate is 52%. In 2008, it was
responsible for 275,000 deaths worldwide. About 88% of which occurred in developing
countries: 53,000 in Africa, 31,500 in Latin America and the Caribbean, and 159,800 in Asia [2].
Since it affects relatively young women, it is an important cause of lost years of life in the
developing world. Yanget al. found that it was responsible for 2.7 million years of life lost (YLL)
worldwide in 2000 and it was the biggest single cause of YLLfrom cancer in the developing
world [28]. In Latin America and the Caribbean, cervical cancer contributes to more years of
life lost than AIDSor tuberculosis [28, 29]. In Brazil, cervical cancer is the second leading cause
of cancer among women and the fourth leading cause of cancer-related deaths in this group
[7,30].
In Brazil, a total of 24,562 new cases of cervical cancer were diagnosed in 2008 which
corresponds to ASRincidence rate per 100,000 of 24.5 [2]. For 2012, a total of 17,540 casesare
expected corresponding to a ASRof 17 [5]. Screening has lead to less than expected impact in
reducing cervical cancer incidence in most Latin American countries, despite substantial efforts
and healthcare investments [7]. In Brazil the mortality rate remains stable and high around
10.9 deaths per 100,000 in 2008 (11,055 deaths in total) [5].
2.2.2 HPV infection and cervical disease
Over 100 HPVtypes have been characterized molecularly and about 40 types are able to infect
the genital tract. HPVinfection is categorised by HPVtype and carcinogenic risk as 1) high risk
types (HR HPV), including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82; and
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2) low risk types (LRHPV), including 6, 11, 26, 32, 34,40,42,44, 53, 54, 55, 57, 62, 64, 67, 69,
70, 71, 72, 81, 83, 84, 89 and others [31].
Human papillomavirus consists of 8,000 base-pair long circular DNA molecules wrapped into a
protein shell that is composed of two protein molecules (Ll and L2). The genome has the
coding capacity for these two proteins and at least six early proteins (El, E2, E4-E7).These
early proteins are necessary for the replication of the viral DNA and for the assembly of the
newly produced virions within the infected cells [32].
Papillomavirus are well adapted to their natural host tissue, the differentiating epithelial cell of
skin or mucosae, and exploit the cellular machinery for their replication. The cycle starts when
infectious particles reach the basal layer of the epithelium through small breaks. It is believed
that for maintenance of the infection, the virus has to infect an epithelial stem cell. The
replication cycle is divided in two parts. First, the viral genome is replicated to a low copy
number and maintained at this low copy number within the initially infected, but still
replication competent, cells [33]. The proteins El and E2 are necessary for this viral DNA
replication at this stage. It is believed that during viral persistence, the immune system keeps
the infection in this contained state. Second, the basal cells are pushed to the suprabasal
compartment, they lose their ability to divide and instead initiate the terminal differentiation
programme. Papillomaviruses replicate in this compartment, and for their release into the
environment, occurs on the basisof the disintegration of the epithelial cells that is part of their
natural turn-over at the superficial layers [32].
The critical molecules in the process of virus replication are the viral proteins E6and E7,which
interact with a number of cellular proteins. In experimental systems these interactions have
been shown to induce proliferation and eventually immortalization and malignant
transformation of cells. The best characterized interactions are with the proteins pRBand p53,
which are pivotal in cell cycle control, and are mutated in numerous cancers. Binding of E7 to
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pRB activates the DNA replication process, whether E6 targets p53 which controls cellular
apoptosis (Le. programmed cell death). The constant activity of viral proteins E6 and E7 leads
to increasing genomic instability, accumulation of oncogene mutations, further loss of cell-
growth control and eventually cancer [34]. There are differences between the E6/7 proteins of
high-risk and low-risk types, but these are often of a quantitative rather than a qualitative
nature [32].
Although the presence of HPV is necessary for the development of cervical cancer, being
detected in 5%-40% of asymptomatic women of reproductive age [32, 35], most infected
women do not develop the cancer. In fact, 90% of infected women clear the infection within 2
years [36]. Other cofactors for the development of cervical cancer include tobacco smoking,
high parity, use of contraceptives, and co-infection with other STls (e.g. herpes, Chlamydia and
HIV) [37].
Women who do not clear the infection are likely to develop pre-invasive (or pre-cancerous)
cervical cancer lesions [38]. This process is more likely to occur in the transformation zone,
where the ectocervical epithelium (vagina) transforms itself into endocervical epithelium
(uterus) through a process called metaplasia [39]. Alternative names for pre-cancer lesions are
cervical intraepithelial neoplasia (CIN) and squamous intraepithelial lesions (SIL) [38]. CIN
lesions are subdivided into three grades: CIN 1 - mild, CIN2 - moderate and CIN 3 - severe
dysplasia. The SIL (Bethesda) system is more often used to classify cytological specimens and
there are only two categories: low grade SIL (LSIL) and high grade SIL (HSIL) [40,41]. It is often
considered that LSIL encompasses CIN 1 and HSIL encompasses CIN 2 and 3. However, it is
important to point out that the test can also generate more uncertain results, also called
equivocal results. Among these equivocal results one of the most frequent, which is also
associated with an increased risk for underlying high grade pre-cancer lesion is the atypical
squamous cells of unknown significance (ASC-US).
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As discussed in the next section, most screening efforts focus on detecting the pre-cancer
lesions and to treat them according to their risk of progression to invasive cancer, Le. follow
more closely those women with LSIL and removing the CIN2/3 lesion of those women with
HSIL results [6]. While the median age of women with CIN 3 is 27-30, the median age of
women with invasive cervical cancer is skewed to older ages [38]. Women with screen-
detected cases of invasive cancer tend to be on average 10 years older than women with CIN
3, which suggest a long average sojourn time in CIN 3 state [38].
Women infected with HIV (WHIV) are at increased risk of HPV infection, particularly by HPV
types with a high risk of causing cervical cancer [10]. HIV-mediated immunosuppression
appears to reduce clearance of HPV and increase the risk of cervical disease progression [11].
Cervical cancer ranks as one of the most common cancers found in WHIV [42]. HAART has the
potential to restore the immune response, therefore, reducing the risk of HPV infection and
persistence [13, 14]. This should decrease the occurrence of pre-cancerous and cancerous
lesions, however, the observed decrease in cervical cancer incidence has been smaller than
expected [15,43].
The HPV-related disease with the greatest burden is squamous cells carcinoma of the cervix,
however, the virus also plays a role in other diseases with lower burden such as genital warts,
cervical adenocarcinoma, recurrent respiratory papillomatosis, anal cancer and others [32, 37].
HPV 6 and 11 alongside other low risk HPV types cause ana-genital warts (condylomas). Whilst
of those infected only a small percentage (between 1 to 5%) develops genital warts, those
infected can still transmit the virus. Warts are benign but their location and their recurrent
nature are causes of distress and social stigma [44].
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2.2.3 HPV/Cervical cancer control
Cervical cytology has been used in the developed and parts of the developing world as the
main tool for population cervical cancer screening programmes [6]. In Brazil, it was
incorporated as a nation-wide screening programme in 1998 [7]. The pap smear test, which is
the popular name of cervical cytology, is not only capable of detecting the cancer at its early
stages, but especially of detecting pre-cancer lesions, allowing their cure using relatively simple
procedures. The test involves collecting cells from the outer opening of the cervix of the uterus
and the endocervix, smearing them on a glass slide, and then reading the slide under a
microscope [40]. According to a systematic review, its sensitivity varies from 30% to 87% and
its specificity from 86% to 100% [45]. The pap test is highly dependent on the conditions of
specimen collection, training of cytopathologists, and appropriate quality control of its various
steps [8]. Deficiencies in these areas are the main reasons for the low coverage and low
performance observed in lessdeveloped countries [9] when compared to developed countries.
Liquid-based cytology (LBC) is a variation of conventional cytology in which the material is
placed in a vial of preservative fluid. The sample of cells suspended in this fluid can be spun
automatically at the laboratory using a machine [46]. The advantages of this method are two-
fold: firstly the cells are spread in an even layer on the slide minimizing contamination by
blood and mucus, and secondly the same specimen can be used for HPV triage (reflex HPV
test). Although initial studies pointed to a 12% improvement in sensitivity of LBCcompared to
conventional cytology [46], a recent systematic review did not support the claim that LBC
performs better than conventional cytology [47]. The main disadvantage of this technology is
its marginal gain in respect to a substantial additional cost of implementation, which makes it
particularly not attractive for resource-limited settings, as discussed by Caetano et al. in a
study conducted in Brazil looking at different primary screening strategies [48].
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HPVDNAassayshave great potential to be used as a primary screening test, and as secondary
screening to select which women who have equivocal cytological results should be referred to
colposcopy [6]. Studies have shown that HPV DNA tests like Hybrid capture 2 (HPV HClI)
demonstrated substantially higher sensitivity than cytology (around 84%), and slightly lower
specificity (around 73%) in the detection of pre-cancer lesions [6, 49, 50]. The test does not
rely so heavily on the training of collectors and cytopathologists, however, this technology may
be more expensive than cytology [7, 51]. It is worth noting that HPV HCII is an alternative
approach to polymerase chain reaction (PCR),which is more sophisticated than HClI and has
mainly been used for research purposes [52].
In resource-limited settings, low cost strategies like direct visual inspection (DVI), visual
inspection with acetic acid (VIA) and visual inspection with Lugol's iodine (VIU) have been used
[53]. As the name suggests, DVI consists mainly of the visualization of the cervix using a
speculum and appropriate lighting. In the case of VIA, the examiner impregnates the cervix
with acetic acid which makes cervical intraepithelial lesions whiter than usual, facilitating its
identification and allowing further screening with more sensitive and specific technologies. VIU
uses Lugol's iodine for the same purpose. It is worth mentioning that in the past these low-cost
technologies were used in Brazil [40]. Nonetheless, nowadays cytology is the recommended
screening technology widely used in the country and recommended by the Brazilian cervical
cancer screening guideline [40].
A series of new technologies have been proposed for cervical cancer screening like full
spectrum HPVgenotyping, careHPVtest, HPVmRNA test, HPVviral load, HPVintegration, p16
EUSA, methylation markers, chromosomal abnormalities and others [6, 52]. However, the
majority of them are still at a testing stage and have not been officially incorporated into any
screening guideline due to their high complexity aswell as high costs.
25
In recent years two HPV vaccines were developed, a bivalent vaccine covering two of the main
carcinogenic HPV types (16 and 18) and a quadrivalent vaccine covering these two oncogenic
types as well as two other non-oncogenic types associated with the development of genital
warts (6 and 11) [44, 54, 55]. In RCTsconducted in young females not previously infected with
high risk HPV, the quadrivalent vaccine has been shown to reduce by 99% (95%CI 93-100) the
rate of HPV 16 or 18-related cervical lesions CIN2+[26]. The vaccine also reduce by 100%
(95%CI 94-100) the rate of HPV 6 and ll-related anogenital warts [55].
The bivalent vaccine has shown similar results to the quadrivalent vaccine in terms of
protection against HPV 16 and 18-related disease. Vaccine efficacy against HPV16 and 18-
related CIN2+ was 98.1% (95%CI 88.4-100) [23], mean follow-up of 34.9 months. Posterior
studies have shown a sustained protection for up to 5 years for both vaccines [25, 54, 56];
however, longer follow-up will be needed to determine whether a booster vaccine is
necessary. Both vaccines show various degrees of protection against carcinogenic HPV types
not included in the vaccine [23, 57, 58]. HPV vaccination has been in incorporated in the
vaccination schedule of many countries. For example, Australia, Denmark and France provide
the quadrivalent vaccine, while the Netherlands provides the bivalent vaccine for pre-
adolescent girls. The UK also provides the bivalent vaccine; however, it was recently
announced that it will switch to the quadrivalent vaccine in September 2012. In Brazil, none of
the vaccines has been incorporated in the publicly funded vaccination programme yet.
When pre-invasive cancer lesions CIN 2/3 are detected through screening (HSIL result), they
are usually confirmed by a biopsy and treated using a number of alternative methods. The
most commonly used are loop electrosurgical excision procedure (LEEP) and cryotherapy. The
former uses an electrosurgical current to remove the pre-cancer lesion. The later uses freezing
to destroy the lesion. These treatments have been proved to be quite effective in preventing
recurrent disease [59-61].
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Once invasive cancer develops, if left untreated it will progress and eventually cause death.
Invasive cervical cancer can be classified in four stages under the International Federation of
Gynaecology and Obstetrics (FIGO) classification system. At stage 1 the cancer remains
confined to the uterus. By stage 2 the tumor invades beyond the uterus but not to the pelvic
wall. At stage 3 the cancer extends to the pelvic wall and/or involves lower third of the vagina
and/or compromises the kidney function. By stage 4 the cancer is invades the mucosa of
bladder or rectum and/or extends beyond the pelvis. Depending on the staging, management
strategies may involve: total or radical hysterectomy, pelvic Iymphoadenectomy, external
pelvic irradiation, brachitherapy, or even pelvic exenteration [62].
2.3 Economic evaluation
Economic evaluation of health care interventions has been defined as the comparative analysis
of alternative courses of actions in terms of both their costs and consequences [63]. The
purpose of cost-effectiveness analysis (CEA), which is currently the most used type of
economic evaluation, is to compare the cost and effects of one intervention with at least one
alternative intervention [63]. In this type of analysis the effects are usually measured in
number of casesdetected, years of life saved or quality-adjusted life years. When comparing a
new intervention with a current intervention, four possible scenarios arise, which are
represented in the cost-effectiveness plane (CEplane) in figure 2.1. In the plane, the horizontal
axis represents the effectiveness, the vertical axis the cost of the new intervention both
relative to a comparator, which is the origin of the graph. In quadrant II, the new intervention
dominates the comparator, which means it is more effective and cheaper. In quadrant IV, it is
the opposite; being less effective and more expensive the new intervention is dominated by
the current intervention. In quadrant I, the new intervention is more expensive but also more
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effective and this is the scenario most often found in economic evaluation. Here, and also in
the quadrant III, there is no clear dominating intervention [8,10].
By dividing the difference in intervention and comparator costs by the difference in
intervention and comparator effects the results can be expressed as an incremental cost-
effectiveness ratio (ICER), which tells us the cost of one additional unit of health gain. The
decision to switch to the new treatment depends on the value placed by society on this
additional health gain, or its willingness-to-pay (A), represented as a dashed line in the figure
2.1. Any new intervention depicted by a point to the right of the A is considered to be cost-
effective and should be adopted on the basis of representing better value for money than the
current strategy. A further concept in decision analysis is 'extended dominance'. This can occur
when three or more options are being compared, and one option has a higher ICER than a
more effective comparator [8].
Figure 2.1: Cost-effectiveness plane
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The randomized clinical trial (ReT) is considered the gold standard for testing hypothesis about
particular clinical parameters, and can also be used to collect data on resource use [64].
However, the increasing demand for formal analysis on costs and health outcomes over long
time horizons to inform decision making in health care persists to highlight limitations in trials
as the only basis for these decisions. These limitations relate to factors such as short-term
follow-up, the use of intermediate end-points and partial comparisons of options. The
approach that has since surfaced is to synthesise data on costs and health outcomes for cost-
effectiveness analysis is decision modelling [63].
2.3.1 Decisionmodels
There are many model classifications. Most models are classified as being population-based
(also referred as compartmental), or individual-based [65]. Markov models are a good example
of a compartmental model. These models were used in the cost-effectiveness analyses
presented in chapters 5 and 6. They consist of a set of mutually exclusive and collectively
exhaustive health states; each state representing the average characteristics of a group of
individuals. The finite time horizon of the analysis is divided into intervals which are called
Markov cycles. In each cycle, patients can either remain in the same health state or make a
transition from one state to another. Each of the possible transitions depends on a transition
probability. If these transition probabilities are constant, the model is called Markov chains. If
they vary according to other parameters such as age, they are called Markov processes. Health
states can either be 'transient' or 'absorbing'. Markov models are often useful to represent
processes that progress over a long time period and where there are repeated events, such as
chronic diseases. A limitation of the Markov model is the 'memory-less' feature, called the
Markov assumption. It means that the transitions probabilities are independent of past health
states and thus the likelihood of a given event at a specified time is not influenced by
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preceding events [65]. This is particularly a limiting factor when modelling screening protocols
in which the history does affect current transition probabilities. This can be achieved in a
Markov model by having health states that represented both the underlying disease state and
the previous history. This meant that the number of states in the model is likely to be large to
accommodate all the potential health states/history compartments [65].
Individual-based modelling (or micro-simulation) is a valuable way to circumvent the problem
of having to keep track of the patient history to define the future transitions without having
various compartments. This type of model was used in the final empirical analysis presented in
chapter 7. Different than in Markov models, in individual-based models (IBM) each patient's
individual history is simulated and recorded over time according to a random process.
Individual-based models may represent discrete-time, according to the time cycle used in the
model, or may represent discrete-events in continuous time. Despite being more flexible than
Markov models, individual-based models tend to be more data demanding and computational
intensive [65, 66]. Network model is a type of individual-based models which characterizes in
detail the pattern of contact between individuals in the population [67].
Models can be also classified as open or closed. Open models are the models that allow people
to enter the model (e.g. birth or immigration) and/or leave the model (e.g. death or
emigration). The model used to evaluate the vaccine in chapter 7 is an open model. Closed
models do not allow individuals to enter or leave the initial population. The two Markov
models used to evaluate screening can be classified as closed models. Another classification of
models considers the nature of the transition probabilities, dividing them in static or dynamic
[68]. Static models have transition probabilities that are fixed over time. Markov models pose
as a good example of these models as well as decision trees. Dynamic models have transition
probabilities that vary over time, commonly being dependent on the number of individuals in a
certain state of the model. For example, in the case of infectious diseases, the transition
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probability from a susceptible state to an infected state (the force of infection or incidence
rate) is dependent on the number of infectious individuals in the population [68, 69]. In
chapter 7, the individual-based model used to evaluate the quadrivalent vaccination is a
dynamic model that considers the mixing of individuals according to their age and sexual
behaviour. It is important to point out that different models may be combined, for example a
compartmental model and an IBM [27]. Thesecombinations are often called hybrid models.
2.3.2 Uncertainty in economic evaluation
As previously said cost-effectiveness models require information of many types and sources. It
is reasonable to say that the information used has different levels of uncertainty and that this
uncertainty may influence the cost-effectiveness results. Uncertainty in EEis usually divided in:
methodological uncertainty, which is related to the methods of measurement and valuation
(e.g. instruments to value health outcomes, discount rates); structural uncertainty, which is
related to the scientific understanding of the natural history of the disease; and parameter
uncertainty, which is related to parameters that could (in principle) be sampled (e.g. transition
probabilities) [70].
Sensitivity analysis is traditionally perceived as an important part of any EE[71]. It basically
focuses on how methodological uncertainty, parameter uncertainty and, potentially, structural
uncertainty influence the EEresults [70]. The sensitivity analysis may also explore the extent to
which the results can be applied to different scenarios, different patients groups and contexts
[72]. The sensitivity analysis section may be divided in deterministic sensitivity analysis (DSA)
and a probabilistic sensitivity analysis (PSA).DSAis usually where one or a few parameters are
varied at a time and the results of the analysis are recalculated [72]. However, many argue that
given the potential interaction of many parameters in the model, instead of analyzing
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parameter uncertainty individually (DSA), it is better to consider the uncertainty of all
parameters simultaneously (PSA) [65, 70, 73, 74].
In a PSA, probabilities distributions are assigned to the parameters, those that could be in
principle estimated from sample data, and samples are drawn at random from these
distributions to generate large number of Monte Carlo simulation results of the output
parameters of interest [65]. Using the results of the PSA, cost-effectiveness acceptability curve
(CEAC) can be obtained. The CEAC shows the proportion of times a strategy is the optimal
strategy at different values of society's willingness to pay for an additional health gains [75].
It can be useful to think of a hierarchy of uncertainty, such that, for example, parameter
uncertainty is conditional on the model structure [70]. Due to the abundant possible (but not
as likely) model structures and the lack of consensus regarding the incorporation of these
structures in EE, most researchers and guidelines advocate that structural uncertainty should
not be considered in the PSA, and, if possible, be considered in a scenario analysis [65, 76].
Methodological uncertainty also shouldn't be included in a PSA [70]. However, in principle,
structural uncertainty could be handled as part of the PSA by ascribing probabilities to
alternative assumptions based on the analyst or the appraisal committee's views [73].
Validation and calibration are also important tools to handle uncertainty in economic
modelling assessments. These approaches are based on confronting the model output with
observational data. If the model produces a "good fit" to the data it is often said that the
model was validated. This adds more certainty to the internal validity of the model, in other
words it increases its credibility to inform policy decisions. If the model does not produce a
good fit, it is important to investigate model assumptions that produce a better fit in a process
called calibration [77]. Calibration has been particularly useful when there is limited
understanding of complex biological systems of diseases, as well as, in the case of
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unobservable or unavailable parameters. These methods are discussed in greater detail in
chapter four and applied in the three empirical chapters.
3 Literature review
The literature review was divided in two steps. The first step was to search electronic
databases in order to identify economic evaluations of cervical cancer screening strategies.
The second step was to perform a similar search but looking at economic evaluations of HPV
vaccination.
3.2 Economic evaluation of cervical cancer screening strategies
A systematic literature review of economic evaluations of cervical cancer screening strategies
was undertaken with three overall objectives. Firstly, to ascertain that the two screening
economic evaluations proposed in this thesis had not been conducted before. Secondly, to
evaluate the modelling methods used, such as the type of model and whether or not,
calibration was performed. Thirdly, to evaluate the cost-effectiveness results.
3.2.1 Searchstrategy
Medline and EMBASE databases were searched from 01/01/00 to 01/01/12. This time period
was chosen because, more recently, there have been a number of changes to the screening
alternatives available. The search words are provided at the end of the thesis in the search
strategies section. The inclusion and exclusion criteria are summarized in the table 3.1 below.
The search results are illustrated in Figure 3.1. After reviewing the titles of the database initial
results, and, if necessary the abstract, a total of 69 papers were identified, of those 49 were
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included. The main reason for excluding articles was because they were not original research
papers, and many of the original papers were not modelling-based studies.
Table 3.1: Inclusion and exclusion criteria - EEscreening studies
Inclusion criteria Exclusion criteria
Sources Peer-reviewed journal article Others
Article type Original research Review article
News article
Editorial
Conference abstract
Study type Cost-effectiveness analysis Cost-benefit analysis
Cost-utility analysis Cost-minimization analysis
(modelling-based) Costing analysis
Programme studied HPV/Cervical cancer screening HPV vaccine
HPV vaccine + HPV/Cervical
cancer screening
Language English, Portuguese and Spanish Others
Figure 3.1: Results of the literature review of screening studies
MI:DLlNI: initial search EMBASE initial search
1021 hits 1306 hits
1 1
MEDLINE titles EMBASE titles
identified identified
54 49
I I
!
Total of titles
Identified
69
(34 overlap papers)
1
Papers excluded
20
1
Total of papers
included
49
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3.2.2 Modelling methods
As shown in table 3.2, 42 of the 49 studies used a static compartmental model (i.e. Markov
model) for estimating the health outcomes and cost impact of different screening strategies ..
Most of these models were built in Treeage Data or Microsoft Excel. Only 2 studies used an
individual-based model and they were published between 2000 and 2002, as shown in figure
3.2 [78, 79]. These studies used the MISCAN model, which is an IBM developed in the
Netherlands that has been used to evaluate many screening programmes (e.g. prostate,
cervical cancer, colon) [78, 79]. Static models were used in all the other studies. One reason
why dynamic models might not have been used is that there is considerable uncertainty
regarding the extent pre-cancer lesion treatment affects the infectiousness of individuals, but
even if it does, the number of treated women in the whole population is so small that it would
have negligible impact on the force of infection. One study by Dewilde et al. performed a
comparative analysis of modelling approaches impact on the cost-effectiveness results [80].
They examined the effect of a multiple cohort model on the incremental cost-effectiveness
estimates of cervical screening programmes, compared to a single cohort model. They found
that the ICERwas 30% higher when using multiple cohorts instead of a single cohort.
Figure 3.2: Modelling methods used in screening studies
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As can be seen in table 3.2, 31 of the 49 included studies performed model validation and/or
calibration. From 2009 onwards, all the studies based on compartmental models were either
validated or calibrated. In spite of the fact that validation or calibration almost seemed to have
become a prerequisite for cervical cancer screening cost-effectiveness analysis, most of these
studies included very little information on the validation or calibration procedure used. In the
studies that included more information about the calibration there was great variation in the
methods used and little discussion of the limitations.
3.2.3 Cost-effectiveness results
In figure 3.3, we can observe in black and dark grey respectively the developed and developing
countries for which CEAs of cervical cancer screening have been performed. Even though low- and
middle-income countries bear the greatest burden of cervical cancer, most cost-effectiveness
analysis of cervical cancer screening tends to focus on high-income countries. However, in the last
four years there seems to be a slight increase in the number of analysis focusing on resource-limited
settings, as showed in figure 3.4.
Figure 3.3: Countries for which CEA cervical cancer screening were performed
Black: high-income countries for which cost-effectiveness studies of screening were performed, Dark grey: Low- and
middle-income countries for which cost-effectiveness studies of screening were performed, Pale grey: countries for which
no cost-effectiveness studies of screening were performed
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Figure 3.4: CEAsof cervical cancer screening - setting and year of publication
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A total of 30 of the 49 screening economic evaluations modelled primary and secondary screening.
Considering the studies that evaluated HPV testing for secondary screening, approximately 70%
found HPV triage to be a cost-effective intervention [20, 82-84, 91, 92, 97, 99, 100, 102, 105, 108,
109, 114, 115]. Only three of those studies were from low- and middle-income countries [91, 92,
114]. While investigating different combinations of primary and secondary screening in South Africa,
Vijayaraghavan et al. found that primary screening with cytology and secondary screening with HPV
testing was not only more effective but also less costly than cytology-based primary and secondary
screening [91]. Andres-Gamboa et al. found that HPV testing can even be a cost-effective primary
screening tool in Colombia if the cost of the test is under US$31 [92]. The Thai study found that the
optimal strategy was VIA and immediate treatment every five years from ages 35 to 55 [114].
However, these finding may have limited transferability to other middle-income countries at the
higher end of the income spectrum. However, none of the three studies focused solely on the
secondary screening or considered immediate colposcopy as secondary screening strategies.
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Immediate colposcopy as secondary screening may be cost-effective for L1MC, because medical
labour is relatively less expensive than in high income countries.
Three studies from developed countries (Netherlands, UK and US) focusing solely on the use of HPV
testing in secondary screening were identified [18-20]. All three found HPV testing to be a cost-
effective strategy to triage those women presenting equivocal results during routine screening. Note
that the Dutch and British studies considered those women presenting ASCUS and LSIL results all
together and the North American study considered only those with ASCUS results. Given that liquid-
based cytology was considered as a possible primary screening strategy in developed countries, all
three analyses considered this scenario and the use of reflex HPV testing. However, it is worth
mentioning that the Dutch study found HPV triage to be cost-effective for both settings where
conventional and liquid-based cytology is current practice. A study by Vilayaraghavan et al.,
considered HPV 16/18 genotype triage as a way to compensate for the low specificity of using high
risk HPV testing as primary screening, which was found to be cost-effective for the US [84].
Chapter six addresses the cost-effectiveness of screening strategies for HIV-infected women. Only
two studies considering screening among the HIV-infected women were identified in the literature
[22,91]. In fact the South Africa analysis did not focus solely on HIV-infected women, but the overall
population [91]. It only considered a subgroup (i.e. a proportion) of HIV-infected women in this
population due to the important burden of HIV/AIDS in this country. It is also important to stress
that the possibility of acquiring HIV/AIDS and its impact on the HPV/Cervical cancer natural history
Were modelled in very simplified manner. They found that primary HPV testing was a cost-effective
screening strategy for the overall female population of South Africa. The study by Goldie et al.[22]
Was actually an updated version of a previous study [21] from the same group published in 1999 that
did not consider screening strategies involving HPV testing. In the study published in 2001, the
authors extended the analysis to include HPV testing strategies, and found that primary HPV in
addition to the two initial cytological tests was a cost-effective screening strategy for HIV-infected
41
women in the US [22]. A limitation of the three studies is that they consider a narrow range of
possible combinations of screening frequency, and of primary and secondary screening technologies.
Given that the time horizon of my initial literature review did not include the Goldie et al. study from
1999, I decided to include the keywords HIV, AIDS, human immunodeficiency virus, and acquired
immunodeficiency syndrome to the initial screening search strategy and to search over an unlimited
time horizon. However, no other relevant study was identified.
3.3 Economicevaluation of HPV vaccines
In a similar fashion to the review of screening cost-effectiveness studies, a systematic literature
review of HPV vaccination cost-effectiveness studies was undertaken with three overall objectives.
Firstly, to ascertain that the vaccine economic evaluation proposed in this thesis had not been
conducted before. Secondly, to evaluate the modelling methods used, such as the type of model and
whether or not calibration was performed. Thirdly, to evaluate the cost-effectiveness results.
3.3.1 Search strategy
Medline and EMBASE database were searched from 01/01/00 to 01/01/12. Given that the
development of the HPV vaccines occurred within the last 10 years, the cut-off year 2000 was
chosen. The search words are provided at the end of the thesis in the search strategies section. The
inclusion and exclusion criteria can be found in table 3. The search results are illustrated in Figure
3.5. After reviewing titles and abstracts of the database initial results, and if necessary the abstract, a
total of 138 papers were identified. During data extraction 64 papers were excluded mainly due to
the fact that they were review articles or conference abstracts.
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Table3.3: Inclusion and exclusion criteria - HPV vaccine EE studies
Inclusion criteria Exclusion criteria
Sources Peer-reviewed journal article Others
Article type Original research Review article
News article
Editorial
Conference abstract
Study type Cost-effectiveness analysis Cost-benefit analysis
Cost-utility analysis Cost-minimization analysis
(modelling-based) Costing analysis
Programme studied HPV vaccine HPV/Cervical cancer screening
HPV vaccine + cancer screening Cervical cancer treatment
Language English, Portuguese or Spanish Others
Figure 3.5: Results of the literature review of the HPV vaccine EE studies
MEDLINE initial search EM BASE initial search
374 hits 951 hits
1 1
MEDLINE titles EMBASE titles
identified identified
78 128
I I
1
Total of titles
identified
138
(68 overlap papers)
1
Papers excluded
64
1
Total of papers
included
74
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3.3.2 Modelling methods
As shown in table 3.4, 57 of the 74 studies used a compartmental model (static or dynamic) for
estimating the health outcomes and cost impact of HPV vaccines. These models were built in
Treeage Data, Microsoft Excel, MatLab, Mathematica, Netlogo and C++. Only 18 studies used an
individual-based model and most of these studies were published by the same research group (Sue
Goldie's group) as hybrid models. A similar modelling approach was later used by Bogaards et
al.[124].
Figure 3.6: Modelling methods used in HPV vaccination CEAs
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These hybrid models consist of a simpler dynamic compartmental model which provides the force of
infection at endemic equilibrium that is used in the IBM. The IBM is more complex and capable of
representing in more detail the pre-cancer and cancer states as well as screening schedules. Only 2
studies used an integrated dynamic IBM[125, 126]. Less than half of the vaccine studies (28 studies)
used a dynamic model in order to take into account the herd-immunity effect[l27, 128]. However,
more than half of them calibrated the model against setting-specific empirical data.
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By comparing the results of tables 3.2 and 3.4, it becomes evident that the great majority of the
vaccine studies were published more recently than the screening EEstudies, and that a greater
fraction of the vaccine EEwere calibrated. As observed in the screening studies, the rigour in
calibrating the models varied a lot. However, the richness of some of the calibration methods
applied in the vaccination studies could not be fully represented in table 3.4. For example, in the
works by Goldie et al. [191, 198, 199], they developed an individual-based model that was initially
populated with age-specific inputs parameters derived from the literature. A distinguishing feature
of this analysis is the great number of calibration targets: 68 calibration targets including for
example type- and age-specific prevalence of HPV,age-specific prevalence of CIN lesions, as well as
age- and type-specific duration of HPV infections. The same group also calibrated a dynamic
compartmental model in order to derive HPV16 & 18 per partnership transmission rates as well as
HPVclearance and invasive cancer progression rates.
The Dutch research group [200] used a Bayesian approach in the calibration of a dynamic
compartmental model of 14 high-risk HPVtypes to age-dependent prevalence HPVprevalence data.
This process allowed the estimation of type-specific viral transmissibility and infection-induced
resistance. These estimates were later incorporated in an individual-based model used in the
economic evaluation of the bivalent vaccine [201]. In the studies by Jit et al. [165, 202], calibration
was used in two steps of the analysis that originated two separate papers. In the first step, a Markov
model was constructed with the main purpose to estimate the type-specific rates of cervical lesions
progression and regression in women infected with high-risk HPV. In fact the model explored
different assumptions about the way lesions regress (model structure), the accuracy of screening
tests, and the age-specific prevalence of HPVinfection, considering in total 216 scenarios.
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Figure 3.7: Cost-effectiveness studies by setting
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As can be seen in figure 3.7, most studies were published from 2007 onwards. After a peak in 2008,
there seems to be a slow decline in publications, and the proportion of analysis from low- and
middle-income countries has increased. This could be explained by the fact that many developed
countries have already included one of the two HPV vaccines in their publicly funded national
immunization programme, and the inclusion in low- and middle-income countries is still under
negotiation.
3.3.3 Cost-effectiveness results
As can be observed in figure 3.8, HPV vaccination has been evaluated for most countries. Comparing
this map to the screening map in figure 3.3, we noticed that for developing countries the vaccine has
been more widely evaluated than the screening. In table 3.4, we observe that 90% of the studies
analyzed only one of the two vaccines. Most of the studies (60%) evaluated the bivalent vaccine. The
studies that evaluated the quadrivalent were more likely to use QALY to measure outcome, as it can
better capture the qualitative gains related to the prevention of genital warts. Although the ICER
estimates varied widely according to the setting, in high-income countries vaccination strategies
were deemed cost-effective in more than 90% of the studies. When we consider middle-income
countries, this percentage drops to 75%.
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Figure 3.8: Countries for which CEAsof HPV vaccination were performed
Black - high-income countries for which cost-effectiveness studies of the vaccine were performed, Dark grey- Low- and
middle-income countries for which cost-effectiveness studies of the vaccine were performed, Pale grey - countries for
which no cost-effectiveness studies of the vaccine were performed
For most low-income countries, the vaccines were not cost-effective at current prices, but could be
cost-effective at a cost per vaccinated woman around 25 international dollars (I$). All the 7 studies
that evaluated the both vaccines found that, at the same cost per dose, the quadrivalent vaccine
was more cost-effective. Jit et al. observed that the cost of the bivalent vaccine would have to drop
around 25% for it to become as cost-effective as the quadrivalent vaccine [165].
In almost all the studies, vaccination of boys was not cost-effective [27, 133, iSS, 157, 187, 188,
194]. Neither was the vaccination of women above age 30 [156]. The cost-effectiveness of catch up
campaigns varied a lot according to the setting and the age range considered. In most middle-
income country analyses, catch up campaigns were not cost-effective. One interesting analysts
performed by Goldie et al., found that vaccine campaigns focusing on the worst-off groups could be
more cost-effective than the overall population [134]. This reflects the fact that non-screened
women are the ones that benefit the most from the vaccine. Most of the studies (70%) considered
cytology as the screening strategy to which compare the vaccination to or to be used in addition to
vaccination.
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Out of the 74 studies, only 4 evaluated HPV vaccination for Brazil [3, 27, 154, 191]. All these studies
considered only the bivalent vaccine. Only one study used a dynamic model, which was in fact a
hybrid model using a static IBM previously built to evaluate the vaccine for the country [27]. The
other two were multi-country comparison using simpler Markov models [3, 154]. None of the
studies used QALYs as the outcome measure. Although the static model used by Goldie et al. [191]
did not capture the herd immunity benefit conferred by the vaccine and the screening strategies
considered did not reflect the current practice in Brazil, the result showed that the vaccine would be
cost-effective at current prices and potentially very cost-effective at lower prices and coverage rates.
When the vaccination of pre-adolescent girls was evaluated using the hybrid model, the cost-
effectiveness results became more attractive than the static results. In fact the vaccination of girls
was very cost-effective according to a threshold based on the country's GDP throughout most
scenarios evaluated. The vaccination of boys was not an attractive option for Brazil from the cost-
effectiveness point of view. The two other multi-country analysis also found the vaccine to be very
cost-effective according the GDP-based threshold [3, 154].
As we compare the results of the two literature reviews, it becomes dear that the cost-effectiveness
of HPV vaccination has been studied far more than the cost-effectiveness of cervical cancer
screening strategies. It is also evident that the most of the vaccine and screening countries target
high-income countries. This is particularly true in the case of cervical cancer screening studies. It is
also worth mentioning that many studies evaluated more or less the same interventions for the
same overall population. Very few studies focused on high risk subgroups.
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4 Calibrating models in economic evaluation: a seven-step approach
4.2 Preamble to research paper 1
In the background chapter, the conceptual review identified the importance of taking into account
uncertainty in economic evaluation. Calibration is a useful method to handle model uncertainty,
especially parameter uncertainty. Whilst studying the calibration methods used in the studies found
in the literature review, I realized the importance of model calibration methods for population-wide
interventions such as screening and vaccination. I also realized that the lack of standards in using
these methods in the economic evaluation literature could undermine the credibility of analysis'
results. After searching the literature for review papers looking at how to best calibrate disease
economic models, no paper could be found.
Researchpaper 1 aims to provide guidance on the structured use of model calibration in economic
evaluation in health. Therefore, the definitions related to model calibration were clarified in detail.
The rationale for calibration was discussed considering its value beyond elicitation of unknown
parameters, which is its most common use in the cost-effectiveness literature. The calibration
process was divided in seven different steps, according to the practical decisions analysts face in
calibrating disease economic models. In each of these steps, the alternative methods that could be
used were explained and compared. At the end of the paper, new areas of research were identified
and the need to promote better practicesin economic evaluation was highlighted.
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Abstract
In economic evaluation, mathematical models have a central role as a way of integrating all the
relevant information about a disease and health interventions, in order to estimate costs and
consequences over an extended time horizon. Models are based on scientific knowledge of disease
(that is likely to change over time), simplifying assumptions and input parameters with different
levels of uncertainty; therefore it is sensible to explore the consistency of model predictions with
observational data. Calibration is a useful tool for estimating uncertain parameters, as well as more
accurately defining model uncertainty (particularly with respect to the representation of correlations
between parameters). Calibration involves the comparison of model outputs (e.g. disease
prevalence rates) to empirical data, leading to the identification of model parameter values that
achieve a good fit.
This paper provides guidance on the theoretical underpinnings of different calibration methods. The
calibration process is divided into seven steps and different potential methods at each step are
discussed, focusing on the particular features of disease models in economic evaluation. The seven
steps are: (1) Which parameters should be varied in the calibration process?, (2) Which calibration
targets should be used?, (3) What measure of goodness-of-fit should be used?, (4) What parameter
search strategy should be used?, (5) What determines acceptable goodness-of-fit parameter sets
(convergence criteria)?, (6) What determines the termination of the calibration process (stopping
rule)?, (7) How should the model calibration resultsand economic parameters be integrated?
The lack of standards in calibrating diseases models in economic evaluation can undermine the
credibility of calibration methods. In order to avoid the scepticism regarding calibration, we ought
to unify the way we approach the problems, report the methods used and continue to investigate
different methods.
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Introduction
In economic evaluation, mathematical models have a central role as a way of combining relevant
information about a disease and health interventions, in order to estimate costs and consequences
over an extended time horizon [63]. Models incorporate assumptions that allow a simpler
representation of a complex reality, and there is always uncertainty around the true values of model
input parameters. As George Box famously stated "all models are wrong, some are useful" [2]. An
important step towards proving the credibility and usefulness of a model is the process of
calibration. This involves comparing model outputs to empirical data, known as calibration targets
(e.g. disease prevalence rate), and exploring variations (within a-priori plausible bounds) of the
parameters of the model to identify combinations that provide a better fit to the data [77,203].
A common use of calibration in economic evaluation is in situations where mean parameter values
to populate the model are not observable, such as rates of clinical presentation in screening models
[66]. More recent applications of calibration in economic evaluation have extended the technique to
exploring uncertainties, and making adjustments where required, to a broader range of model
inputs depending on the consistency between model outputs and observational data [165, 204].
Since models are central to economic evaluation, the methods used for model calibration and the
way calibration results are incorporated within the analysis have the potential to influence both the
base case cost-effectiveness results and the variance in estimates of uncertainty. Despite the
increasing use of model calibration within economic evaluation [205], most health technology
assessmentguidelines and textbooks have little to sayan how it should be used [63, 76, 206-209]. If
calibration is to become more widely used and accepted, it is important that the methods used are
coherent, well implemented and clearly reported.
This paper first outlines the definitions and rationale for calibration in economic evaluation.
Secondly, the steps for implementing calibration in economic evaluation and the methods for
integrating economic evaluation are reviewed with reference to existing examples in the literature.
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A practical application of the sevenstagesof calibration is also presented in another paper in this issue
[210], in the form of an examplemodel that isavailableto download.
Background
Definitions
In the literature, terms like model calibration, fitting, and validation are sometimes used to describe
similar processes [74, 77, 199]. The simple comparison of model outputs with observed data relates
to the concept of validation (or external validation), which is a familiar idea in economic evaluation
[203, 206, 211]. Nonetheless, the use of the term validation is controversial. As argued by Cooper,
[77] following in the tradition of Popper, [212] if the model passes the confrontation with data
several times, we can gain more credibility in the model, but we cannot be sure that the model is
valid. In disease modelling, especially infectious disease modelling, fitting is habitually used to
describe the particular process of finding the input parameter values that generate a good fit of the
model to observational data [77, 213, 214]. Calibration is often used as synonym for fitting [198],
even though calibration can be seen as a more comprehensive process that may also take into
account different model structures in the fitting procedure [66, 165, 202]. In this paper, we will use
the term calibration as a synonym for fitting, as it is more commonly used in the economic
evaluation literature.
Although representing a different process, cross-validation is a term that is related to the concept of
calibration. Cross-validation describes the comparison of results of a model with the results of other
models built for similar purpose [203, 208], but has also been used to describe the post calibration
assessmentof model outputs with observed data not included in the model calibration [204].
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Rationale for calibration
An important part of model development is to check that the predictions of the model are consistent
with other data sources describing the model outputs, such as disease prevalence and mortality
rates. Calibration has traditionally been seen as a way to make adjustments to "unobserved" or
unavailable parameter values, [19, 66, 186] in order to achieve a good fit with the data, but as we
will discuss, it can also be used to adjust all the epidemiological parameters.
Some calibration approaches also generate a number of different sets of plausible estimates that fit
with the observed data. Used in this way, a further rationale for model calibration is that it is an
additional tool to handle uncertainty surrounding the diseasemodel beyond conventional sensitivity
analysis. Importantly, because the calibration process compares the combined output predictions
across all the model inputs it gives the analyst further insight into the correlations between input
parameter estimates [74, 215]. This is particularly beneficial given that it is often difficult to identify
and quantify correlation between parameters in diseasemodels [74].
Model calibration methods
Model calibration and particularly model fitting resembles the estimation of coefficients in linear
regression, where we try to find the coefficients of the regression function (parameter values) that
identify outputs that best fit the data. In a similar approach to Stout, [205] we have categorised the
calibration process into seven stages,which are discussedin the following sections:
1. Which parameters should be varied in the calibration process?
2. Which calibration targets should be used?
3. What measure of goodness-of-fit should be used?
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4. What parameter search strategy should be used?
5. What determines acceptable goodness-of-fit parameter sets (convergence criteria)?
6. What determines the termination of the calibration process (stopping rule)?
7. How should the model calibration results and economic parameters be integrated?
Parameters to include in the calibration
The most common use of calibration is to estimate unobservable model parameters by only allowing
these parameters to vary in the calibration process [94, 186,216]. In the case of screening models, a
common example is the clinical presentation rate in the absence of screening, because the
denominator (the population of undiagnosed individuals) cannot be observed. Moreover, even when
we have observed parameters directly, these parameters may have different levels of precision,
leading some to advocate that all natural history and other relevant parameters in the model
(unobservable and observable) should be allowed to vary in the calibration process [199, 202, 204].
The comprehensive inclusion of parameters facilitates the representation of correlation between
input parameters, and permits the testing and adjustment of the global consistency of the model.
Selection of calibration targets
The selection of the calibration targets is another important step in the calibration process. There
are no exact criteria to choose the calibration targets that are necessary to the process. However, it
is sensible to say that the most important selection issue is the availability of good quality data to
use as calibration targets [217]. Good quality can be basically translated into substantial sample size
and lack (or limitation) of study biases. The choice is also determined by the complexity of the
model, as simple models only produce a limited number of outputs to be compared with targets.
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The intervention being evaluated is also going to determine the choice of target, for example if we
are evaluating a screening test to detect human papillomavirus (HPV) type 16 we should be more
concerned that our model produces consistent HPV 16 prevalence rates than other HPV types
prevalence rates.
If local data are available, they should be used. When using non-local data, consideration should be
given to the impact of alternative patterns of disease incidence and management pathways on
output parameters [218].
Calibration targets can be a single summary statistic (e.g. mean disease incidence rate) or a series of
statistics (e.g. age-specific disease incidence curve) [202, 205, 219]. It is also important to stress that
the use of cross-sectional data as calibration targets deserves careful interpretation due to birth
cohort effects. For example in a cervical cancer screening model, in order to use cross-sectional data,
it tends to be assumed that each member of the cohort experiences the same pattern of screening
and treatment over her lifetime [104, 202]. However, such patterns were significantly different
before 1990 in most countries, when nation-wide screening programmes were set in place and high
coverage rates were achieved across age groups. The most common way to circumvent this problem
is to calibrate the model against pre-1990 data to represent natural history in the absence of
screening.
Goodness-of-fit (GOF) measures
It is important to evaluate how close the model predictions are to the target data. This can be done
in a qualitative way by, for example, visually comparing the age-specific incidence curve predicted by
the model and the one derived from observed data. However, this involves subjective judgements
that are best avoided if we want model calibration to be more of a science than an art. In the
statistics literature, the most commonly used measures of goodness-of-fit GOF are least squares, chi-
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square (or weighted least squares), and the likelihood [77, 220]. We first discuss the use of
alternative GOF measures in the context of calibrating to a single target, followed by a discussion of
fitting multiple targets.
Least squares
Least squares relies on calculating the sum of square errors, Q(8), between the empirical data and
the model output for each input parameter value [66, 217]. The values that best fit the data are the
ones that minimize this sum [203]. In equation 2.1, 2.2 and 2.3, we are considering a series of
statistics, for an age-specific calibration target.
Q(B) =L (y(a) - [(alB)) 2
a
(2.1)
Where 8 is the input parameter or a vector of parameters (0), y(a) represents the observed data
estimate (e.g. HIV incidence rate) for age a, and f(a I8) represents the model output for age a given
input parameter 8. The advantages of this approach are that it is intuitive and not very data-
demanding. The main disadvantage is that it does not take into account the precision of the
empirical data, for example, estimates of disease incidence at different ages may come from
different studies with different samples sizes, therefore having different levels of certainty.
Chi-square
The chi square (l) is similar to the above measure, but it overcomes the different levels of certainty
problem by dividing the least square error by its standard deviation, as can be seen in equation 2.2
[220]. Therefore it places more weight on the more reliable estimates, those with large sample size
and small standard deviation. Note that this is only one of many chi square tests (e.g. Pearson's chi-
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square) - statistical procedures whose results are evaluated by reference to the chi square
distribution.
x' =L (yea) ~~eaI9)) 2
a (2.2)
Likelihood
One of the most popular GOF measures that, like chi square, also takes into account levels of
certainty of the observed data aswell as informing confidence intervals of the goodness-of-fit when
referring to the chi square distribution is the likelihood [198, 199, 221]. In fact, if the measurement
errors are normally distributed, the chi square will give the same results as the likelihood [77]. Unlike
the least square and the chi square, which try to minimize the result of the above functions, for the
likelihood we try to maximize how likely a particular set of parameters is, given the empirical data
[220]. For example, the following describes the likelihood function for a binomial process [68] such
as infection prevalence basedon serological data:
L(e) =n p(ale)y(a)(l - p(ale))n(a)-y(a)
a
(2.3)
Where p(a 18) represents the proportion of age a seropositive individuals predicted by the model
using input parameter 8, where y(a) represents the number of observed seropositives at age a. The
second part of the equation, (1 - p), refers in a similar way to the seronegatives, where n(a) is the
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size of the sample at age a. The set of parameters that gives the maximum value of function 2.3 is
the best-fit set [77].
Comparing the three methods mentioned above, it is important to say that in the likelihood
approach the full probability model of data may not be easy to specify. Also, for complex models it
may be more difficult to find the parameters that maximize the likelihood. By looking at the
equations, we can see that the likelihood approach requires more data than the other two methods.
In the case of chi-square, the level of precision of the calibration target is only captured in the a
parameter, while in the likelihood approach we need for example the number of positives, and
sample size).
Multiple goodness-of-fit estimates
It is preferable to calibrate disease models to multiple calibration targets, in which case it is
necessary to obtain a combined measure of GOF across all calibration targets. This is also called
rnultl-objective optimization [222]. One option is to treat all calibration targets as independent
targets and then sum the GOF measures across the different targets. This task can be performed
using different methods (e.g. global criterion method and lexicographic method) [222, 223].
The global criterion is given by the sum of GOF of each calibration target, which may be weighted.
The most commonly used in the disease modelling field is the weighted GOF approach [191, 224].
This approach consists of weighting each calibration GOF estimate (for each calibration target) and
then summing across all targets. The weights are usually determined by the analyst or a group of
experts based on the importance and/or the existence of biases in the estimate of the target [224].
In the lexicographic approach, the calibration targets are ranked in order of importance, and the
process of finding the optimal parameter values is done step-by-step starting with the most
important calibration target and proceeds according to the order of importance [217, 225].
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An alternative general approach involves defining multi-dimensional integrals that represent
correlations between the calibration targets. Ideally, such integrals are solved analytically to identify
the set of parameter values that maximise the likelihood across all calibration targets. However, in
many cases the integral cannot be solved analytically, and numerical integration methods are
required. It is also the case that the process of defining the correct multi-dimensional integrals is a
difficult task that requires specialist mathematical expertise [226].
Parameter search strategies
The terms parameter search strategy, search algorithm or optimization method all refer to the
method used to search for parameter values or sets of values that produce model outputs that
match specified calibration targets most closely. Broadly speaking, optimization is the process of
finding the conditions that give the maximum and minimum value of a function [227]. Parameter
search in optimization is a large field of operational research. There are various methods for the
solution of different types of optimization problems. These methods can be classified according to
the existence of constraints, the nature of the design variables, the physical structure of the
problem, the nature of the equations involved, the deterministic nature of the variables, the
separability of the functions, the number of objective functions, and others [227]. Unfortunately,
there is no perfect optimization algorithm. It is advocated that the analyst should consider the most
appropriate methods for his/her problem and even try more than one method or combinations of
methods in a comparative way [220, 227]. In the caseof diseasemodels used in economic evaluation
that are usually nonlinear (e.g. Markov models, micro-simulations), with multiple-objective functions
(multiple GOF estimates), with and without parameter constraints (a-priori bounds), there are a
number of alternative strategies that could potentially be applied as calibration search strategies for
diseasemodels [202, 219, 221, 224, 228-232]. Numerical methods are the most general methods of
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optimization, which are required if the integral for the GOFmeasure(s) cannot be solved analytically
[66,222].
Figure4.1: Grid with Pi = 3
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Ii - u, = lower and upper bounds of the two variables (i = 1,2), P = number of possible parameter
values.
The parameter search takes place across the different possible combinations of parameter values
(Le. the parameter space).Conceptually, if just two parameters (Xl and X2) were varied in the model
the space could be represented in two dimensions. By considering this two dimensional space as in
figure 4.1, it is simple to understand how the grid parameter search method works [227, 230]. For
example, if the lower and upper bounds of the two variables are l, - u, (i = 1, 2), for simplicity we
could divide the ranges into Pi- 1 equal parts, in figure 1 Pi = 3. This method involves setting up a
suitable grid in the parameter space, evaluating the GOF estimate at all the grid polnts, in the
example 9 points, and finding the grid point that best minimize the GOF. With each additional
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parameter, the number of dimensions required to represent the space also increases accordingly,
and in most practical problems the grid search methods requires prohibitively large numbers of
model evaluations. For example a model including 20 parameters, only considering the Pi = 3, would
require 320 = 3,486,784,401 evaluations.
Figure 4.2: Random search method in economic evaluation disease models
I Assign distribution to parameters I
I Randomly draw values from these distributions l~
l Find!(Xj) I
I II Calculate the GOF I Set i=i+l
l Record the parameter set values and GOF I
I Is i > total of iterations IJ
No
Yes
I Analyze the convergence of all recorded sets I
I Is convergence satisfied? I cl Discard sets IJ INo
Yes
I Use set(s) in the EE I
GOF = Goodness-of-fit, i = number of current iteration, f(xj) = output of the model for iteration i.
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To date, the most common approach for parameter searching that has been utilised in economic
evaluation are the random search methods [66, 217, 233]. As described in Figure 4.2, in a random
search method distributions are assigned to each parameter in the model and multiple sets of
parameter values are sampled using a random number generator [222]. Eachset is then used in the
model and the GOF is calculated. The set (or sets) that results in the optimum GOF result(s) are
selected according to the convergence criteria (see next section).
The main advantages of the random search strategy is that it is intuitive, and relatively easy to
program. The main disadvantage is that random searching is not efficient in covering the entire
parameter space. With a random search strategy, increasing numbers of searches improves the
chance that the global extrema has been identified, but we cannot be certain that a local extrema
has been identified. In more complex models, with greater numbers of parameters and larger
parameter space, random search methods have limitations in the processingtime required to search
for the global extrema.
Many parameter search strategies like random search as well as probabilistic sensitivity analysis
employ sampling methods in order to obtain values from the parameter distributions. There are
various sampling methods that can be used to sample from distributions. The random sample is the
most obvious alternative, even though it may not be the most efficient way to sample the parameter
space. Let's consider an example with two parameters, parameter Xl that follows a normal
distribution and X2 that follows a uniform distribution, as represented in figure 4.3. Figure 4.4 shows
examples of three sampling methods; A) random sampling, B) full factorial sampling, C) Latin
Hypercube sampling for a simple caseof 10 samples for those two parameter, or distributions. In the
random sampling, we can find that some areas are not sampled and others are more greatly
sampled; in full factorial sampling, a random variable is picked in each and every interval; in Latin
hypercube, a value is chosen once and only once from each interval.
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The full factorial sampling method uses a value from every sampling interval for each possible
combination of parameters [234]. This approach has the advantage of exploring all the parameter
space but it is computationally inefficient and time-consuming for complex models. Latin hypercube
is a more efficient and increasingly popular sampling method that was introduced in the field of
disease modelling by Blower et al. [235]. Figure 4.3 shows examples of probability density functions
associated with parameters Xl and X2 used in figure 4.4. Since Latin hypercube sampling was used,
the distributions were divided in intervals with equal probability, and one sample was obtained from
each of those intervals. For each parameter a probability density function is defined and divided into
N intervals with the same probability (figure 4.3). A parameter value is picked randomly from every
interval and this procedure is performed for every parameter. As can be seen in figure 4.4C, a
parameter value from each sampling interval is used only once in the analysis but the entire space is
equitably sampled.
Figure 4.3: Examples of probability density functions associated with parameters Xl and X2
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Figure 4.4: Results of 3 sampling methods
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One of the most widely used optimization tools is the Microsoft ExcelSolver. In the case of non-
linear models, it employs a generalized reduced gradient method, as implemented in the GRG2code
[236, 237]. The gradient methods make use of the gradient of a function, which is an n-parameters
vector given by:
df
dx;
df
Vf= dX2
df
dx.;
The gradient has an important property. If we move along the gradient direction from any point in
the parameter space, the function value increasesat the fastest rate. Therefore, the negative of the
gradient vector represents the direction of steepest descent. Optimization methods that use the
gradient vector can be expected to find the minimum point faster. As the name suggests, the
generalized reduced gradient method is a modified version of the reduced gradient method that was
presented originally for solving problems with linear constraints only.
In order to solve the optimization problem that is presented in a spreadsheet format, ExcelSolver
extracts the problem from the spreadsheet cells and internally builds a representation of the model
that is suitable for GRG method. In more general terms, this is the Jacobian matrix of partial
derivatives of the problem functions (objective and constraints) with respect to the decision
variables [236]. In linear models, the matrix entries are constant, and only need to be evaluated
once at the start of the optimization. In nonlinear models, the Jacobian matrix entries are variable
and have to be re-calculated at each new trial point. The Jacobian matrix is approximated using the
finite differences method [238].
When using the ExcelSolver, it is important to remember that ExcelSolver assumesthe model to be
non-linear as default. The path and scaling factors used by generalized reduced gradient method will
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depend on the starting point. It is recommendable to try different starting points. If the software
reaches roughly the same final point, we can be fairly confident that this is a global extrema.
Otherwise, we can select the best results of the solutions obtained or try other optimization
methods.
Figure 4.5: Downhill simplex steps
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Downhill simplex (DS) also known as the Neider-Mead method doesn't require the evaluation of
derivates like the gradient methods, only function evaluation. It is not as fast as some gradient
methods. Nonetheless, it is a very popular optimization method, because it requires concise code,
and makes almost no special assumption about the function being minimized [220]. A simplex is a
geometrical figure consisting, in N dimensions, of N+l point (or vertices) and all their
interconnecting line segments. In two dimensions the simplex is a triangle. In three dimensions it is a
tetrahedron, as represented in figure 4.5. As previously mentioned, the number of dimensions is
determined by the number of input parameters varied in the optimization process.
The DS method must be initialized not just with one point (set of parameter values) but with N+l
points, in order to constitute an initial simplex. By conceptualizing the disease model's GOF as a
surface with peaks (poor fitting parameter sets) and valleys (better fitting parameter sets), the DS
method takes a series of steps (reflection, expansion, contraction, reduction), as represented in
figure 4.5, most steps just move the point of the simplex where the GOF is largest ("highest point")
through the opposite face of the simplex to a lower point to search for potential areas of the
parameter space that might fit the data better. The movement of the simplex resembles an amoeba
searching for a "valley floor". The main disadvantage is that it can be slow and only one best-fit
parameter set emerges at the end of the process. In order to gain more confidence that the best fit
parameter set does not represent a local extrema, the algorithm is usually run a few times from
different starting points (different simplexes) [227, 239].
Simulated annealing is a more complex parameter search method that has attracted significant
attention as an efficient alternative for large scale optimization problems [165, 222, 224] particularly
ones where a desired global extrema is hidden among many poorer local extrema. Simulated
annealmg is based on the thermodynamics of the crystallization of metal, where parameter
searching involves the introduction of an artificial parameter called temperature that determines the
probability of accepting a set of random parameter values. At initial high temperatures, the
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probability of accepting a new set of parameter values is higher, which means that the algorithm is
allowed to widely explore the parameter space. Like in the downhill simplex, by conceptualizing the
model's GOF as a surface with peaks (poor fitting parameter sets) and valleys (better fitting
parameter sets), it is apparent that bigger "jumps" avoid the algorithm falling into a local minimal
GOF. Slowly decreasing the temperature allows the algorithm to find the parameter set with the
lowest GOF [224, 227].
Like in the downhill simplex method, in simulated annealing only one parameter set emerges at the
end of the process. However, simulated annealing is more efficient than the downhill simplex and it
can also be used in problems of combinatorial optimization. In the case of disease models this would
allow us to consider sets of possible model structures in the calibration process [220]. In a recent
study, Chung Vi et al. found that simulated annealing outperformed genetic algorithm in the
calibration of a micro-simulation model, the Lung Cancer Policy Model [224, 240].
Mixed approaches have been suggested, where methods like random search or grid search can be
used to predict the region of the parameter space in which the global extrema is placed. Once this
region is located, more efficient guided techniques can be used to find the precise location of the
global extrema [222]. In general, if time allows, analysts should consider the application of more
than one method or combinations of methods in a comparative way [220, 222].
Convergence (or Acceptance) criteria
Convergence criteria, acceptance criteria, and the acceptance threshold are terms that describe the
process of defining acceptable sets of input parameter values. In the example of the random search
method described above, if the analyst is only looking for the parameter set that best minimize the
GOF estimate (or maximize, depending on the GOF measure used), this is our acceptance criterion
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[186]. However, there are potentially more than one parameter set that can give you the same GOF
estimate.
Moreover, to inform analysis of uncertainty, it is necessary to identify a set of input parameter
values that produce an acceptable fit according to the analyst's objectives [222]. Analysts often
define a GOF threshold based on "plausible" visual fit [202, 217]. This means that the predicted
output parameters of many parameter sets are plotted and the analyst arbitrarily defines the worst
fitting set that is acceptable. The GOFof this parameter set is used as the threshold value and all the
parameter sets that produce a better GOFin comparison with the threshold are deemed acceptable.
Another approach is to define target ranges based on the data informing the calibration target(s)
and select those parameter sets that produce model output within those ranges [204, 241]. An
alternative approach is to define a confidence interval around the GOFof the best fit parameter set
and to deem acceptable (or statistically indistinguishable) all the parameter sets with GOFestimates
within that interval [191, 199].
Stopping rule
The stopping rule or termination criteria determine whether the calibration process (or the search
for parameters) is complete. There are two broad criterion that can be used: acceptability of the
convergence of the model outputs to the observed calibration targets and/or completion of a
specified number of searches (or iterations within the parameter space) [17,30,43].
A simple calibration objective (or convergence criteria) may require that one parameter set is
identified in which the model outputs are within the 95% confidence intervals of the observed
calibration target values, or that a specified number of parameter sets achieve that level of accuracy.
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Integrating the results of the calibration and the economic parameters
The last step of the process is to integrate the results of the model calibration within the full
economic model. There are many ways of doing it, and the choices made in the previous steps of the
calibration processwill determine the most sensible way. The simplest approach is to use the point
estimates derived from the best fitting set of calibrated input parameters. However, where
probabilistic sensitivity analysis (PSA)is used a more elaborate approach is required. Treating the
calibrated parameters as independent parameters, fitted values that passedthe acceptance criteria
may be used to derive an independent probability distribution for each parameter. However, the
ability to represent parameter correlation is an important attribute of the calibration process and so
a PSAshould reference all parameter sets deemed acceptable in the calibration process. Two broad
alternatives are to report the range of cost-effectiveness results associatedwith multiple parameter
sets within the acceptance region, implicitly assigning an equal probability of relevance to all
included parameter sets, [204] or to sample acceptable parameter sets one at a time, with the
probability of a parameter set being sampled defined asa function of its overall GOF[242-246].
Bayesian methods
Bayesian methods provide a theoretical underpinning for dealing with parameter uncertainty.
Bayesianupdating involves defining a prior distribution for the model parameter set. Once defined,
the prior can be updated via Bayes' theorem to reflect the additional information given in the
likelihood function for the data, to give the posterior (Le. updated) distribution reflecting the
remaining uncertainty around the true values of the parameter. An approach known as Markov
Chain Monte Carlo (MCMC) can be used to generate a sample from the joint posterior density
function of the model parameters. The resulting samples will capture the degree of correlation
between parameter values implied by the data and the model structure, so that uncertainty around
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cost-effectiveness is accurately stated. Software packages such as WinBUGS can be used to fit
models to data and generate MCMCsamples.
Whilst MCMCmethods overcome some of the computational difficulties involved in Bayesianmodel
calibration, many challenges remain. One issue is on how the prior distribution should be specified.
A common approach is to set 'vague' priors, so that their influence on the posterior distribution is
negligible. Ideally this should be confirmed with sensitivity analysis using several alternative vague
priors, to assesswhether this choice has any meaningful impact on the results. Whilst some see the
subjective nature of prior distributions as undermining the approach, it can also be seen asone of its
strengths. Priors can be chosen to reflect sources of information beyond the dataset, thereby more
appropriately reflecting the available evidence base. Elicitation of expert opinion is a common
source ofthis additional information [247].
A further challenge is that, despite the benefits of MCMC, computation of the posterior distribution
may still be computationally expensive. This can be a particular issue where the likelihood is a
complex function of the model parameters, as may often be the casewhen calibration is required.
De Angelis et al. provide an example where Bayesianmethods are used to estimate the prevalence
of HCV [248]. The disease is asymptomatic for most of its long incubation time, and direct data on
prevalence is not available. The authors develop a WinBUGSmodel to estimate this parameter from
indirect information such as the results of screening programmes in at-risk populations. As well as
only informing the desired parameter indirectly, the available data sources are potentially biased.
The authors demonstrate how Bayesian evidence synthesis can be used to explore the impact of
alternative models of this bias, and present several measures of GOFthat can be used in Bayesian
calibration models. Other examples of this recent approach include Welton et al. and Goubar et al.
[249,250].
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Discussion
Calibration of computer models is being used actively in many research fields. Diseasemodels used
in economic evaluation require information of various types and sources with different levels of
certainty. Calibration poses not only as a useful tool of estimating parameters but also a way of
dealing with model uncertainty by testing and adjusting the consistency of the model when
compared to empirical data. In this paper, we divided the calibration process in seven steps and
examined the different methods used in each step, focusing on the particular features of disease
models in economic evaluation. The seven steps are: (1) Which parameters should be varied in the
calibration process?, (2) Which calibration targets should be used?, (3) What measure of goodness-
of-fit should be used?, (4) What parameter search strategy should be used?, (5) What determines
acceptable goodness-of-fit parameter sets (convergence)?, (6) What determines that the calibration
process should stop?, (7) How should the model calibration results and economic parameters be
integrated?
To identify guidance on the use of calibration in health economic decision models, we searched in
the main health economics textbooks [63, 65, 71, 209, 251] using the words model calibration,
fitting, optimization and validation. Only in one of the textbooks [209] model calibration was
addressed: "There may be several parameters within the model...which can be dialled up and dialled
down to try to achieve calibration. While statistical methods can, in principle, be used to achieve
optimal calibration, ...in practice the process of calibration is more art than science". This sole and
rather sceptical statement is a good illustration of how the lack of standards can undermine the
credibility of a methodology.
Guidelines in economic evaluation and decision analysis in health from the UK,Canada,Australia and
the International Society of Pharmacoeconomics and Outcomes Research(ISPOR)were searched in
the same way as the textbooks [76, 206-208]. The British and Canadianguidelines recommend only
that the model should be validated. The Canadianguidelines particularly recommend that the results
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of the model (e.g. health outcomes) should be calibrated and compared against reliable
independent data sets (e.g. national cancer statistics). Any difference should be explained, or used
to inform adjustments in the model. The British guidelines make a strong case about the need to
explore uncertainty in the model; it also suggests that a probabilistic sensitivity analysis is the
preferred method to deal with parameter uncertainty. A brief recommendation could be found in
the report of the ISPORtask force on good research practice in modelling studies: "Models should be
calibrated ...when there exist data on both model outputs and model inputs, over the time frame
being modelled ...The calibration data should be from sources independent of the data used to
estimate input parameters in the model". Nothing was found in the Australian guideline.
Conclusion
As presented in this review, a considerable number of studies that apply calibration methods in
economic evaluation can already be found in the literature. However, if we are to change the
current sceptical.view of calibration process and incentivize good practice in its usage, we ought to
unify the way we approach the problems, report the methods used and continue to investigate
different methods. Further studies should address the impact of different ways of calibrating
economic models on the final economic results. This should be done for the different levels of the
calibration process. Additional investigation of the performance of different calibration methods in
the particular case of disease modelling is also important. All this further evidence will permit us to
better define what constitutes good-practice when calibrating models for economic evaluation, and to
improve guideline's recommendations.
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5 Economic modelling assessment of screening strategies for women
presenting equivocal cytological results in Brazil
5.2 Preamble to research paper 2
In the literature review chapter, it was observed that most cervical cancer screening cost-
effectiveness analyses focused on primary screening. However, as pointed out by a few authors,
screening strategies focusing on groups with higher risk of having pre-cancer and cancer lesions
were likely to be more cost-effective than those applied to the overall population. It was also clear
that despite the greater burden of cervical cancer in developing countries, most cost-effectiveness
analysis of cervical cancer screening were performed for developed countries [19, 99, 252]. In order
to help inform cervical cancer screening policies in developing countries focusing on high risk groups,
this paper analyzesthe optimal cervical cancer screening strategies for women presenting equivocal
cytological results using Brazil asa casestudy.
This study compared the lifetime cost-effectiveness of alternative triage strategies involving repeat
cytology, HPV DNA HClI test and colposcopy according to different age strata. This is the first
economic evaluation focusing on strategies for managing women presenting atypical squamous cells
of undetermined significance smear results in a developing country. An important strength of the
model is that it usesdata from a cohort study conducted in Brazil, the Ludwig-McGill cohort study. It
was calibrated to 'region-specific targets using the structured approach proposed in chapter 4, which
adds to the internal validity of the analysis. The economic parameters were derived in Brazil,
however, they are likely to be similar to other developing countries, particularly middle-income
countries, which add to the external validity of the study.
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Abstract
In Brazil, current management of women with screening results of atypical squamous cells of
undetermined significance (ASC-US) is to offer repeat testing at 6-month intervals. Alternative
management strategies that have been adopted in many high-income settings are to offer
immediate colposcopy referral or to utilise HPV DNA testing as a triage for colposcopy referral, and
to consider different strategies according to women's age. The objective of this study was to
evaluate the lifetime cost-effectiveness in terms of cost per years of life saved (YLS) of these
alternative strategies for a middle income setting.
A Markov model was developed using data from the Ludwig-McGill cohort study and calibrated to
independent observational datasets and local cost estimates obtained. In the base-case analysis,
repeat cytology was the least costly strategy, but also the least effective. HPV triage for all women
was the strategy with the best cost effectiveness profile (ICER 10,303.54 US$/YLS and the highest
probability of being cost-effective) according to WHO standards for cost-effectiveness. Whilst there
was a slight further gain in effectiveness with immediate colposcopy referral, it was also significantly
more expensive and did not appear to be cost-effective.
Threshold analysis indicated that an HPV test would have to be more than twice as expensive as a
cytology test for HPV triage to no longer be cost-effective. In conclusion, our results indicate that in
middle income settings HPV triage is likely to be the optimal strategy for managing women
presenting with ASC-US results.
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Introduction
Although screening has reduced the incidence of cervical cancer worldwide, it is still a leading cause
of death among women in middle- and low-resource settings [28, 29]. In most countries in the Latin
American and the Caribbean region despite investments in cytology based screening the impact in
reducing cervical cancer rates has been lessthan expected [7]. In Brazil, cervical cancer is the second
leading causeof cancer among women and the fourth leading causeof cancer-related deaths in this
group [7, 30].
Whilst the recently developed human papillomavirus (HPV)vaccine represents an important tool to
reduce cervical cancer incidence, it is only recommended for young women [253] and it has not yet
been incorporated in most low- and middle-income countries vaccination schedules. An alternative
option is to improve the efficiency of cervical cancer screening, for example by changing the
management of women with equivocal cytology results. Previous studies in the USand the UK have
shown that the HPVDNA test for high-risk genotypes is cost-effective for this purpose [99, 252]. In
low- and middle-income countries, no cost-effectiveness analysis has been published targeting
management strategies for women presenting with equivocal results.
The current practice in Brazil is that women with atypical squamous cells of undetermined
significance (ASC-US)results are recalled for repeat smears every six months and only return to
routine screening intervals after two consecutive negative test results. Those that favour the use of
repeat cytology argue that most women have either no lesion or a lesion that is likely to regress in
the absence of treatment. Since HPV is present in all cases of cancer and pre-cancer lesions, an
alternative is to test ASC-USresults with HPVDNA testing (for high-risk genotypes) which is more
sensitive than cytology, and to perform colposcopy only in women with positive test results [19, 99,
252]. A further option is to offer immediate colposcopy to manage these women, since more than
one third of all biopsy-confirmed high grade cervical neoplasia are identified in women with ASC-US
cytology results [254]. Despite having a high sensitivity in identifying cervical neoplasia, colposcopy is
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more costly and potentially raises more anxiety in women when compared to repeat cytology and
HPV testing. Determining the most advantageous management for ASC-US requires a formal setting-
specific analysis of costs and health outcomes of alternative strategies.
The objective of this study was to identify the optimal strategy for the management of women
having ASC-US at routine cytological screening in Brazil as a case study. We developed a
mathematical model to compare the lifetime effects, costs, and cost-effectiveness of strategies
involving the cervical cytology, HPV DNA with the Hybrid Capture 2 assay (Qiagen, Hilden, Germany),
and colposcopy.
Materials and Methods
Mathematical model
We used a Markov model which simulates the natural history of cervical carcinogenesis using a
sequence of transitions among health states (Figure 5.1). The model was developed in TreeAge Pro
2009 (Willianstown, Massachusetts, USA). For our analyses, a hypothetical cohort of women age 18
were entered into the model and followed until age 80. The model reflects current scientific
understanding of pre-invasive and invasive disease [99, 199]. Health states in the model, descriptive
of the patient's underlying true health, were defined to include HPV infection status, grade of
cervical intraepithelial neoplasia (ClN), and stage of invasive cancer. HPV infection was stratified by
HPV type categorized as 1) high risk types (HR HPV), including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, and 68; and 2) low risk types (LR HPV), including 6, 11, 26, 32, 34, 40, 42, 44, 53, 54, 55, 57,
62, 64, 67, 69, 70, 71, 72, 81, 83, 84, 89 and others [31]. The classification between high and low risk
was used because of its strong empirical value in stratifying risk predictions [199, 255].
The incidence rates of HPV as well as clearance rates were obtained from the Ludwig-McGill cohort
study, a longitudinal study of the natural history of the HPV infection and cervical neoplasia in the
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city of Sao Paulo, Brazil [255-257]. Prevalence rates and transition probabilities between health
states were obtained from the literature. Where available, estimates were based on published
studies conducted in Brazil or Latin America [257-259]. Appendix A table A.l shows the values of
these and other variables used in the model pre-calibration. All probabilities of transition were
calculated for a 6-month time frame, which is the cycle length of the model. This cycle length was
chosen becausemost of events in the management of this diseaseoccur either in 6-month intervals
or on an annual basis [7].
Invasivecancer was stratified according to the cancer staging system of the International Federation
of Gynaecology and Obstetrics (FIGO)[62]. The probability of survival was based on stage and time
post-diagnosis [260]. Alongside the probability of dying from cervical cancer, the probability of
women dying from other causeswas also explicitly modelled asa competing risk, using life tables for
the female population of Brazil [261].
Assumptions were necessaryfor the model:
• All casesof pre-cancer lesions begin with an HPVinfection [99, 252, 262].
• Consistent with the latest scientific evidence, it was assumed that invasive cancer could not
occur in the absenceof infection with a HRHPVtype [199].
• Becausemost of the epidemiological studies classify women as having HRor LRHPVtypes
and because the natural history implications of multiple infections are uncertain and occur
in less than 10 percent of our study population, we elected to model women as having
either HRor LRHPVtypes [199].
• Following the structure of previous models [99, 199, 204, 252], we assumed that an
individual can only acquire either a HR or LR HPV type, only once this current HPV type
infection has resolved can they change risk groups, ascan be seen in Figure 5.1.
• Conventional cytology could only result in: negative, ASC-US,LSIL (low grade squamous
intraepithelial lesion), HSIL (high grade squamous intraepithelial lesion). Although other
84
cytology results are possible and there is great variability in ASC-US results, the cytology
results were simplified as above, in the same manner as previous modelling studies, because
there is lack of data available as most test accuracy studies present their results in a similar
way [7,45,198,252].
• Women who survive after five years are assumed to have the same life expectancy as
women in the general population [260, 263].
Figure 5.1: Natural History Model
t t t t
*Both the possibility of dying from other causes and of staying in the same state applies to all states,
but were not shown in this figure.
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Model calibration
Calibration of the model was conducted using a random search algorithm programmed in Microsoft
Excel Visual Basic for Applications [217, 222]. First, we estimated initial plausible ranges for each
natural history parameter based on primary data from Brazil and published literature (appendix
table 1) [199, 256-258, 264]. These ranges were used to assign uniform distributions to these
parameters. About 10,000 sets of input parameters values were randomly sampled and the residuals
between the model predictions for each input parameter set and published age-specific HR-HPV
prevalence and age-specific CIN 1 prevalence were used to calculate the chi-squared goodness-of-fit
(GOF) [191, 257, 258, 265]. We selected the best input parameter set based on the estimates of the
GOF. Pre- and post-calibration age-specific HR-HPV prevalence rates predicted by the model as well
as calibration targets with 95% confidence intervals (Cl) can be observed in Figure 5.2. Additional
figures showing the calibration results can be found in the appendix figure 5.1 and 5.2.
Figure 5.2: Age-specific HR HPV prevalence rate (calibration process)
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Screening protocol and modelling
In Brazil routine cervical cytology is performed once a year on women aged 25 to 60, and after two
consecutive negative results, every three years [7]. In our model, women had the possibility to move
among health states that represented both their underlying disease state and their previous
screening history within that screening round. Using this approach, the model tracked women's
previous screening story (within that screening round) and, depending on the strategy used, either
direct them to colposcopy, HPVtesting, or repeat cytology. This approach also allowed us to deal
with the lack of data on regression and progression rates of the lesionsof women presenting ASC-US
results, since these rates were dependent on the underlying disease states (figure S.l). The
screening result would only change in the underlying diseasestate, if it led to a successful treatment
intervention. We assumed that HPVDNA testing was undertaken using hybrid capture 2 assay for
human papillomavirus DNA (Qiagen, Hilden, Germany) The hybrid capture 2 method (HClI) was
chosen for being the most widely used method in HPV screening worldwide. Since according to
Brazilian guidelines [7] women could not return to routine screening until they have had two
consecutive negative smears this meant that the model had to be large to accommodate all the
potential health states. Consequently, our model included 51 underlying states.
Strategies evaluated
Given an ASC-USresult in routine screening, five management strategies were evaluated:
Strategy A: Repeat cytology every 6 months. Return to routine screening (every three years) only
after two consecutive negative cytology results. In caseof a second abnormal smear, patients were
referred to colposcopy.
Strategy B: Referral to colposcopy.
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Strategy C: Referral for HPVtesting. In case of a positive result they were referred to colposcopy,
otherwise they had to repeat cytology (as in strategy A).
Strategy 0: If women were 30 years old or more they were referred to colposcopy (as in strategy B),
otherwise they had to repeat cytology (as in strategy A).
Strategy E: If women were 30 years old or more they were referred to HPVtesting (as in strategy C),
otherwise they had to repeat cytology (as in strategy A).
In all strategies, women with HSIL cytology results were referred directly for colposcopy, and
negative cytology results followed the routine screening schedule. Women having LSILresults were
referred to repeat cytology in 6 months, as in strategy A. The 30-years cut-off was chosen because
studies have shown that above this age the incidence of CIN 2-3 and cervical cancer increase
dramatically, and because, even though HPV infection is common in younger women, it is likely to
regress naturally [266, 267]. The values of the parameters related to the screening strategies in
evaluation are presented in Table 5.1. The test characteristics of cervical cytology were derived from
previous accuracy studies [45, 198].
According to the Brazilian Guideline for Cervical Cancer Screening, if no lesion was found at
colposcopy the patient would be referred to repeat cytology in 6 months time (as in strategy A) [7].
If a lesion was found at colposcopy and the cytology result was HSILthe "see and treat" approach
was adopted, otherwise a biopsy was performed. The sensitivity and specificity of colposcopy used
in the model were based on a meta-analysis conducted by Mitchell et al. [268]. Those patients
presenting a biopsy compatible with CIN lor negative diagnosis were referred to repeat cytology in
6 months or routine screening, respectively. All the patients presenting a biopsy showing cervical
cancer would be subjected to clinical staging work-up [62].
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Costs and health outcomes
The perspective of the analysis was the health system. Table 5.1 includes the cost parameters used
in the model. All costs were adjusted to year 2008. The monetary unit was the US dollar (US$)
according the annual average exchange rate of US$l = R$1.86 [269]. The costs were mainly obtained
from the CBHPM - Asssociacao Medica Brasileira [9,48].
Table 5.1: Main parameters used in the base-case and sensitivity analysis
Parameter Mean Minimum Maximum Reference
Screening coverage* 63% 50% 75% [9]
Sensitivity of HPV test* 94% 92% 96% [50]
Specificity of HPV test* 67% 58% 76% [50]
Sensitivity of Colposcopy* 96% 95% 97% [268]
Specificity of Colposcopy* 48% 47% 49% [268]
Discount Rate* 5% 0% 10% [270]
Cost of pap smear* 13.67 10.94 16.41 [9]
Cost of colposcopy* 25.42 20.34 30.51 [9]
Cost of HPV testingt 13.67 [9]
Cost of biopsy 65.70 [9]
Cost of staging invasive cancer 246.64 [9]
Cost invasive cancer stage 1 6,171.42 [9]
Cost invasive cancer stage 2 17,225.92 [9]
Cost invasive cancer stage 3 17,517.7 [9]
Cost invasive cancer stage 4 13,929.41 [9]
Cost of invasive cancer follow-up
61.63 [9]exams
All costs are aggregate costs in US dollars, index year 2008. The costs variation was assumed to be
±20% of the mean value [9]. Invasive cancer was stratified according to the cancer staging system of
the International Federation of Gynaecology and Obstetrics [62]. *Parameters varied in the one-way
sensitivity analysis. tParameter varied in the threshold analysis.
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The cost of a medical visit, a nurse visit, and a hospitalization day were provided by Hospital de
Clfnicasde Porto Alegre - Universidade Federal do Rio Grande do Sui, one of the main university
public hospitals in Brazil. Since the HPV HCII test is not currently performed in Brazilian public
hospitals, we had to assume a plausible cost for the test in the public system in the base-case
analysisand to explore its variation in the sensitivity analysis. For the base-caseanalysis,we consider
the cost of HPVHCIItest to be the same as the cost of pap smear, since similar or lower prices have
been achieved in other settings [99]. Our model was able to predict the proportion of patients in
each health state for all the cycles. This information was used to calculate the expected costs and
expected years of life of hypothetical cohorts subjected to different screening strategies. The main
health outcome modelled was years of life saved (YlS) that was obtained by subtracting the
expected years of life of a screening strategy in respect to the next least costly strategy. Quality-
adjusted life years (QALYs)were not used in this study, becauseno studies measuring the quality of
life in patients with pre-cancer or cancer lesions of the cervix in the Brazilian population were found.
Expected costs and years of life were discounted at an annual rate of 5%, in concordance with
Brazilianguidelines [270].
Base-caseanalysis
Using the best set of natural history input parameters obtained through calibration, we estimated
the expected costs and effectiveness of each strategy in the base-caseand sensitivity analysis. We
calculated the incremental cost-effectiveness ratios (ICER)by the dividing the difference in cost
between strategies by the difference in effectiveness [63]. Options that were dominated (Le. they
are more costly but less effective than another alternative or a combination of alternatives) were
excluded. Since in the Brazilian Guidelines for Health Technology Assessment there is no
recommended threshold to determine whether an intervention is cost-effective (Le. represents
good value for money), one heuristic has evolved from the Commission on Macroeconomics and
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Health [271] and was used to extrapolate a threshold for Brazil. This Commission suggested that a
cost-effective interventions would avert one additional disability-adjusted life year (DALY) for less
than three times the average per capita gross domestic product (GDP) and a very cost-effective
intervention would avert one additional DALY for less than the average per capita GDP for a given
country or region. We extrapolated these thresholds and assumed that what society's willingness to
pay (WTP) for one DALY is equivalent to its WTP for one YLS. This has been the approach used in
previous economic evaluations performed in Brazil and other developing countries [166, 191, 272].
According to the International Monetary Fund 2008 estimates [212], this infers a threshold of 25,876
US$/YLS for a cost-effective intervention and a threshold of 8,625 US$/YLS for a very cost-effective
intervention.
Sensitivity Analysis
To access parameter uncertainty, one-way, scenario, threshold and probabilistic sensitivity analysis
were conducted. In the one-way sensitivity analysis key parameters were varied using minimum and
maximum estimates, as shown in Table 5.1. In order to evaluate the best and the worst scenario in
terms of sensitivity and specificity of each screening test, the sensitivity and specificity were varied
together, minimum value of both and maximum value of both. Given that the HPV vaccine may be
introduced in the Brazillan health system in the medium or long run, an attempt was made to
explore how the vaccine may affect the results of this analysis, considering a decrease in the
incidence of HR HPV of 70% [199]. As the final cost for the HPV HClI test for Brazil is not established,
we undertook a threshold analysis to explore the maximum price at which HPV triage would still be
deemed cost-effective. To explore the joint uncertainty across parameters a probabilistic sensitivity
analysis was also conducted. Gamma distributions were assigned to all cost parameters, since they
are restricted from 0 to positive infinity. Beta distributions were assigned to diagnostic accuracy
estimates and coverage, since they are restricted from 0 to 1. By sampling from the above
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distribution, 10,000 estimates for the costs and effects of each strategy were generated. Cost-
effectiveness acceptability curves (CEAC)were used to depict the level of uncertainty for the optimal
strategy at different willingness to pay thresholds for an additional YLS[65].
Results
Base-case analysis
Table 5.2 presents the base-case incremental cost-effectiveness results. When we look at the
expected years of life estimates of the five strategies, like in previous studies we notice that the
differences between strategies are marginal [99, 252]. However, there is a substantial difference in
terms of expected lifetime costs. In order to identify which strategy represents better value for
money, we have to consider the costs and effectiveness of the strategies in relative terms by
considering the ICERin respect to the threshold. As illustrated in Figure 5.3 and Table 5.2, the
cheapest and least effective strategy was repeat cytology (strategy A). Adopting HPV triage for
women over 30 (strategy E)was slightly more expensive, but also more effective in terms of years of
life saved. At an incremental cost-effective ratio of $1,915, this is very cost-effective option for
Brazil. Moving to a strategy of also including HPVtriage for women under 30 (strategy C)would also
be cost-effective at an additional $10,304 per year of life saved.Whilst immediate colposcopy for all
Women gave a slight additional gain in life years, the additional cost led to an incremental cost-
effective ratio higher than is considered to be cost-effective for this setting.
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Table 5.2: Base-case incremental cost-effectiveness results
Strategy Expected Incremental Expected Incremental ICER
Costs (US$) Cost (US$) Effect. (YL) Effect.(YLS)
(US$/YLS)
Strategy A- 140.9404 18.83023
Repeat cytology
Strategy E- HPV 141.9783 1.037864 18.83077 0.000542 1,914.87
test ~ 30
Strategy D- 142.9630 18.83081 Dom.
Colposcopy ~ 30
Strategy C - HPV 144.1832 2.204957 18.83098 0.000214 10,303.54
test to all
Strategy B- 145.9959 1.812672 18.83104 0.00006 30,211.19
Colposcopy to all
US$ = US dollars, YL = years of life, YLS = years of life saved, leER = incremental cost-effectiveness
ratio, Dam. = dominated,Strategy A - Repeated cytology, Strategy B - Immediate colposcopy to all,
Strategy C- HPV test to all, Strategy D - Immediate colposcopy to those age 30 or more, Strategy E-
HPV DNA test to those age 30 or more.
Sensitivity analysis
In the one-way analysis, the ranking of the strategies remained unchanged for almost all input
parameters. The results were most sensitive to changes in the cost of colposcopy, and the diagnostic
accuracy of HPV testing. Only when considering the lowest cost for colposcopy or the worst
combination of sensitivity and specificity of HPV testing does immediate colposcopy become the
most cost-effective option. Whilst the discount rate seemed to play an important role in determining
the magnitude of the incremental cost-effectiveness ratio of the different strategies [209], it did not
change the conclusions. When considering the possible effect of the HPV vaccine by decreasing the
incidence of HR HPV by 70%, HPV triage for all women remained the optimal strategy. In the
threshold analysis, if the cost of HPV HClI test was more than twice the cost of cytology (over 26
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US$), all strategies involving HPV testing become dominated. In this scenario, the optimal strategy
would be immediate colposcopy.
Figure 5.4 reports the results of the probabilistic sensitivity analysis. This shows a high degree of
certainty about the conclusions. Again when we consider a cost-effective threshold of three times
the GDP for Brazil (25,876 US$/YLS), HPV triage for all women is the strategy with the highest
probability of being cost-effective, 49% of the simulations. If we consider the threshold
recommended by the Commission for Macro- Economics in Health for very cost-effective
interventions (8,625 US$/YLS), HPV triage for women above 30 years-old was the strategy with the
highest probability of being cost-effective, 53% of the simulations.
Figure 5.3: Cost-effectiveness plane (base-case)
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Figure 5.4: Cost-effectiveness acceptability curve
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Discussion
Our results suggest that although HPV testing to triage women with ASC-US results is a more costly
strategy than repeated cytology (current protocol), it also saves more years of life. The gain in life
years is likely to occur due to earlier referral of at risk women and also the losses to follow-up that
Occur with repeat screening protocols. The additional cost of HPV testing strategies is mainly due to
the fact that more women that need colposcopy are detected and referred. Colposcopy is costly
because it is performed by a trained physician. If we consider a very cost-effective threshold given by
Brazil's GDP per capita, HPV triage for women over the age of 30 is the strategy with best cost-
effectiveness profile (ICER below the threshold and highest probability of being cost-effective in the
probabilistic sensitivity analysis). However, if we consider a cost-effective threshold given by three
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times Brazil's GDP per capita, HPV triage for all women is the strategy with the best cost-
effectiveness profile. In the one-way sensitivity analysis,we showed that the results were insensitive
to changes in the input parameters. Evenwhen considering a reduction of HRHPVincidence due to
the vaccine, HPVtesting for all women remained the optimal strategy. In the threshold analysis, we
found that the cost of HPVtest would have to be nearly twice the cost of cytology for the strategies
involving HPVtest no longer to be cost-effective.
To the best of our knowledge, this is the first cost-effectiveness analysis of strategies for managing
women presenting ASC-USsmear results in a resource-limited setting. Our model estimates of
incremental YLSwere similar to those reported in previous studies in high-income countries and we
draw the same conclusion about the advantage of HPVtriage compared to routine screening [19, 99,
252]. While our model was estimated and calibrated from data mostly collected in Brazil and the
current Brazilian screening strategy was used as the baseline strategy, it is likely that the results can
be extrapolated to other middle-income countries with similar conditions.
Our model estimates of incremental YLSwere similar to those reported in previous studies in high-
income countries. The HPVHClI test also presented a better cost-effectiveness profile than other
strategies evaluated in those studies. It is worth pointing out that the strategies evaluated in the
other studies were also slightly different than our study. For example, in the study conducted by
Legood et al. [99] liquid-based cytology (LBe)was always used as the method of routine screening.
Our decision not to include LBCin the analysis reflected current practice in Brazil (which favours
conventional cytology), and becauseof a previous economic evaluation conducted in Brazil [48] that
had shown it was not cost-effective.
An important strength of our model is that the incidence rates of HPVas well as clearance rates
were obtained from a cohort study conducted in Brazil, the Ludwig-McGill cohort study [256].
Another distinctive feature of our model is the use of calibration [19, 99, 252]. It allowed us to make
sure that despite parameter uncertainty, our natural history model was capable of simulating
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prevalence and incidence rates of key events that fitted targets derived from studies conducted in
Brazil and Colombia [257-259]. Unlike other studies [19, 252], in our study a probabilistic sensitivity
analysis was conducted and presented, which made it possible to explore in more depth the
uncertainty surrounding the cost and tests accuracy parameters and consequently the decision.
An important limitation of our current study is that it lacks information on the quality of life related
to the different states in the model. Although colposcopy is more accurate than the other tests
evaluated there are potentially negative psychological effect associated with this examination. On
one hand, this could represent a decrease in quality of life and, therefore, affect our results. On the
other hand, the other strategies studied have longer follow-up periods and also involve colposcopy,
which means longer periods of anxiety over the results of the tests and strategies that do not
completely avoid the necessity to perform a colposcopy.
The model was calibrated to cross-sectional data from a screened population assuming that each
member of the cohort experiences the same pattern of screening and treatment through her
lifetime. However, it is likely that older women were subject to different patterns than younger
Women. This may explain that model fit is better for younger women and older women. Although
the probabilistic sensitivity analysis allows us to investigate the global impact of parameter
uncertainty in the model results, it assumes that parameters are independent not allowing us to
explore the correlation of parameters in the model.
This analysis lndlcates a number of areas requiring further research. It would be valuable to obtain
QALYsestimates for screening and cervical cancer management in the Brazilian population that
could be used in future economic evaluations. A clear obstacle not only for this analysis but for
health decision making in the country is the absence of a cost-effectiveness threshold that directly
reflects the preferences of the Brazilian society. Hence, it is important to address this matter in the
near future.
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The incorporation of the highly efficacious HPVvaccine, which has been strongly endorsed by the
Pan American Health Organization [253], is likely to have major implications in the screening
strategies. If the prevalence of HPV,and consequently cervical cancer and its precancerous lesions, is
significantly reduced with the introduction of the vaccine, it will be possible to change the routine
screening protocol and, for example, extend the screening intervals or use different approaches.
Refinements of mathematical and economic models are necessaryto better inform vaccination and
screening decision in the future [165, 273]. A further option not evaluated here is the potential to
use HPV testing as a primary screen, triaged by cytology [274]. The use of transmission dynamic
models would make it possible to better evaluate the optimal screening strategy in a scenario that
includes the HPV vaccine [128]. Also as more data becomes available on the implications of
simultaneous infection of multiple types as well as HPVcross-immunity, future models should be
able to incorporate these possibilities.
In conclusion, in our analysis repeat cytology for all women with ASC-USresults in routine screening
was the least costly strategy but also the one with the least YLS.Immediate colposcopy for all these
women was the strategy with greater YLSbut also the one with the highest costs. HPVtesting for all
women with ASC-USresults was the strategy with the best cost effectiveness profile. These results
proved to be robust through an extensive sensitivity analysis.
Potentiat conflict of interest
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Appendix A
Table A.1: Parameters used in the natural history model (pre-calibration)
Parameters Range Reference
Prevalence
Prevalence of HPV, age 18
Low risk type (LR HPV) 0.1-0.19 [191, 257, 258]
High risk type (HR HPV) 0.15-0.26 [191,257,258]
Prevalence of LSIL(LR) , age 18 0.0097 -0.0582 [191,275]
Prevalence of LSIL(HR) , age 18 0.0103-0.0618 [191,275]
Progression
Well to LRHPV 0.003-0.013* [257,259]
Well to HR HPV 0.003-0.091 * [257,259]
LRHPV to LSIL 0.005-0.036 [276]
HR HPV to LSIL 0.013-0.059 [276]
LRHPV to HSIL 0.0019-0.0039 [199]
HR HPV to HSIL 0.002-0.022 [199]
LSILto HSIL (LR) 0.0005-0.0044 * [199]
LSILto HSIL (HR) 0.0029-0.0222 * [199]
HSIL to Stage 1 (HR) 0.00059-0.0340* [199]
Regression
LRHPVto Well 0.09-0.44 [255]
HR HPV to Well 0.09-0.44 [255]
LSILto LRHPV 0.06-0.026 [199]
LSILto HR HPV 0.06-0.026 [199]
HSIL to LRHPV 0.0089-0.034 [252]
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HSILto HR HPV 0.0089-0.034 [252]
HSIL to LSIL(LR) 0.007-0.027 [252]
HSILto LSIL(HR) 0.007-0.027 [252]
Invasive Cancer progression rates
Progression rate Stage 1 to Stage 2 0.03-0.23 [191]
Progression rate Stage 2 to Stage 3 0.13-0.33 [260]
Progression rate Stage 3 to Stage 4 0.34-0.54 [260]
Cancer stage-specific probability of symptoms
Stage 1 0.04-0.12 [191]
Stage 2 0.08-0.16 [260]
Stage 3 0.27-0.47 [260]
Stage 4 0.58-0.78 [260]
Annual probability of survival after invasive cancer
diagnosis*
Stage 1 0.968-0.976 [260]
Stage 2 0.906-0.960 [260]
Stage 3 0.706-0.914 [260]
Stage 4 0.398-0.859 [260]
*Age-specific rates.
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Figure A.l: Age-specific CIN 1 prevalence rate (calibration result)
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6 Economic modelling assessment of cervical cancer screening among HIV-
infected women in Brazil
6.2 Preamble to research paper 3
In the background chapter, it was pointed out that the HIV-infected women are at increased risk of
HPV infection and that HIV-mediated immunosupression increases their risk of developing cervical
cancer. In spite of the fact that the HIV/AIDS pandemic is most strikingly impacting women in
resource-limited countries, no cost-effectiveness study of cervical cancer screening among HIV-
infected women in a developing country was found in the literature review. The objective of this
research paper was to provide information on the optimal cervical cancer primary and secondary
screening strategies for HIV-infected women in resource-limited settings, using Brazil as a case
study.
This study compared the lifetime cost-effectivenessof various combinations of primary and secondary
screeningtechnologies for different CD4cell count strata among HIV-infectedwomen in Brazil. For this
analysis,the Markov model described in the previous chapter was modified in order to incorporate
HIV-mediated immunosupression. This is the first economic evaluation of its kind in a developing
country. The calibration approach proposed in chapter 4 was particularly useful in this analysis,
because there are many unknowns regarding cervical carcinogenesisamong co-infected women. An
important strength of the model is that it was calibrated to country-specific data from the
IPEC/FIOCRUZWomen's HIV-infected cohort, which adds to the internal validity of the analysis.This
analysis highlights the potential for calibration to be usedwhere parameters are unknown but there
is data to calibrate to. The economic parameters were derived in Brazil; however, they are likely to
be similar to other developing countries, particularly middle-income countries.
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6.3 Research paper 3
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Abstract
Due to the recent widespread availability of Highly Active Antiretroviral Therapy (HAART) in middle-
income countries there has been an increase in life expectancy for women on HAART, but no
corresponding decrease in cervical cancer incidence. This study evaluates the optimal cervical cancer
screening strategy for HIV-infected women in a middle-income country. We developed a
mathematical model which simulates the natural history of the HPV infection, as well as the HIV-
mediated immunosupression among women in Brazil. Our model was calibrated using data from the
IPEC/FIOCRUZ Women's HIV-infected cohort. The model compares the lifetime effects, costs, and
cost-effectiveness of strategies combining cytology, HPV DNA test, and colposcopy at different
screening intervals for different CD4 count strata (27 strategies in total). We found that the strategy
with the best cost-effectiveness profile (cost-effectiveness ratio - U$4,911/year of life saved [YLS]
and probability of being cost-effective - 86%) was HPV testing followed by cytology triage every year
for all HIV infected women, considering a very cost-effective threshold given by Brazil's GDP per
capita (US$8,625/YLS). The results were robust to changes in the input parameters as demonstrated
in one-way, scenario, threshold and probabilistic sensitivity analysis. Our study indicates that annual
HPV testing followed by cytology triage for all HIV-infected women is likely to be very cost-effective
in a middle-income country like Brazil. The results reflect the synergic effect of using a highly
sensitive screening test (HPV DNA test) in sequence with a highly specific test (cytology).
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Introduction
Currently, the HIV/AIDS pandemic is most strikingly impacting the poorest and the youngest in
resource-limited settings, with women being overrepresented in these groups [277]. HIV-infected
women are at increased risk of HPVinfection, and have higher rates of infection with high-risk HPV
types (HR-HPV)[11, 278, 279]. Furthermore, HIV infection has been shown to increase a woman's
risk of developing cervical squamous intraepithelial neoplasia and invasive cervical cancer [12, 42].
With the widespread availability of Highly Active Antiretroviral Therapy (HAART)there has been a
dramatic increase in the life expectancy of people infected with HIV [277, 280]. Unfortunately, the
incidence of cervical cancer among HIV-infected women has not decreased [281, 282]. In many
resource-limited settings, cytology based screening programmes have been less than optimal in
reducing the burden of cervical cancer [283-285]. Alternative strategies involve the combination of
HPVDNA testing (for high-risk types), cytology and colposcopy. HPVDNA testing is more sensitive
than cytology, but less specific [6, 50]. Colposcopy is more sensitive and specific than both tests but
also more expensive [268]. Determining the optimal management for HIV-infected patients requires
a formal analysis of costs and health outcomes of alternative strategies. A previous study in the US
has shown that the HPVDNA test for high-risk types is cost-effective for this purpose [21, 22]. In
middle-income countries, no cost-effectiveness analysis has been published targeting HIV-infected
Women.
The objective of this study was to identify the optimal strategy for screening of HIV-infected women
in a middle-income country using Brazil as a case study. We developed a mathematical model to
compare the lifetime effects, costs, and cost-effectiveness of strategies combining the cytology, HPV
DNA testing, and colposcopy at different screening intervals for different CD4 count strata. The
model was calibrated to cohort data on HIV-infected women in Brazil [286,287].
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Materials and Methods
Mathematical Model
We developed a Markov model which simulates the natural history of the HPV infection [288]. It
was later modified to also reflect the HIV-mediated immunosupression [22]. Women representative
of the HIV-infected population in clinical follow-up start in the model at age 18 and are followed
until age 80. Health states in the model, descriptive of the patient's underlying true health, were
defined to include HPV infection status, grade of cervical intraepithelial neoplasia (ClN), stage of
invasive cancer and CD4status. HPVinfection was stratified by HPVtype categorized as 1) high risk
types (HR-HPV),including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; and 2) low risk types
(LR-HPV),including 6, 11, 26, 32, 34,40,42,44, 53, 54, 55, 57, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84,
89 and others. The classification between high and low risk was used becauseof its strong empirical
value in stratifying risk predictions [31, 288]. Invasive cancer was stratified according to the cancer
staging system of the International Federation of Gynaecology and Obstetrics (FIGO)[62, 288]. Each
of the health states in the model was further stratified according to the patient's CD4cell count, as
performed in previous modelling studies. Three CD4 count strata were used: greater than 500
cells/mm", 200 to 500 cells/mm", and less than 200 cells/mm' [289]. In the beginning of each time
step and depending on the previous health state, women could die from AIDS, cervical cancer or
other causes.Those women who survived could change to different CD4strata. After that the HPV-
related health s-tatechangestook place according to CD4-specifictransition probabilities.
All probabilities of transition were calculated for a 6-month time frame. This cycle length was chosen
because most of events in the management of these two diseasesoccur at 6-month intervals [18,
88]. All casesof pre-cancer lesions were assumed to result from an HPV infection [199, 202, 288].
Consistent with the latest scientific evidence, invasive cancer could not happen in the absence of
infection with a HR-HPVtype [199, 288, 290]. Becausemost of the epidemiological studies classify
women as having HR- or LR-HPVtypes and because the natural history implications of multiple
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infections are uncertain, we decided to model women as having either HR-or LR-HPVtypes [175,
199, 288]. Following the structure of previous models, we assumed that an individual can only
acquire either a HR-or LR-HPVtype, only once this current HPVtype infection has cleared can they
change risk groups [199, 288].
We also assumed that cytology could only result in: negative, ASC-US(atypical squamous cells of
undetermined significance), LSIL (low grade squamous intraepithelial lesion), HSIL (high grade
squamous intraepithelial lesion) [288]. Although other cytology results are possible, the cytology
results were simplified asabove, in the sameway as previous modelling studies [45, 198, 288]. In the
model, women who develop cervical cancer are subjected to stage- and time-specific survival rates.
Five years after cervical cancer diagnosis and treatment women are assumed to have the same life
expectancy as women in the general HIV-infected population [288, 291]. It is worth noting that
women with low CD4count have shorter life expectancy not only becausethey face the possibility of
dying of AIDS,but also because they face a higher probability of progressing and dying from cervical
cancer than women with high CD4count.
One of the greatest challenges of the study was to find parameters values that could accurately
represent the reality of HIVand HPVinfection among women in Brazil. This is important because of
the different epidemiological patterns and standards of health care among countries. We initially
searched the literature looking for input parameters from studies conducted preferably in Brazil or
Latin America. Given the scarcity of country- or region-specific input data and the availability good-
quality data from the IPEC/FIOCRUZWomen's HIV-infected cohort, we decided to calibrate the
model to cohort data [286, 287].
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Model Calibration
Age-specific prevalences of CD4 count <200 cells/mm3, HR-HPVand CIN 2-3 were estimated from
the cohort to be used as calibration targets [286, 287]. More details on the model calibration are
provided in the appendix B. The CD4 count <200 cells/mm3 prevalence was chosen as calibration
target because it is expected that this group of patients would have higher prevalence of HPV
infection and related disease. HR-HPVprevalence was chosen because new screening technologies
focus on detecting HR-HPVinfection; therefore it would be important to make sure that our model
correctly predicts age-specific HR-HPVprevalence rates. Finally, the choice of CIN2-3 prevalence
rates was due to the fact that the main goal of cervical cancer screening is to detect and treat pre-
cancertesions like CIN2-3before they progress to cervical cancerper se.
Parameters were varied within initial plausible ranges based on primary data from Brazil and
published literature (appendix B table B.l and B.3) [35, 191, 199, 258, 264, 292]. Given the lack of
data on HPV related parameters for the different CD4strata, we assumed that they would have a
multiplicative relation to the observed parameters in non-HIV infected women and we randomly
generated a series of multipliers (from 1 to 10). A total of 100,000 sets of input parameters values
were randomly sampled. The residuals between the model predictions for each input parameter set
and cohort-base calibration targets were used to calculate the chi-squared goodness-of-fit (GOF).
We selected the best input parameter set based on the lowest GOF and the condition that the
parameter set produced model outputs confined to the 95% confidence intervals (Cl) of the
calibration targets [293]. The post-calibration parameters can be found in the appendix table B.4. It
is worth noting that these parameters are dependent on the model structure as well as the
calibration process. Pre- and post-calibration age-specific CD4 count <200 cells/mm3, HR-HPVand
CIN2-3 prevalences predicted by the model as well as calibration targets with 95% Cl can be
observed in Figure 6.1a,b,c.
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Screening Protocol and Modelling
In our model, women had the possibility to move among health states that represented both their
underlying disease state and their previous screening history within that screening round [40, 288].
Using this method, the model tracked women's previous screening history and, depending on the
option being considered, either directed them for triage with colposcopy, HPVtesting, or cytology
[40,288].
The probability of a test result was determined by the underlying diseasestate that is the sensitivity
and specificity [40, 288]. The screening result would only change the underlying disease state, if it
led to a positive triage test and, subsequently, to successful treatment [40, 288]. According to
Brazilian guidelines [7] women could not return to routine screening until they have had two
consecutive negative cytology results which meant that the model had to be complex enough to
accommodate all the potential health states and screening stories [40, 288].
Screening Strategies Evaluated
The current practice in Brazil is that HIV-infected women are screened for cervical cancer with
cytology every 6 months, and after two consecutive negative results, every year (primary screening),
as recommended by the CDCguidelines [7]. In order to define relevant primary and secondary
screening strategies to be evaluated, we reviewed the literature and consulted clinical experts.
Secondary screening (or triage) is performed in those women who presented an abnormal or
Positive result in primary screening. The health technologies evaluated in the primary and secondary
screening were HPV DNA test, cytology and colposcopy. HPV DNA hybrid capture 2 test (HClI);
Qiagen, Hilden, Germany; was chosen for being the most widely used method in HPV screening
Worldwide [6]. The other two tests are the tests currently used in Brazil's cervical cancer screening
programme. The screening intervals included every 2 years, every year, and every 6 months. Since
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there is evidence to believe that HIV-mediated immunosupression influences the defences against
the HPVinfection and the development of pre-cancer and cancer lesions,we also analyzed screening
strategies oriented only to women with CD4 count <200 cells/mm3. The combinations of primary
and secondary screening strategies evaluated are listed in table 6.2.
In the caseof cytology, women presenting negative results in primary screening followed the routine
screening schedule, and in secondary screening they had to repeat cytology in 6 months [288].
Women with LSILor ASC-USresults in primary screening were referred to either cytology in 6
months, immediate colposcopy or HPVDNAtesting [288]. Those presenting LSILor ASC-USresults in
secondary screening were submitted to immediate colposcopy [288]. In all strategies, women
presenting HSILcytology results were referred directly to colposcopy [288]. In the case of HPV
testing, women with positive results in primary screening were submitted to either cytology or
colposcopy [288]. Those with negative results in primary screening followed the routine schedule,
while in secondary screening they were submitted to cytology [288]. In the case of colposcopy, if a
lesion was found the "see and treat" approach was adopted, otherwise a biopsy was performed.
Those patients presenting a biopsy compatible with CIN 1 or negative diagnosis were referred to
repeat cytology in 6 months and routine screening, respectively [40, 288]. Where a biopsy result
indicated cervical cancer, these women would be referred for clinical staging [62].
Costs and Health Outcomes
The perspective of the study was the health system. Table 6.1 presents the cost parameters used in
the model. All costs were adjusted to the year 2008. The monetary unit usedwas the USdollar (US$)
according the annual average exchange rate of US$l = R$1.86 [269].
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Table 6.1: Main parameters used in the base-case and sensitivity analysis
Parameter Mean Minimum Maximum Reference
Sensitivity of cytology* 58% 30% 87% [45,198]
Specificity of cytology* 95% 86% 100% [45,198]
Sensitivity of HPV test* 94% 92% 96% [50]
Specificity of HPV test* 67% 58% 76% [50]
Sensitivity of Colposcopy* 96% 62% 97% [268,294]
Specificity of Colposcopy* 48% 47% 49% [268]
Discount rate* 5% 0% 10% [270]
Cost of pap smear* 13 10.94 16.41 [9]
Cost of colposcopy* 25 20.34 30.51 [9]
Cost of HPV testingt 13 10.94 26 [9]
Cost of biopsy 65 52 78 [9]
Cost of one LEEP 21 16 25 [9]
Cost of conization 204 163 245 [9]
Cost of staging invasive cancer 246 196 295 [9]
Cost invasive cancer stage 1 6,171 4,936 7,405 [9]
Cost invasive cancer stage 2 17,225 13,780 20,670 [9]
Cost invasive cancer stage 3 17,517 14,013 21,020 [9]
Cost invasive cancer stage 4 13,929 11,143 16,714 [9]
Cost of cancer follow-up exams 61 48 73 [9]
Cost of HIV care >500 CD4§ 371 296 445 [9]
Cost of HIV care 200-500 CD4§ 494 395 592 [9]
Cost of HIV care <200 CD4§ 1,037 829 1,244 [9]
All costs are aggregate costs in US dollars, index year 2008. The costs variation was assumed to be
±20% of the mean value [9]. Invasive cancer was stratified according to the cancer staging system of
the International Federation of Gynaecology and Obstetrics [62]. *Parameters varied in the one-way
sensitivity analysis. tParameter varied in the threshold analysis. §Aggregate cost for 6-months
period.
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Since the HPV HClI test is not currently performed in Brazilian public hospitals, we had to assume a
plausible cost for the test in the public system in the base-case analysis and to explore its variation in
the sensitivity analysis [288]. For the base-case analysis, we consider the cost of HPV HCII test to be
the same as the cost of pap smear, since similar or lower prices have been achieved in other settings
[18, 288]. We used years of life saved (YLS) as the main health outcome modelled. Quality-adjusted
life years (QALYs) were not used in this study, because no studies measuring the quality of life in
patients with pre-cancer or cancer lesions of the cervix in the Brazilian population were available.
Expected costs and years of life were discounted at an annual rate of 5%, as recommended by the
Brazilian guidelines for health technology assessment[295].
Base-case analysis
Using the best set of natural history input parameters obtained through calibration, we calculated
the expected costs and effectiveness of each strategy in the base-case and sensitivity analysis. After
ranking them in order of increasing cost and eliminating all dominated strategies (those that cost
more and generate less benefits than any combination of other strategies), we calculated the
incremental cost-effectiveness ratios (ICER) [65]. Since in the Brazilian guidelines for health
technology assessment there is no recommended threshold to determine whether an intervention is
cost-effective (Le. represents good value for money), a heuristic one has evolved from the
Commission on Macroeconomics and Health [271] and was used to extrapolate a threshold for Brazil
[288]. This Commission suggested that a cost-effective interventions would avert one additional
disability-adjusted life year (DALY) averted for less than three times the average per capita gross
domestic product (GDP) and a very cost-effective intervention would avert one additional DALY for
less than the average per capita GDP for a given country or region [271]. We extrapolated these
thresholds and assumed that society's willingness to pay (WTP) for one DALY averted is equivalent to
its WTP for one YLS [288]. This has been the approach used in other economic evaluations
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performed in Brazil and various developing countries [166, 191, 272]. According to the International
Monetary Fund 2008 estimates, this infers a threshold of 25,876 US$/YLSfor a cost-effective
intervention and a threshold of 8,625 US$/YLSfor a very cost-effective intervention.
Sensitivity Analysis
One-way and scenario sensitivity analyseswere performed. In the one-way sensitivity analysis key
parameters were varied using minimum and maximum values, as shown in Table 6.1. In order to
evaluate the best and the worst scenario in terms of sensitivity and specificity of each screening test,
the sensitivity and specificity were varied together, minimum values for both and the maximum
value for both. We also consider an additional scenario using the sensitivity and specificity estimates
of colposcopy reported by Pretorius et al. (62.4%and 93.7%, respectively) [294]. As the final cost for
the HPV HClI test for Brazil is not established, we conducted a threshold analysis to explore the
maximum cost at which the decision would change. To explore the joint uncertainty across
parameters a probabilistic sensitivity analysis was also conducted. Gamma distributions were
assigned to all cost parameters, since they are limited from 0 to positive infinity. Beta distributions
were assigned to diagnostic accuracy estimates, since they are limited from 0 to 1. By sampling from
the above distribution, we generated 10,000 estimates for the costs and effects of each strategy.
These estimates were plotted on the cost-effectiveness plane. Cost-effectiveness acceptability
curves (CEAC)were used to depict the level of uncertainty for the optimal strategy at different
willingness to pay thresholds for an additional YLS[65]. As we increasewhat society is willing to pay
for an additional health gain, the probability that the next strategy with a higher incremental cost-
effectiveness ratio will fall below the willingness-to-pay threshold increases.
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Results
Base-case analysis
Table 6.2 presents the base-case incremental cost-effectiveness results. When we look at the
discounted expected years of life estimates of the 27 strategies, similarly to previous studies, we
notice that the differences in effectiveness between strategies are small. However, there are greater
differences in terms of expected costs. In figure 6.2 by looking to the right of the current screening
strategy, we can observe that adopting HPVtesting in primary screening every 2 years only for those
women with CD4 count < 200 and cytology every year for all the others followed by cytology triage
was the least costly option and saved more years of life than the current screening strategy. Figure
6.2 also shows that the cost-effectiveness frontier is only composed by strategies that use HPV
testing in primary screening. At an incremental cost-effective ratio of U$4,911 per year of life saved,
to annually screen all HIV infected women using HPVtesting followed by cytology triage is a very
cost-effective option for Brazil.Whilst HPVtesting every 6 months followed by colposcopy triage for
all HIV infected women was the most effective strategy, it was also the most costly strategy. At an
incremental cost-effective ratio of U$160,02s, it was not cost-effective.
Sensitivity analysis
In the one-way sensitivity analysis, the results were most sensitive to changes in the cost of
colposcopy, and the diagnostic accuracyof HPVtesting. However, they did not change the ranking of
strategies in the cost-effectiveness frontier. The same can be said about the scenario analysis using
alternative sensitivity and specificity estimates of colposcopy. The discount rate seemed to play the
most important role in determining the magnitude of the incremental cost-effectiveness ratios.
Nonetheless, it also did not change the order of strategies that compose the cost-effectiveness
frontier.
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In the threshold analysis, if the cost of HPV HCII test was greater than 2.2 times the cost of cytology
(over 30 US$), primary HPV testing every 2 years followed by cytology triage for all HIV infected
women became the very cost-effective strategy. Note that, as showed in figure 6.2, all strategies
involving cytology and excluding HPV produced less years of life than the strategies including HPV
test.
Figure 6.3 reports the results of the probabilistic sensitivity analysis. If we consider the threshold
recommended by the Commission for Macroeconomics in Health for very cost-effective
interventions (8,625 US$/YLS), HPV testing every year with cytology triage for ali HIV infected
women was the strategy with the highest probability of being cost-effective, 86% of the simulations.
When we consider a cost-effective threshold of three times the GDP for Brazil (25,876 US$/YLS), HPV
testing every 6 months with cytology triage for all HIV infected women is the strategy with the
highest probability of being cost-effective, 100% of the simulations. It is noteworthy that there is no
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defined threshold for Brazil, therefore when analyzing the CEAC we should consider threshold
ranges around the very cost-effective and cost-effective thresholds.
Figure 6.3: Cost-effectiveness acceptability curve
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Discussion
Several studies demonstrated that HIV infected women are at increased risk of developing cervical
disease [11, 278, 279]. The cost-effectiveness of screening tests for cervical cancer in the general
population has been widely studied. However, there is a lack of evidence on the optimal screening
strategy for HIV-infected women, particularly in resource-limited settings. Our results suggest that
compared with the current screening protocol of cytology every year [296], further gains in life years
would be achieved through annually screening all HIV-infected women using HPV testing as the
primary screening test. This gain in life years is likely to occur due to the greater sensitivity of the
test and also the losses to follow-up that occur with repeat screening protocols. The additional cost
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of HPV testing strategies is mainly due to the fact that more women that need colposcopy are
detected and referred.
If we consider a very cost-effective threshold given by Brazil's GDPper capita, HPVtesting followed
by cytology triage every year for all HIV infected women is the strategy with best cost-effectiveness
profile (leER below the threshold and highest probability of being cost-effective in the probabilistic
sensitivity analysis). The results reflect the synergic effect of using a highly sensitive screening test
(HPVDNAtest) in sequence with a highly specific test (cytology). In the one-way sensitivity analysis,
we showed that the results were robust to changes in the input parameters. In the threshold
analysis, we found that the cost of HPVtest would have to be more than twice the cost of cytology
for the strategies mentioned above to be dominated and for primary HPV testing followed by
cytology triage every 2 years to become a very cost-effective strategy.
To the best of our knowledge, this is the first cost-effectiveness analysis focusing on cervical cancer
screening for HIV infected women in a middle-income country. Our model estimates of incremental
"
YLSwere similar to those reported in previous studies in high-income country [21, 22] and we draw
similar conclusions about the advantage of HPV testing combined with cytology [22]. While our
model was calibrated using data collected in Brazil and the current Brazilian screening strategy was
used as the baseline strategy, it is likely that the results can be extrapolated to other middle-income
countries with similar conditions.
It is worth pointing out that the strategies evaluated in the other studies were slightly different than
the ones evaluated in our study. Goldie et al.[21] published in 1999 a cost-effectiveness analysis that
did not consider screening strategies involving HPVtesting. In a subsequent report [22] published in
2001, the authors extended the analysis to include HPV testing strategies. However, both studies
consider a narrower range of possible combinations of screening frequency, and of primary and
secondary screening technologies.
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An important strength of our model is that the incidence rates of HPV as well as the progression and
regression rates of cervical cancer lesions were obtained by calibrating the model to data from the
IPEC/FIOCRUZWomen's HIV-infected cohort. This allowed us to make sure that, despite parameter
uncertainty, our natural history model was capable of simulating prevalence and incidence rates of
key events related to both HIV and HPV that accurately fitted targets derived from a study that
represents the female HIV-infected population in a middle-income country. Unlike other studies [21,
22], in our study a probabilistic sensitivity analysis was conducted and presented, which made it
possible to explore in more depth the joint uncertainty surrounding both the costs and accuracy of
the tests, and consequently the decision.
A limitation of our current study is that it lacks information on the quality of life related to the
different states in the model, which would allow us to consider a more comprehensive measure of
effectiveness. Nonetheless, if we consider the minimal changes in quality of life due to cervical pre-
cancer and cancer lesions observed in studies in high-income countries [185], we do not anticipate
that our results would change much by using QALYs instead of YLS.The evaluation did not include
screening strategies like visual inspection with acetic acid. Although they are not relevant in Brazil,
they may be relevant in countries with a lower income. It would be beneficial to include estimates of
cervical cancer incidence and mortality for HIV infected women from a middle-income country as
targets in the calibration process. However, this information could not be found in the literature and
the Brazilian cohort study used to calibrate the model had a limited sample size to detect a
substantial number of cervical cancer cases and cervical cancer-related deaths.
This analysis indicates a number of areas requiring further research. It would be valuable to obtain
QALY estimates for screening and cervical cancer management in Brazil that could be used in future
economic evaluations. Refinements of mathematical and economic models are important to better
inform screening decision in the future. Also as more data becomes available on the implications of
simultaneous infection of multiple types as well as HPV cross-immunity, future models should be
120
able to incorporate these possibilities. It is important to point out that "cost-effective" means "good
value for money". It does not mean "affordable". To assessaffordability it would be necessary to
perform a full budget impact analysis.
In our analysis HPVtesting followed by cytology triage for all HIV-infected women is likely to be cost-
effective in middle-income countries like Brazil. In addition, integration of HPV testing in
combination with existing HIV laboratory infrastructure could yield further savings.This would make
the cost-effectiveness profile of primary HPV testing triaged by cytology even more attractive.
Future studies should explore these possibilities in more detail, particularly in other resource-limited
countries where the lack of compliance with quality control procedures undermines the
effectiveness of cytology. More epidemiological studies and cancer registry data are needed to
improve our understanding on the interaction of the two infections. In conclusion, given the recent
huge advances in HIV survival delivered through the widespread availability of HAART,enhancing
cervical cancer prevention and implementing annual screening with primary HPVtesting triaged by
cytology is likely to be a very cost-effective policy option.
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Appendix B
The Markov model describing the HPV infection and HIV-mediated immunosupression (Appendix
figure B.1), which is an extension of a previously published model [288], was developed in TreeAge
Pro 2009 (Willianstown, Massachusetts, USA). The transition probabilities were estimated by
calibrating the output of the model to data from the IPEC/FIOCRUZWomen's HIV-infected cohort.
The calibration of the model was conducted using a random search algorithm programmed in C++
(Appendix figure B.2) [240, 293]. In the calibration process 99 HIV- and HPV-related input
parameters were varied and the model output was fitted to the age-specificCD4<200, HR-HPVand
CIN2-3prevalence rates. Pre-calibration parameter rangesare given in the table below.
Figure B.1: HPVand HIVnatural history model
HPV
HIV
Both the possibilities of dying from other causesand of staying in the same state apply to all states, but were
not shown in this figure. lR-HPV = low risk type human papillomavirus, HR-HPV = high risk type human
papillomavirus, CIN = cervical intraepitheliallesion, CC= cervical cancer, Stage = FIGOinvasive cancer stage.
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Figure B.2: Randomsearch algorithm in economic evaluation
I Assign distribution to parameters I
I Randomly draw values from these LJ
I Findf(X;) I
I II Calculate the GOF I Set i=i+l
I Record the parameter set values and GOF I
I Is i > total of iterations II
Yes
No
I Analyze the convergence of all recorded sets I
I Is convergence satisfied? I J Discard sets II INo
Yes
I Use set in the EE I
GOF= Goodness-of-fit, i = number of current iteration, f(xi) = output of the model
for iteration I, EE= Economic Evaluation. Seechapter 4 for more detail on this algorithm.
The pre-calibration parameter ranges (uniform distributions) were based on the 95% confidence
intervals of studies obtained through literature review. We used uniform distributions, because we
did not have a prior belief about the appropriate distribution of the transition probabilities. Sincethe
ranges obtained from the literature were mainly from developed countries, we used them as
starting points for the exploration of wider intervals. We searched over a range of multipliers that
were applied to these pre-calibration ranges. The multiplier rangeswere based on plausibility, from
1 to 10 [191]. Our convergence criteria were: the input parameter set had the lowest goodness-of-fit
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(GOF)and the parameter set produced model outputs confined to the 95% confidence intervals (Cl)
of the calibration targets.
The chi-squared GOFwas defined by the formula:
x2 =I (yea) ~:eaIO)) 2
a
Where 8 is the set of input parameters, y(a) represents the observed data estimate (e.g. HR-HPV
prevalence) for agea,f(a I8) represents the model output for age a given input parameter 8, and 0 is
standard deviation. All three calibration targets, which are represented in the equation by y(a), were
estimated from the same study, the IPEC-FIOCRUZWomen's HIV-infected cohort study.
IPEC-FIOCRUZ Women's HIV-infected cohort
To study the natural history of HIV infection in women, a prospective open interval cohort was
established at the Evandro Chagas Clinical Research Institute (lPEC), Oswaldo Cruz Foundation
(FIOCRUZ),Rio de Janeiro, Brazil. From May 1996 through December 2007, a total of 731 HIV-
infected women enrolled into the cohort after signing an informed consent that inquired on their
willingness to participate and attend all medical appointments. Participants were included in the
cohort regardless of their CD4 cell counts or current antiretroviral status. Cohort procedures have
been described [287], and previous analysesare published [286, 297, 298]. Socio-demographic and
clinical characteristics of the women attended in the cohort can be found in these studies.
Beyond HIV care, the women followed in the cohort receive gynecological care at the same
institution which maximizes completeness of clinical, laboratory and antiretroviral use information.
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Also, it facilitates adherence to study procedures thus allowing for inclusion of women from
different demographic and clinical profiles.
At cohort entry, women were subjected to conventional Papanicolaou (Pap) test, HPV-DNAtest and
colposcopy, irrespective of the Pap test results. Women with evidence of sexually transmitted
infections were managed according to the Brazilianguidelines [299]. Paptest was performed with an
Ayre's wooden spatula and an endocervical brush and classified according to the Bethesda 2001
classification system. Digene Hybrid Capture 2 assay (HClI, Qiagen, Gaithersburg/MD/USA) with
probes for high- and low-risk HPVwas the HPV DNA test used. Specimens were obtained with a
cervical brush and stored in frozen conservative media until processing. HPVtypes were classified
into two groups: low risk (6, 11, 42, 43 and 44), and high risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59 and 68). A standardized diagnostic colposcopic evaluation was performed by trained
gynecologists. Colposcopic results were classified according to the International Cervical Pathology
and Colposcopy Federation, 2002 [300]. CD4+ T-cell counts (Becton Dickinson FACScan)were
obtained from the participant's medical record.
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Table B.l: Pre-calibration parameter ofthe HPV natural history model
Parameters Range Reference
Prevalence
Prevalence of HPV, age 18
Low risk type (LR HPV) 0.1-0.19 [35, 191, 258]
High risk type (HR HPV) 0.15-0.26 [35, 191, 258]
Prevalence of CIN 1 (LR), age 18 0.0097 -0.0582 [191,275]
Prevalence of CIN 1 (HR) , age 18 0.0103-0.0618 [191,275]
Progression
Well to LRHPV 0.003-0.013* [35,301]
Well to HR HPV 0.003-0.091 * [35,301]
LRHPV to CIN 1 0.005-0.036 [276]
HR HPV to CIN 1 0.013-0.059 [276]
LRHPV to CIN 2-3 0.0019-0.0039 [199]
HR HPV to CIN 2-3 0.002-0.022 [199]
CIN 1 to CIN 2-3 (LR) 0.0005-0.0044 * [199]
CIN 1 to CIN 2-3 (HR) 0.0029-0.0222 * [199]
CIN 2-3 to Stage 1 (HR) 0.00059-0.0340* [199]
Regression
LRHPVto Well 0.09-0.44* [255]
HR HPVto Well 0.09-0.44* [255]
CIN 1 to LRHPV 0.06-0.026 [199]
CIN 1 to HR HPV 0.06-0.026 [199]
CIN 2-3 to LRHPV 0.0089-0.034 [252]
CIN 2-3 to HR HPV 0.0089-0.034 [252]
126
CIN 2-3 to CIN 1 (LR) 0.007-0.027 [252]
CIN 2-3 to CIN 1 (HR) 0.007-0.027 [252]
Invasive Cancer progression rates
Progression rate Stage 1 to Stage 2 0.03-0.23 [191,260]
Progression rate Stage 2 to Stage 3 0.13-0.33 [260]
Progression rate Stage 3 to Stage 4 0.34-0.54 [260]
Cancer stage-specific probability of symptoms
Stage 1 0.04-0.12 [191,260]
Stage 2 0.08-0.16 [260]
Stage 3 0.27-0.47 [260]
Stage 4 0.58-0.78 [260]
Annual probability of survival after invasive cancer
diagnosist
Stage 1 0.968-0.976* [260]
Stage 2 0.906-0.960* [260]
Stage 3 0.706-0.914* [260]
Stage 4 0.398-0.859* [260]
*Age-specific rates.
tDoes not include the competing probability of death by AIDS, and were not considered in the
calibration due to lack of data.
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Table B.2: Probability of cytological result given histological status*
Histological status
Cytology results Normal CIN 1 CIN 2-3
Negative 0.95 0.3 0.2
ASC-US 0.03295 0.3276 0.212
LSIL 0.01345 0.3136 0.36
HSIL 0.0036 0.0588 0.228
*From Goldhaber-Fiebert [198]
Table B.3: Pre-calibration parameters of the HIV natural history model
Parameters Range Reference
Prevalence
Prevalence of CD4 count strata at age 18
CD4 >500
CD4499-200
CD4< 200
0.287-0.8
0.096-0.325
0.04-0.2
Progression
CD4 >500 to CD4 499-200
CD4 499-200 to CD4 < 200
CD4 <200 to Death AIDS
0.0160- 0.1439
0.0235- 0.2115
0.0567- 0.3402
Regression
CD4 499-200 to CD4 >500
CD4 < 200 to CD4 499-200
0.0500- 0.1500
0.0045- 0.1500
[302,303]
[302,303]
[302,303]
[289,304]
[289,304]
[289,304]
[289,304]
[289,304]
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Table B.4: Post-calibration parameter of the HPV natural history model for CD <200
Parameters Value
Prevalence
Prevalence of HPV, age 18
Low risk type (LR HPV)
High risk type (HR HPV)
Prevalence of CIN 1 (LR) , age 18
Prevalence of CIN 1 (HR) , age 18
0.0158
0.0198
0.0018
0.0062
Progression
Well to LRHPV
Well to HR HPV
LRHPV to CIN 1
HR HPV to-CiN 1
LRHPV to CIN 2-3
HR HPV to CIN 2-3
CIN 1 to CIN 2-3 (LR)
CIN 1 to CIN 2-3 (HR)
CIN 2-3 to Stage 1 (HR)
0.0259-0.1802*
0.0301-0.5647*
0.0438
0.1114
0.0108
0.0165
0.0006-0.0192 *
0.0029-0.09*
0.00061-0.15*
Regression
LRHPVto Well
HR HPVto Well
CIN 1 to LRHPV
CIN 1 to HR HPV
CIN 2-3 to LRHPV
CIN 2-3 to HR HPV
0.0980-0.2547*
0.0319-0.1814*
0.1527
0.1016
0.0078
0.0047
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CIN 2-3 to CIN 1 (LR) 0.0085
CIN 2-3 to CIN 1 (HR) 0.0117
Invasive Cancer progression rates
Progression rate Stage 1 to Stage 2 0.3861
Progression rate Stage 2 to Stage 3 0.6566
Progression rate Stage 3 to Stage 4 0.9936
Cancer stage-specific probability of symptoms:j:
Stage 1 0.0731
Stage 2 0.1220
Stage 3 0.3427
Stage 4 0.5966
*Age-specific rates.
:j:Assumed to be independent of CD4 strata.
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Table B.5: Post-calibration parameter of the HPV natural history model for (D 200-499
Parameters Value
Prevalence
Prevalence of HPV, age 18
Low risk type (LR HPV)
High risk type (HR HPV)
Prevalence of (IN 1 (LR) , age 18
Prevalence of (IN 1 (HR) , age 18
0.0329
0.0631
0.0052
0.0049
Progression
Well to LRHPV
Well to HR HPV
LRHPV to (IN 1
HR HPV to (IN 1
LRHPV to (IN 2-3
HR HPV to (IN 2-3
(IN 1 to (IN 2-3 (LR)
(IN 1 to (IN 2-3 (HR)
(IN 2-3 to Stage 1 (HR)
0.003-0.013*
0.003-0.091 *
0.0396
0.1031
0.0024
0.0150
0.0005-0.0044 *
0.0029-0.0222 *
0.00059-0.0340*
Regression
LRHPVto Well
HR HPVto Well
(IN 1 to LRHPV
(IN 1 to HR HPV
(IN 2-3 to LRHPV
(IN 2-3 to HR HPV
0.0907 -0.2232 *
0.0218-1879*
0.2037
0.1540
0.0133
0.0050
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CIN 2-3 to CIN 1 (LR) 0.0154
CIN 2-3 to CIN 1 (HR) 0.0151
Invasive Cancer progression rates
Progression rate Stage 1 to Stage 2 0.0784
Progression rate Stage 2 to Stage 3 0.6465
Progression rate Stage 3 to Stage 4 0.8086
Cancer stage-specific probability of svmptomst
Stage 1 0.0731
Stage 2 0.1220
Stage 3 0.3427
Stage 4 0.5966
*Age-specific rates.
:j:Assumed to be independent of CD4 strata.
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Table B.6: Post-calibration parameter of the HPV natural history model for (D ~500
Parameters Value
Prevalence
Prevalence of HPV, age 18
Low risk type (LR HPV)
High risk type (HR HPV)
Prevalence of (IN 1 (LR) , age 18
Prevalence of (IN 1 (HR) , age 18
Progression
0.0884
0.1733
0.0180
0.0359
Well to LRHPV
Well to HR HPV
LRHPV to (IN 1
HR HPV to (IN 1
LRHPV to (IN 2-3
HR HPV to (IN 2-3
(IN 1 to (IN 2-3 (LR)
(IN 1to (IN 2-3 (HR)
(IN 2-3 to Stage 1 (HR)
0.003-0.013*
0.003-0.091 *
0.0107
0.0352
0.0004
0.0058
0.0005-0.0044 *
0.0029-0.0222 *
0.00059-0.0340*
Regression
LRHPVto Well
HR HPVto Well
(IN 1 to LRHPV
(IN 1 to HR HPV
(IN 2-3 to LRHPV
(IN 2-3 to HR HPV
0.1466-0.2721 *
0.0639-0.2833 *
0.2281
0.2213
0.0275
0.0152
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CIN 2-3 to CIN 1 (LR) 0.0262
CIN 2-3 to CIN 1 (HR) 0.0151
Invasive Cancer progression rates
Progression rate Stage 1 to Stage 2 0.0672
Progression rate Stage 2 to Stage 3 0.1899
Progression rate Stage 3 to Stage 4 0.4221
Cancer stage-specific probability of symptoms:!:
Stage 1 0.0731
Stage 2 0.1220
Stage 3 0.3427
Stage 4 0.5966
*Age-specific rates.
:!:Assumed to be independent of CD4 strata.
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Table B.7: Post-calibration parameters ofthe HIV natural history model
Parameters Value
Prevalence
Prevalence of CD4 count strata atage 18
CD4 >500
CD4499-200
CD4 < 200
0.7472
0.2004
0.0524
Progression
CD4 >500 to CD4 499-200
CD4 499-200 to CD4 < 200
CD4 <200 to Death AIDS
0.1031
0.0572
0.3053
Regression
CD4 499-200 to CD4 >500
CD4 < 200 to CD4 499-200
0.0305
0.1054
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7 Economic modelling assessment of the HPV quadrivalent vaccine in Brazil
7.1 Preamble to research paper 4
In the background chapter, it became clear that the HPVvaccination programmes have the potential
to reduce the incidence of HPV-related diseasessuch as cervical cancer and genital warts worldwide.
While reviewing the cost-effectiveness analysis of HPVvaccination, it became evident that, even
though the cost-effectiveness of the bivalent vaccine has been analyzed for many countries including
in Brazil, the quadrivalent vaccine has not yet been analyzed for asmany countries and not for Brazil.
It was also identified that most studies performed in developing countries tend to make use of
Simpler modelling methods that do not account for the herd immunity effect. This research paper
aim is to inform the vaccination policy in Brazil by assessing the cost-effectiveness of the
quadrivalent HPVvaccine for the pre-adolescent female population of the country.
This study is basedon a fully integrated individual-based dynamic model that includes the HPVtypes
16 and 18, which are responsible for most cervical cancer cases, and types 6 and 11, which are
responsible for most genital warts, allowing a thorough evaluation of the quadrivalent vaccine in
addition to the current cervical cancer control strategies in Brazil. The gender, age and sexual
behaviour of each individual in the model determine the probability of acquiring different HPVtypes,
in other words the force of infection. The model was calibrated to five age-specific and non-age-
specific targets using the calibration approach proposed in chapter 4. The economic parameters are
country-specific but the results could be extrapolated to other middle-income countries.
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Abstract
We examined the cost-effectiveness of the quadrivalent HPV vaccine for the pre-adolescent female
population of Brazil. Using demographic, epidemiological and cancer data, we developed a dynamic
individual-based model representing the natural history of HPV/cervical cancer as well as the impact
of screening and vaccination programmes. Assuming the current screening strategies, we calculated
the incremental cost-effectiveness ratio (ICER) for cohorts with and without vaccination taking into
account different combinations of vaccination coverage (50%, 70%, 90%) and cost per vaccinated
Woman (US$ 25, US$ 55, US$ 125, US$ 556). The results varied from cost-saving (coverage 50% or
70% and cost per vaccinated woman US$ 25) to 5,950 US$/QALY (coverage 90% and cost per
vaccinated 556 US$). In a scenario in which a booster shot was needed after 10 years in order to
secure lifelong protection, the ICERresulted in 13,576 US$/QALY. Considering the very cost-effective
and cost-effective thresholds based on Brazil's GDP per capita, apart from the booster scenario
which would be deemed cost-effective, all the other scenarios would be deemed very cost-effective.
Both the cost per dose of vaccine and discount rate (5%) had an important impact on the results.
Vaccination in addition to the current screening programme is likely to save years of life and,
depending on the cost of vaccination, may even save resources. Price negotiations between
governments and manufacturers will be paramount in determining that the vaccine not only
represents good value for money, but is also affordable in middle-income countries like Brazil.
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Introduction
Cervical cancer is the second most common causeof cancer among women in developing countries
[1]. This neoplasm has an especially profound societal impact because it primarily affects women in
their 30s to their 50s, a time when they are likely to be raising and supporting families. In the Latin
American region, despite the investments in cytology based screening, the impact in reducing
cervical cancer incidence rate has been less than expected [5]. In 2012, a total of 17,540 new cases
of cervical cancer are expected in Brazil [5].
Human papillomavirus (HPV) types 16 and 18 are associated with 70% of cervical cancers [305],
while types 6 and 11 are associated with 90% of anogenital warts [306]. There are two vaccines
currently available that prevent infections by types 16 and 18 [23], and one of them also prevents
infections by types 6 and 11 [25]. Clinical trials have shown that these vaccines present excellent
immunogenicity and reactogenicity profiles [23, 25]. Although having great potential to help reduce
cervical cancer incidence in a country like Brazil, neither vaccine has been introduced in the publicly
funded national immunization programme.
Determining the most advantageous HPV vaccination and cervical cancer screening strategy for
Brazil requires a long term analysis of costs and health outcomes of vaccination and screening
strategies. Mathematical models offer the opportunity to synthesize the best available data and
project the impact of the vaccine in order to evaluate its cost-effectiveness over a period of time
beyond those used in clinical trials. Dynamic individual-based models allow for more realistic
representation of the disease as well as a broader analysis of the benefits of the vaccine. The
bivalent vaccine has been previously evaluated for Brazil using a dynamic individual-based model
[27], however, the quadrivalent vaccine has not yet been evaluated.
To assess the cost-effectiveness of the quadrivalent HPV vaccine for the pre-adolescent female
population of Brazil, we developed a dynamic individual-based model that simulates the natural
history of the HPV infection. This analysis is an addition to the previous studies [27, 191], as it is a
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fully integrated individual-based dynamic model that not only includes the HPVtypes 16 and 18, but
also types 6 and 11, allowing a thorough evaluation of the quadrivalent vaccine.
Materials and Methods
HPV/Cervical cancer model
We first developed an open dynamic individual-based model representing the HPVtransmission and
cervical cancer natural history in the heterosexual population of Brazil.The main reason for using of
a dynamic model was to capture the herd immunity effect of the vaccine, as it may have an
important impact on the cost-effectiveness results [128]. The herd immunity effect is the benefit
incurred by unvaccinated individuals of being subjected to a reduced risk of infection due to the
higher prevalence of (vaccine-induced) immune individuals in the population. The individual-based
model was chosen because, when compared to compartmental models, it is more appropriate to
model non-mutually exclusive events and keep track of previous health states as well as screening
results.
The model was built in c++ and ran in parallel in a 32-node computer cluster using OpenMPI. The
basic structure of the model comprises of an outer loop that defined the time steps, and an inner
loop that defined the patients being processed in that time step. The model kept track of the
patient's status in the current and previous time step. It was necessary to keep track of the total
number of infectious individuals in the previous time step in order to define the force of infection in
the current time step. The occurrence of events in the model was given by probabilities and random
numbers. The random number generator, in this casethe linear congruential generator, generates a
floating point number between 0 and 1.
The discrete-time model developed has a cycle length of 1 month. As in previous models [27, 165],
We selected a short cycle length to better portrait the changing nature of HPV infection. Two
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important steps occur within each cycle. In the first step, behaviour and biological events occur. In
the second step, vaccination, screening and treatment events occur. In the first step, the model
considers which health state the individual was in the previous time cycle and according to transition
probabilities for that specific health state, determines which health state the individual will move in
the current cycle. In the second step, the sensitivity or specificity of a screening test coupled with
RNGproduces the result of the screening for that patient. Those individuals that present abnormal
results will be referred to appropriate treatment. The analysis of the impact of vaccination and
screening only happens once the model hasachieved endemic equilibrium.
There is considerable uncertainty regarding the level of natural immunity conferred by different
HPV-types, as well as the duration of immunity [255, 307-310]. As a reflection of this limited
scientific understanding, the model structures adopted in previous modelling studies have varied
from susceptible-infected-susceptible [194, 199, 311] to susceptible-infected-recovered [165, 172,
187, 312]. Following from previous analysis [194, 197, 311, 313], we used a susceptible-infected-
susceptible model. The gender and initial age of individuals were defined in the first cycle of the
model according to census data. In each posterior cycle, the individual's sexual behaviour was
defined according to survey data. The gender, age and sexual behaviour of each individual
determine the probability of acquiring different HPV types, in other words the force of infection.
More details on how the force of infection was calculated can be found in the appendix.
Socia-demographic characteristics
The model represents a stable population of 200,000 individuals, which according to Brazil's
demographic data are 49.5% men and 50.5%women. Individuals were subjected to age- and gender-
specific mortality rates derived from the Brazilian Institute of Geography and Statistics (IBGE)[261].
Individuals younger than 10 years old were not included in the model becausethey have a negligible
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prevalence of sexually acquired HPVinfection. Refer to the appendix for more information on socio-
demographic parameters and their values.
Sexual behaviour
Sexual behaviour was modelled using a structure similar to that previously developed for HIV
transmission [314, 315] and later applied to HPV transmission [27, 165, 316]. Briefly, the model
population was stratified into four levels of sexual activity (highest activity, moderately high activity,
moderate activity, lowest activity) according to the rate of sexual partners change and fourteen age
groups (10-14, 14-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74,
75-82). The stratification was based on gender- and age-specific proportion of the population for
each level of sexual activity, as reported in Table C.4 of the appendix. The average number of new
sexual partners for each sexual activity group was derived from survey studies. The number of sexual
partners in each sexual activity and age group was determined by a sexual mixing matrix. The
parameters of the matrix were governed by two parameters representing the assortiveness of
mixing by age and sexual activity groups. Individuals were assumedto be sexually active from age 15
to age 50, as in previous studies [27, 165, 316].
The force of infection for each age and sexual activity was determined by the distribution of sexual
partners for that age and sexual activity group, the number of HPV infected individuals of the
opposite sex in those groups and the HPV type-specific transmission probability per partnership.
There is no direct information about the probability of HPV transmission per partnership. In
accordance with previous modelling studies [27, 316], each HPVtype per partnership transmission
probability was explored in the calibration exercise.
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Biological process
The HPV infection was stratified by types in three categories: a) HPV 16, b) HPV 18 and c) HPV 6&11.
This classification was used because of its strong empirical value in stratifying risk predictions and
because of the coverage offered by the vaccine. As in previous models, it was assumed that an
individual could only be in one of the three infected categories [27, 165, 199]. A simplified schematic
of the natural history of HPV among men and women are shown in Figure 7.1 and 7.2 respectively.
Health states in the model, descriptive of the patient's underlying true health, were defined to
include HPV infection status, grade of cervical intraepithelial neoplasia (CIN) and presence of genital
warts (GW). All cases of pre-cancer lesions were assumed to result from an HPV infection. HPV- and
cervical cancer-related progression and regression rates were converted to transition probabilities
and are reported in table C.6 of the appendix. The probability of dying from cervical cancer and the
probability of women dying from other causes was also explicitly modelled as a competing risk. Men
were modelled as being carriers of the infection and did not develop GW, as shown in Figure 7.1.
Figure 7.1: Natural history of HPV among men
Birth r 1 Death
~ -..........V Death
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Parameterization and calibration process
The model was initially populated using parameters derived from the published literature.
Preference was given to estimates derived from meta-analyses and from Latin American studies.
Parameters used and their values can be found in the Appendix. Due to great uncertainty, the values
of seven parameters were explored in the calibration exercise. They were: HPV16, HPV18 and HPV
6&11 per partnership transmission probabilities, HPVclearance rate, probability of progression from
HPV6&11 to GW, probability of clearing GW and probability of progression from CIN3 to invasive
cancer. The choice of what input parameters to include in the calibration was based on the level of
parameter uncertainty as well as the importance of the parameter according to the calibration
targets used, as in previous analysis[27, 316].
Calibration of the model was conducted using a random search algorithm [204, 288, 293, 313]. First
we defined initial plausible ranges for each of the seven parameters based on data from the
published literature. These ranges were used to assign uniform distributions to each of these
parameters. A total of 9,000 sets of input parameters values were randomly sampled from these
distributions using the Mersenne Twister random number generator [199]. The residuals between
the model outputs for each parameter set and empirical estimates of HPV 16, 18 and 6&11
prevalence, HPV 16&18 cervical cancer incidence rate and HPV6&11 genital warts incidence rate
were used to calculate the chi-squared goodness-of-fit (GOF). The best input parameter set was
selected based on the lowest estimates of the GOF.Pre- and post-calibration age-specific HPV 16,
18, and 6&11 prevalence rates predicted by the model can be observed in Figure 7.3, 7.4 and 7.5,
where the full dark lines are the calibration targets, the full grey line is the best calibration set and
the dashed grey lines are the other ten best parameter sets. Cervical cancer and genital warts
incidence estimates can be found in table 57 of the appendix. The values of inputs, outputs and
calibrations targets can be seen in table 57 and 58 of the appendix.
144
LI'l
"'".-I
-5
ro
OJ/0
<:
~~
ro
OJ
1 -. -5roOJ0
! !
<: <:
I~ i I~ i
! !
<: <:
-5
ro
OJ I~ i0 I~ i VIc! ! 0"iii bOQ) C
~ "So
<: Q) ttl<: <: u .....c VIttl 0U (!)I
Q) L.L.~
C
0.. 0
Q) 0.. .....
E I~ 0 bOI~ c0 -5 ..c: Q)~ ro .... > "'0OJ ro Q) ~0 OJ 0eo 0 "'0
C ! u! ::!2 u0 ttlE :::l0 "'0
ttl U Q)
> <: M ~Cl. M :;:;:r: o<S ttl~
'+- U)
.....
0
VI
~
> ~
.0 Q)
0
\i!/
"'0 ..c..... Q) 1:::
"!:!! ..... :::l..c U '+-.& VI
ttl C ttl~ ~:::l Q)..... ~
ttl VI Q)0:2 ..c uc
N
.....
ttl.....
r...: <: ..c: ttl UQ) --+ to ..c ttlOJ ..... U~ 0
:::l
Q)
"~
bO '..c: .....i.i: 0 Q)t: :2 Uiii
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Figure 7.4: Prevalenceof HPV-18(women)
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Figure 7.5: Prevalence of HPV-6&11 (women)
0.12
c
Q)
E 0.1
o
2-
::: 0.08
cXS
ID
5: 0.06
I
4-o
~ 0.04
c
Q)
re
~ 0.02
....
0..
o
-, e.
<....", " e,
" ..
.' '~ .
. .. .. .
- •• •• •••••• tI> •• G •••
" .....
..
20-24 25-29 40-44 45-5030-34 35-39
Age (years)
Vaccine and screening characteristics
The parameters related to the interventions can be found in table 7.1. In the model, it is assumed
that vaccination occurs prior to sexual debut (age 10) and would consist of the three recommended
doses. The vaccination would confer type-specific protection. Other parameters subjected to greater
uncertainty such as vaccination coverage, vaccination cost, and duration of protection had their
impact in the cost-effectiveness results explored, as detailed in the results section.
In both vaccinated and unvaccinated cohorts screening was modelled according to the Brazilian
Guideline for Cervical Cancer Screening, in which cytology is performed every 3 years on women
aged 25 to 60 [40]. Invasive cervical cancer cases were treated according to the recommendations of
the International Federation of Gynaecology and Obstetrics (FIGO) [62].
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Economic data
The health system perspective was adopted in the cost-effectiveness analysis as recommended by
the BrazilianGuidelines for Health Technology Assessment [270]. All costs were adjusted to the year
2008 in order to be easily comparable to the estimates of the previous studies [288, 317]. The
monetary unit used was the United States dollar (US$)at the annual exchange rate of US$l = 1.86
Brazilian reais [269]. Since the HPVquadrivalent vaccine is not currently available in the Brazilian
public health system (Sistema Unico de Saude - SUS),we decided to explore different costs in a
similar fashion as performed in previous studies [27, 191]. The highest cost (US$120 per dose) is
based on the price approved by the National Health Surveillance Agency (ANVISA)[318]. The other
estimates (US$27, US$12 and US$5) that potentially reflect the product of price negotiation are
based on the values used in other studies [27, 191]. The costs per vaccinated women consider
freight, supplies, cold chain maintenance, administration, wastage, vaccine support, and
programmatic costs. Quality-adjusted life years (QALYs) were used in order to capture the
qualitative gains related to cervical lesions, and particularly those related to genital warts.
For the sake of comparability of results to the previous analysis as well as the economic evaluations
of the bivalent vaccine, the results were also reported in terms of years of life saved (YLS)[27, 288].
Both costs and health outcomes were discounted at an annual rate of 5%, as recommended by
Brazilian guidelines [270]. Since in the Brazilian guidelines for health technology assessment do not
report the threshold to determine whether an intervention is cost-effective (Le. represents good
value for money), a heuristic one was derived from the Commission on Macroeconomics and Health
[271]. This Commission proposed that a cost-effective interventions would avert one additional
disability-adjusted life year (DALY)for less than three times the average per capita gross domestic
product (GDP)and a very cost-effective intervention would avert one additional DALYfor less than
the average per capita GDPfor a given country. We extrapolated these thresholds and assumed that
society's willingness to pay (WTP)for one DALYaverted is equivalent to its WTPfor one QALY.
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Table 7.1: Interventions and economic parameters
Parameter Mean Reference
Vaccination coverage 50%-70%-90%* [27]
Screening coverage 63% [9]
Sensitivity/ Specificity of cytology 58%/95% [45,175]
Sensitivity/ Specificity of colposcopy 96%/48% [268,294]
Cost of vaccine (per dose) 5-12-27-120* [27]
Cost of vaccination (per woman) t 25-55-125-556* [27]
Cost of pap smear 13.67 [9]
Cost of colposcopy 25.42 [9]
Cost of biopsy 65.70 [9]
Cost of staging invasive cancer 246.64 [9]
Cost invasive cancer stage 1 6,171.42 [9,288]
Cost invasive cancer stage 2 17,225.92 [9,288]
Cost invasive cancer stage 3 17,517.7 [9,288]
Cost invasive cancer stage 4 13,929.41 [9,288]
Cost of invasive cancer follow-up exams 61.63 [9]
Cost of treating genital wartst 65 [193]
Quality of life weight - CINl 0.91 [193]
Quality of life weight - CIN2/3 0.87 [193]
Quality of life weight - Invasive cancer I-II-II-IV 0.65-0.56-0.56-0.48 [165]
Quality of life weight - Invasive cancer survivor 0.84 [193]
Quality of life weight - GW 0.91 [193]
Quality of life weight - No condition 0.93-0.69* [193]
All costs are aggregate costs in USdollars, index year 2008. *Parameters varied in combination.
tAssumed. * Age- and gender-specific QALV weights varied within this range as in Elbasha et al[193].
149
This has been the approach used in other economic evaluations performed in various low and
middle-income countries [103, 166, 191]. According to the International Monetary Fund 2008
estimates, this presumes a threshold of 25,876 US$/QALYfor a cost-effective intervention and a
threshold of 8,625 US$/QALYfor a very cost-effective intervention [212]. The costs and utility
weights used in the analysiscan be found in table 7.1.
Results
The effect of the vaccine the prevalence of HPVtypes in the population can be observed in figure
7.6. Before vaccination starts, the HPVtypes had reached endemic equilibrium in the population, in
other words HPV prevalences are at stable levels only subjected to minor occilation due to
stochasticity. As expected, after vaccination is introduced at a 90% coverage rate we observe a
gradual decline in the prevalence rates. This is followed by a rapid drop due to significant reductions
in HPVprevalence among highly sexually active young females. After some time only HPV 16, the
most virulent, remains endemic at very low levels. These results are similar those found by Van de
Velde et al. [313].
Table 7.2 presents the incremental cost-effectiveness results for different combinations of vaccine
coverage and vaccination costs comparing only screening to screening plus vaccination. As expected
for the same coverage, as the cost of vaccination increases, so does the leER. When we look at the
difference between the US$/QALYand US$/YLSestimates, we can observe that the US$/QALYare
slightly higher. This can be explained by the fact that even though QALYscan capture the genital
warts prevention gain, this effect is offset by age-specific QALYweights, which give less weight to
disease-free years produced by the vaccine, becausethey account for the impact of co-morbidities.
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Figure 7.6: Prevalence of HPV types before and after vaccination
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When we look at the differences between discounted and undiscounted estimates, we notice that
the vaccination becomes slightly more attractive (i.e. lower leER) when estimates are not
discounted. Discounting does not have great effect in the cost of the vaccine, since vaccination costs
incur early in life, however, it does have a great impact in the health gains of the vaccine that occur
later in life when individuals become sexually active. In spite of the great uncertainty to which
vaccination coverage and cost estimates are subjected, all combinations resulted in leERs below the
very cost-effective threshold. In some cases, as for 50% or 70% coverage at US$ 25 per vaccinated
Woman, the vaccine not only saves more QALYs, but it also saves resources as there are less pre-
cancer and cancer lesions to be screened and treated. These findings are similar to previous studies
[3, 27, 187]. As expected, considering a higher screening coverage (100%), vaccination becomes less
attractive, with an leER of 8,159 US$/QALY at a vaccination cost of US$556, coverage of 90% and
discount rate of 5%. This reflects the fact that non-screened women are the ones that benefit the
most from the vaccine.
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Although it is believed that the HPV vaccine provides lifelong immunity as other vaccines (e.g.
Hepatitis B), these beliefs can only be confirmed by follow-up studies currently in progress [319].
Therefore, we evaluated a scenario in which a booster shot was needed after 10 years in order to
secure lifelong protection. In this scenario, vaccination costs, coverage and discount rate were
considered at the highest values, US$556,90% and 5% respectively. These assumptions yielded an
ICERof 13,576 US$/QALY,which is no longer very cost-effective but still cost-effective. It is safe to
infer that using lower input parameters the ICERwill be lower than that.
Discussion
HPVvaccination has been incorporated in publicly funded immunization programmes of many high-
income countries. For example, Australia, Denmark and France provide the quadrivalent vaccine,
while the Netherlands provides the bivalent vaccine for pre-adolescent girls. The UK initially
provided the bivalent vaccine [165]; however, it has recently announced that it will switch to the
quadrivalent vaccine in September 2012 [129, 320]. The cost-effectiveness of the bivalent vaccine
had already been analyzed for Brazil using a dynamic individual-based model [27]. Nonetheless, the
quadrivalent vaccine had never been analyzed for the country using such modelling methods. The
goal of our study was to inform the decision of the Brazilian government whether to introduce the
HPVquadrivalent vaccine for pre-adolescent girls in the public health system using robust modelling
methods.
We found that over a wide range of coverage levels vaccination plus screening always yielded more
health benefits than just screening. However, the costs of the former strategy were not always
higher than the latter. When we considered vaccination coverage of 50% or 70% at a cost per dose
of US$5, the vaccination plus screening strategy was actually less costly than just screening, given
the lower number of pre-cancer and cancer casesto be screened and treated. Taking into account
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the very cost-effective and cost-effective thresholds based on Brazil's GDPper capita, in almost all
scenarios analyzed the vaccination plus screening vaccine strategy would be deemed very cost-
effective. Only in the scenario where a booster is needed after 10 years using vaccination coverage
of 90%and a cost per dose of US$120,the vaccination plus screening strategy was found to be cost-
effective instead of very cost-effective. Our results are consistent with previous analyses [3, 27, 152,
187]. At a cost per vaccinated woman of 1$25and coverage of 50%or 70%,vaccinating girls was also
cost saving [27]. Although these models don't have the exact same structure or input parameters,
their cost-effectiveness estimates were close to ours. For example, at a cost per vaccinated woman
of 1$400,coverage of 75%and discounting at 3%, Kim et al obtained an ICERof 3,940 I$/YLSfor the
bivalent vaccine [27]. When we considered the same three input parameters, we obtained an ICER
of 2,3011$/yLSfor the quadrivalent vaccine.
It is important to point out that the cost-effectiveness threshold basedon the GDPper capita may be
too high for countries in the upper end of the income spectrum. For example, although in the UKthe
threshold is 30,000 £/QALY, the cost-effective threshold based on the GDP per capita would be
around 75,000 £/QALY.Some argue that the real-world threshold for a new intervention should be
the ICERof other intervention competing for the same public investment, for example vaccines
already incorporated in the public health system [321]. In this case, the relevant threshold ratio
could be as low as 500 US$/YLS.Using this lower threshold would imply that for the vaccine to be
considered cost-effective, the cost per vaccinated woman would have to be lower than 125 US$.
Although cost-effectiveness analysis adds information on what constitutes good value for money, it
does not take into account other important considerations such as equity, cultural preferences and
political circumstances. It also does not take into account the impact on the budget of including the
new strategy and which other strategies should be underfunded. In 2007 the Brazilian National
Institute of Cancer assessedthat the vaccination of all women age 11 to 12 at a cost of US$ 120
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would incur in a total of 1.857 billion Brazilian reais, approximately 1 billion US$,which was above
the budget allocated to all immunization programmes in Brazil combined [322].
To our knowledge, there have not been other cost/QALY studies of the HPVquadrivalent vaccine
plus screening using a fully integrated dynamic individual-based model for Brazil.Goldie et al. used a
static individual-based to analyze the cost-effectiveness (cost/YLS) of the bivalent vaccine [191].
Unfortunately the model used did not capture the herd immunity benefit conferred by the vaccine
and the screening strategies considered did not reflect the current practice in Brazil. In another
publication by the samegroup, an attempt was made to incorporate the herd immunity effect of the
vaccine by linking the static individual-based model to a dynamic compartmental model [27].
However, this study only looked at the bivalent vaccine and reported health gains in YLS.They also
used a susceptible-infected-recovered model which is different from our susceptible-infected-
susceptible model. An important aspect of this analysis is that it also considered the vaccination of
boys among the strategies being evaluated, which did not yield attractive cost effectiveness results.
As with all modelling studies there are limitations to our analysis that should be acknowledged.
Regarding model assumptions, similar to previous analysis we did not considered the cross
protection that the vaccine may confer to other HPVtypes not included in the vaccine. However, it
has been pointed out in a recent analysis in the Netherlands that the cost-effectiveness results may
be sensitive to changes in the cross-protection assumptions [201]. The model structure did not take
into account homosexual and bisexual partnerships, since there is a lack of data available to
populate the model. In respect to the framing assumptions, we have not modelled other benefits
and costs of other diseasesassociated with HPVsuch as anal, penile, vaginal, vulvar, head and neck
cancers aswell as recurrent respiratory papillomatoses.
Following from previous analysis [27, 165, 316], the model assumessexual activity only from age 15
to 50. Nonetheless, this could under-estimate the risk of HPV infection for older individuals, what
might under-value the impact of vaccination, particularly booster vaccination. A recent study by
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Insingaet al hasshown that the proportion of infection reappearance for types 6, 11, 16 and 18 after
non-detection varies from 8 to 16% by 36 months [323]. These findings confirmed the results of a
previous smaller study [324]. Accounting for reappearance could have an impact on the model
results, and should be explored in future modelling studies. Nevertheless, we do not anticipate that
it would have a major impact on the cost-effectiveness estimates of the vaccine.
The model assumesthe same clearance rate for the four HPVtypes. However, recent data suggestsa
higher clearance rate for HPV6/11 than for HPV16or 18 [325, 326], which should be considered in
future studies. Country-specific coverage rates were used in the model; therefore, the proportion of
non-screened population modelled is likely to match that found in the Brazilian population.
Nonetheless, it would be beneficial to add more screening-specific data as calibration targets, in
order to increase the level of certainty that the model reflects the screening conditions found in
Brazil. This would be particularly useful in further studies exploring different screening strategies for
the vaccinated and the non-vaccinated cohorts. It would also be important to include other high risk
\
HPV types and other low risk types, and to consider HPV-types individually, while accounting for
cross-protection. This would allow a more appropriate comparison ofthe available vaccines.
Conclusion
We have demonstrated that adding the quadrivalent vaccination of pre-adolescent girls to the
current efforts to control cervical cancer in Brazil can be a highly effective strategy to save years of
life as well as quality-adjusted life years and, in some instances, even to save resources. The
vaccination strategy seemsvery cost-effective for most of the scenarios analyzed considering the per
capita GDP-basedthreshold. However, considering a threshold based on the strategies competing
for investment and the limited vaccination budget, it seems that the inclusion of the vaccine in the
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national immunization programme will be highly dependent on price negotiations between the
government and the manufacturers.
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AppendixC
Force of infection
As in previous studies [27, 316], the force of infection of the three groups of HPV types (16, 18 and
6&11) was calculated in the following way. The cohort is classified into 14 age groups of 5 year each.
In all scenarios the population is considered sexually active from 15 to 50 years old. In the equations
below the age group of the individual in question is represented by i and the age group of the sexual
partner is represented by k. The cohort is also classified according to four levels of sexual activity.
The sexual activity group of the individual in question is represented by j and the sexual activity
group of the sexual partner is represented by I. The time step per cycle is referred by t. The gender is
represented by w if woman and m if man.
~ ~ C") C" k I) Im16tCk,/)Aw16tCi,j) = L.JL.Jcw l,j . PWt i.], , . N k . fJ16
k=1 1=1 mt C ,I)
(eq. 1.1)
.. ~ ~ C") C" k I) Iw16tCk,/) fJAm16tCl,j) = L.JL.Jcm l,j . pm, i.], , . . 16
k=I/=1 NwtCk,/)
(eq. 1.2)
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The basicstructure of the force of infection (A)formula is similar for the three HPVgroups, as can be
seen above in the example of HPV 16 (equations 1.1 and 1.2). The first parameter of formula c
represents the number of new sexual partners per cycle. This parameter was coded as a function
that returns the number of new sexual partners per cycle according to the age and sexual activity
group of the individual in question. The second parameter (p) represents the sexual mixing matrix
which returns the probability that an individual of age i and sex group j forms a partnership with
someone of age k and sex group I. The sexual mixing matrix function was coded according to
equations 2.1 and 2.2. The third component of the formula represents the proportion of infected
sexual partners according to age and sex group, given by the number of infected regardless of the
presence of CIN (1mand Iw) divided by the total number (Nm and Nw) of potential partners for a
certain age- and sex-group. The fourth parameter (~) represents the HPVtransmission probability
per infected-susceptible partnership, which is a function of the HPVtype. The outer summation loop
varies the age groups and the inner summation loop varies the sex group of potential sexual
partners.
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Table C.2: Cumulative proportion of the population by age group
Age Males Females
0-1 0.014758339 0.013710615
2-4 0.075122718 0.069637955
5-9 0.15674556 0.145090661
10-14 0.250158409 0.231803052
15-19 0.341788254 0.318419437
20-24 0.434182056 0.406915261
25-29 0.524764089 0.495703383
30-34 0.607388066 0.578157962
35-39 0.679830878 0.6513167
40-44 0.747497869 0.720026292
45-49 0.808435632 0.7831122
SO-54 0.8601983 0.837611141
SS-59 0.901976158 0.882541069
60-64 0.934532972 0.918166415
65-69 0.958343449 0.945046508
70-74 0.976194073 0.966354052
75-79 0.987868981 0.981484488
80+ 1 1
IBGE (Brazilian Institute of Geography and Statistics) [261]
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Table C.4: Proportion of females and males in each sexual activity group by age [327]
Age (years) Highest activity Moderately high activity Moderate activity Lowest activity
Men
15-19 0.043 0.081 0.369 0.508
20-24 0.042 0.125 0.167 0.667
25-29 0.037 0.111 0.148 0.704
30-34 0.035 0.104 0.139 0.723
35-39 0.034 0.102 0.137 0.727
40-44 0.033 0.098 0.131 0.738
45-49 0.032 0.096 0.128 0.745
Women
15-19 0.014 0.041 0.273 0.672
20-24 0.012 0.094 0.319 0.575
25-29 0.012 0.035 0.201 0.753
30-34 0.010 0.030 0.171 0.790
35-39 0.009 0.027 0.163 0.801
40-44 0.008 0.025 0.152 0.815
45-49 0.008 0.023 0.031 0.938
Table C.s: Mean rate of sexual partner change (new partner per month) by activity group [316]
Age (years) Highest activity Moderately high activity Moderate activity Lowest activity
Men
15-19 1.04167 0.16667 0.09167 0.03167
20-24 1.25000 0.11667 0.03250 0.01167
25-29 1.04167 0.06917 0.02083 0.00667
30-34 0.83333 0.04167 0.01417 0.00500
35-39 0.70833 0.02250 0.00917 0.00333
40-44 0.62500 0.02750 0.00833 0.00333
45-49 0.62500 0.02750 0.00833 0.00250
Women
15-19 1.25000 0.29167 0.11167 0.04000
20-24 1.45833 0.08000 0.03167 0.01167
25-29 1.25000 0.05583 0.01750 0.00667
30-34 0.83333 0.02917 0.01250 0.00500
35-39 0.62500 0.03750 0.01333 0.00333
40-44 0.62500 0.03750 0.00667 0.00333
45-49 0.62500 0.03750 0.00667 0.00250
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Table e.6: Monthly transition probabilities of HPV natural history model
Parameters Value (or range) Reference
Progression
Susceptible to HPV 16 (force of infection) formula above calculated
Susceptible to HPV 18 (force of infection) formula above calculated
Susceptible to HPV 6&11 (force of infection) formula above calculated
HPV 16 infected to CIN 1 0.00819 [264,328]
CIN 1 to CIN 2 (HPV 16) 0.01210 [193,329]
CIN 2 to CIN 3 (HPV 16) 0.01248 [330]
CIN 3 to invasive cancer (HPV 16):1= 0.02218-0.06656 calibrated
HPV 18 infected to CIN 1* 0.00819 [264,328]
CIN 1 to CIN 2 (HPV 18) 0.01210 [193,329]
CIN 2 to CIN 3 (HPV 18) 0.01248 [330]
CIN 3 to invasive cancer (HPV 18):1: 0.02218-0.06656 calibrated
Invasive cancer to death by cancer 0.02171 [193,199]
HPV 6&11 to genital warts 0.01-0.06 calibrated
Regression
HPV 16 to susceptible (clearance rate)* 0-0.06154 calibrated
HPV 18 to susceptible (clearance rate)* 0-0.06154 calibrated
HPV 6&11 to susceptible (clearance rate)* 0-0.06154 calibrated
CIN 1 to HPV 16 0.03270 [257,331]
CIN 2 to ClN 1 (HPV 16) 0.01182 [332,333]
CIN 3 to CIN 2 (HPV 16) 0.00253 [330]
CIN 1 to HPV 18 0.03270 [257,331]
CIN 2 to CIN 1 (HPV 18) 0.01182 [332,333]
CIN 3 to CIN 2 (HPV 18) 0.00253 [330]
Genital warts to HPV 6&11 0.023-0.138 calibrated
=l:Onlypossible if infected with HPV 16 or 18 *Calibrated parameters
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Table C.7: Calibration target and output
Parameter Best set Target Reference
Prevalence 16
Age
20-24 0.0692 0.0458 [27, 258, 265, 334]
25-29 0.0507 0.0255 [27, 258, 265, 334]
30-34 0.0177 0.0270 [27, 258, 265, 334]
35-39 0.0168 0.0158 [27, 258, 265, 334]
40-44 0.0104 0.0173 [27, 258, 265, 334]
45-50 0.0081 0.0113 [27, 258, 265, 334]
Prevalence 18
Age
20-24 0.0240 0.0153 [27, 258, 265, 334]
25-29 0.0175 0.0085 [27, 258, 265, 334]
30-34 0.0060 0.0090 [27, 258, 265, 334]
35-39 0.0050 0.0053 [27, 258, 265, 334]
40-44 0.0030 0.0058 [27,258,265,334]
45-50 0.0029 0.0038 [27, 258, 265, 334]
Prevalence 6&11
Age
20-24 0.0196 0.06 [335]
25-29 0.0148 0.03 [335]
30-34 0.0046 0.02 [335]
35-39 0.0039 0.01 [335]
40-44 0.0029 0.005 [335]
45-50 0.0017 0.01 [335]
Incidence of cervical cancer (HPV 16&18) per 27 20.36 [191,336]
100.000
Incidence of genital warts (HPV6&11) per 100.000 113.5 113.7 [337]
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Table C.8: Calibrated parameter values of the best-fitting set
Parameter Search range Value
0.1-1 0.5549
0.1-1 0.5207
0.1-1 0.5446
0.03-0.06 0.043311
0.04-0.08 0.059798
0.02-0.04 0.032694
0.02-0.04 0.028267
Transmission probability of HPV-16 infection per infected-susceptible
partnership ([316)
Transmission probability of HPV-18 infection per infected-susceptible
partnership ([318)
Transmission probability of HPV-6/11 infection per infected-susceptible
partnership ([36&11)
HPV clearance rate (monthly)
Probability of developing GW (monthly)
Probability of clearing GW (monthly)
Progression from CIN3 to invasive cancer (both 16 & 18) (monthly)
Search ranges were based on previous studies [27,200,316]
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8 Discussion
8.1 Introduction
Although cervical cancer screening has reduced the incidence of cervical cancer worldwide
particularly in high-income countries, it remains a leading causeof death among women in low- and
middle-income countries [2]. Despite recent developments in HPV/cervical cancer screening and
vaccination technologies as well as the sustained socioeconomic development seen in middle-
income countries like Brazil, most of these health technologies have not been studied or
incorporated in the national health system.
The primary aim of this thesis was to evaluate the cost-effectiveness of cervical cancer screening and
HPVvaccination strategies in Brazil.This overall objective was achieved by focusing on three specific
cost-effectiveness analyses:
1. To evaluate the cost-effectiveness of cervical cancer screening strategies for women
presenting equivocal cytological results
2. To evaluate the cost-effectiveness of cervical cancer screening strategies for HIV-infected
women
3. To evaluate the cost-effectiveness of HPVquadrivalent vaccination strategies for women
Whilst studying the calibration methods used in the screening and vaccination studies identified in
my literature review, it became clear the importance of model calibration methods for population-
wide interventions such as screening and vaccination. The lack of standards in calibrating these
models, and how this could undermine the credibility of modelling results were also noticed.
Therefore, an additional objective was added to the thesis:
4. To discussand provide guidance on the useof model calibration in economic evaluation
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The next section summarizes the overall findings from the thesis. Section 8.3 addresses the general
contributions to the literature. Sections 8.4 and 8.5 discuss the limitations and identify areas for
future research. Section 8.6 explores the implications for research and policy making. The last
section provides the conclusion.
8.2 Overall findings of the thesis
The literature review of economic evaluations of HPV/cervical cancer screening studies highlighted the
need for more studies looking at low- and middle-income countries. The review also showed that high
risk groups were rarely analyzed, even though efficient screening and vaccination of these groups is
likely to be very cost-effective. It also unveiled the necessity for a more structured approach to model
calibration in economic evaluation. Research paper 1 discussed the theoretical underpinnings of
different calibration methods, while offering a practical seven-step approach to calibrate models in
economic evaluation. These seven steps are: (1) Which parameter should be varied in the calibration
process? (2) Which calibration target should be used? (3) What measure of goodness-of-fit should be
used? (4) What parameter search strategy should be used? (5) What determines acceptable goodness-
of-fit parameter sets (convergence criteria)? (6) What determines the termination of the calibration
process? (7) How should the model calibration results and economic parameters be integrated? This
approach was successfully used in the three empirical analysis of the thesis, as well as in another study
looking at the impact of different calibration approaches used in a breast cancer model published in
Pharmacoeconomics [210]. This review promotes better practices for calibration in economic evaluation
more generally and is not only confined to cervical cancer screening and vaccination economic
modelling assessments.
Research paper 2, the first empirical analysis of the thesis, looked at potential improvements in the
cervical cancer screening of women presenting equivocal cytological results, which are at higher risk of
having pre-cancer and cancer lesions. It analyzes the cost-effectiveness of five alternative triage
169
strategies for equivocal cytological results in Brazil using a model populated with country-specific data
from the Ludwig-McGill cohort study. Our results suggested that although HPV triage is a more costly
strategy than repeated cytology (current protocol), it also saves slightly more years of life. This small
gain in life years is likely to occur due to earlier referral of at risk women and the decrease in losses to
follow-up that occur with repeat screening protocols. The additional cost of HPV testing is mainly due to
the fact that more women in need of colposcopy are detected and referred. If we consider a very cost-
effective threshold given by Brazil's GDP per capita, HPV triage for women over the age of 30 is the
strategy with the best cost-effectiveness profile (ICER below the threshold and highest probability of
being cost-effective in the probabilistic sensitivity analysis). In the one-way sensitivity analysis, we
showed that the results were insensitive to changes in the input parameters. Even when considering a
potential reduction of HR-HPV incidence due to the introduction of the HPV vaccine, HPV testing for all
women remained the optimal strategy. In the threshold analysis, we found that the cost of HPV test
would have to be nearly twice the cost of cytology for the strategies involving HPV test no longer be
cost-effective.
Several studies demonstrated that HIV infected women are at increased risk of developing cervical
diseases [10, 11]. The cost-effectiveness of cervical cancer screening has been widely studied for the
overall population. However, there is a lack of evidence on the cost-effectiveness of screening strategies
for HIV-infected women, particularly in resource-limited countries. In research paper 3, using a model
calibrated to data from the IPEC/FIOCRUZWomen's HIV-infected cohort we investigated the cost-
effectiveness of cervical cancer screening strategies combining cytology, HPV DNA testing, colposcopy at
different screening intervals for different CD4 count strata (27 in total). Our results suggest that
compared to the current screening protocol based on annual cytology, further gains in life years would
be achieved through annually screening with HPV testing and cytological triage. This gain in years of life
is likely to occur due to the greater sensitivity of the test and the losses of follow-up that occur with
repeat screening protocols. If we consider a very cost-effective threshold, HPV testing followed by
cytology triage every year for all HIV-infected women is the strategy with the best cost-effectiveness
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profile. The results reflect the synergic effect of using a highly sensitive screening test (HPV DNA test) in
sequence with a highly specific test (cytology). In the one-way sensitivity analysis, we showed that the
results were robust to changes in the input parameters. In the threshold analysis, we found that the cost
of HPV test would have to be more than twice the cost of cytology for the strategies mentioned above
to be dominated and for HPV testing followed by cytology triage every 2 years to become very cost-
effective.
Since the bivalent HPV vaccine cost-effectiveness had already been evaluated for Brazil using robust
modelling approaches but not the quadrivalent vaccine, in research paper 4 we presented a cost-
effectiveness analysis of the quadrivalent vaccine using a dynamic individual-based model representing
the natural history of HPV 6, 11, 16 & 18 as well as the impact of screening and vaccination
programmes. We found that over a wide range of coverage rates vaccination plus screening always
yields more health benefits than just screening. However, the cost of the former strategy was often
higher than the latter. When we consider vaccination coverage of 50% or 70% at a cost per dose of US$
5, the vaccination plus screening strategy was actually less costly than just screening, given the lower
number of pre-cancer and cancer cases to be screened and treated. Taking into account the GOP-based
threshold, in almost all scenarios analyzed the vaccination plus screening strategy would be deemed
very cost-effective. Only in the scenario where a booster was needed after 10 years using vaccination
coverage of 90% and a cost per vaccine dose of US$120, the vaccination plus screening strategy would
be cost-effective instead of very cost-effective.
8.3 Main contributions of the thesis
8.3.1 Developing a structured approach to model calibration in economic evaluation
This thesis investigated calibration methods used to handle uncertainty in economic evaluation and
proposed a new practical approach to help unify the way model calibration is implemented in this
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field. To our knowledge this is the first time this has been done in the field of economic evaluation in
health. Other papers focused on diseases modelling and had limited breadth and depth [77,224].
Although this study was recently published, January 2011, it has had a substantial impact, having
already been cited 5 times according to Google Scholar. The paper also suggested potential areas of
future research that have been explored in subsequent publications in the same journal [210].
8.3.2 Estimating the cost-effectiveness of strategies for managing women with equivocal
cytological results in Brazil
According to my review of the literature, this is the first cost-effectiveness analysis focusing solely on
secondary screening strategies for women presenting equivocal results in a resource-limited
country. It is also the first one to evaluate a broad scope of strategies including immediate
colposcopy. Another important advantage of our study over previous analyses is that we used
country-specific data from the Ludwig-McGill cohort to populate the model, which makes it more
likely that our model properly represents the natural history of cervical cancer in this setting. We
found that HPV triage for women over the age of 30 would likely be very cost-effective. Three other
studies from South Africa, Colombia and Thailand focused on primary screening and also modelled
secondary screening but with a limited scope of strategies [91, 92, 114]. Vijayaraghavan et al. found
that primary screening with cytology and secondary screening with HPV testing was not only more
effective but also less costly than cytology-based primary and secondary screening in South Africa
[91]. Andres-Gamboa et al. found that HPV testing can even be a cost-effective primary screening
tool in Colombia if the cost of the test is under US$31 [92]. The Thai study found that the optimal
strategy was VIA and immediate treatment every five years from ages 35 to 55 [114]. However,
these last findings may have limited transferability to other middle-income countries at the higher
end of the income spectrum.
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8.3.3 Estimating the cost-effectiveness of cervical cancer screening strategies for HIV-infected
women in Brazil
The HIV/AIDS pandemic is most strikingly impacting the poorest and the youngest in resource-
limited settings, with women being over represented in these groups [42]. HIV-infected women are
at increased risk of developing cervical disease [10]. Our study is the first cost-effectiveness analysts
focusing on cervical cancer screening strategy for HIV-infected women in a middle-income country.
In fact it is the first time an analysis like this is performed for a country besides the US.Goldie et al.
in 2001 analyzed the cost-effectiveness of cervical cancer screening for HIV-infected women in the
US [22]. An important advantage of our study is that our model was calibrated to country-specific
data derived from the IPEC/FIOCRUZWomen's cohort study. Although the HIV/AIDS and
HPV/cervicaI cancer prevalences are different in Brazil compared to the US,the findings of the two
studies were not very different. Goldie's study found that primary HPVin addition to the two initial
cytological tests was a cost-effective screening strategy. Our study found that HPVtesting followed
by cytology triage annually for all HIV-infected women is likely to be very cost-effective.
8.3.4 Estimating the cost-effectiveness of HPVquadrivalent vaccine in Brazil
HPV \laccination has a great potential to reduce cervical cancer incidence as well as other HPV-
related diseasesin a country like Brazil. However, neither of the two vaccines has been introduced in
the publicly funded national immunization programme. Four previous studies evaluated the cost-
effectiveness of HPV vaccination for Brazil [3, 27, 154, 191]. Nonetheless, all these studies
considered only the bivalent vaccine and only one study used a dynamic model, which was in fact a
hybrid model based on a static IBM previously built to evaluate the bivalent vaccine for many
countries. Our analysis is the first to evaluate the cost-effectiveness of adding the quadrivalent
vaccine to the cervical cancer screening in Brazil. It is also the first to analyze HPVvaccination for
Brazil using a fully integrated dynamic IBM allowing a thorough evaluation of the quadrivalent
vaccine. Another advantage of our analysis compared to the one performed by Kim et al. is that we
173
used QALYas the health outcome measure instead of YLS,which allowed us to better capture the
quality dimension of the vaccine's benefits [27]. Considering very cost-effective and cost-effective
thresholds based on Brazil's GDPper capita, in almost all scenarios of our analysis the vaccination
plus screening strategy would be deemed very cost-effective. Our results are consistent with
previous analyses [3, 27, 154, 191]. For example, at a cost per vaccinated woman of 1$400 and
coverage of 75%, Kimet al. obtained an ICERof 3,940 I$/YLSwhich is comparable to an ICERof 4,858
US$/YLSthat we obtained when using a cost per vaccinated woman of US$556 and coverage of 70%
[27].
8.4 Limitations
While this thesis proposed a structured model calibration approach and presented comprehensive
economic modelling assessments of cervical cancer screening and HPV vaccination strategies, as
with all modelling studies it has limitations. This section acknowledges the general weaknesses of
the thesis addressingeach research paper individually.
8.4.1 Calibrating models in economic evaluation: a seven-step approach
This article outlines the definitions and rationale for calibration in economic evaluation. It also usesa
selective review to discussa practical seven-step approach for implementing calibration in economic
evaluation with a special focus on cervical cancer screening and HPVvaccine studies. This approach
was later used in the three empirical analysis presented in chapters five, six and seven. It was a
valuable opportunity to test whether the theoretical recommendation were realistic according to
the different conditions faced by analysts. For example, theoretically, random number generators
like Latin hypercube and factorial sampling are more comprehensive in covering the parameter
space; however, they also represent great addition in terms of computational demand when dealing
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with large models, as the ones used in the empirical analysis; thus, compromising their overall
efficiency. It also important to acknowledge that had the authors more time and computational
resources to perform the empirical analyses; it would have been beneficial to explore different
parameter search strategies as well as ways to integrate the modelling results and the economic
parameters. Due to the limited experience of the authors with IBM, we may have underestimated
the computational challenges of varying many input parameters in the calibration process as well as
integrating the IBM results with economic parameters in a PSA.
Although deviating from the main empirical objective of this thesis, a more systematic and
comprehensive review could have been done looking at the optimization engineering and
operational research literature, as well as drawing from examples related to others diseases. This
would increase the external validity of the findings. In the paper, uncertainty is divided in three
dimensions: methodological uncertainty, structural uncertainty and parameter uncertainty. We did
not discuss the importance of conceptual uncertainty that refers to sources of uncertainty that arise
at the stage of framing the health problem. This becomes clearer when we think of the potential
benefits of the HPV vaccine, in respect to the many diseases related to HPV such as anal, penile,
vaginal, vulvar, head and neck cancers as well as recurrent respiratory papillomatoses. Marco Mesa-
Frias, Anna Foss and Tazio Vanni discussed the importance of conceptual uncertainty in more detail
in another publication focusing on environmental health impact assessment, recently accepted for
publication in the International Journal of Environmental Health Research.
8.4.2 Economic evaluation of strategies for managing women with equivocal cytological results
in Brazil
This study evaluated the lifetime cost-effectiveness of strategies for managing women with
equivocal cytological results in Brazil in terms of cost per YlS. An important limitation of our study is
that it lacks information on the quality of life related to the different states in the model. Although
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colposcopy is more accurate than the other tests evaluated, there are potentially negative
psychological effects associated with the examination. On the one hand this could represent a
decrease in quality of life, therefore, affecting our results. On the other hand, the other screening
strategies have longer follow-up periods and also involve colposcopy, which means longer periods of
anxiety over the results of the tests and strategies that do not completely avoid the necessity to
perform a colposcopy.
Regarding the screening strategies evaluated, it would be beneficial to consider setting-specific
cytology performance estimates. It would also have been interesting to explore the use of HPV
testing as a primary screening strategy, as it circumvents the notoriously high false negative rate of
cytology. We could have also included LBe as a variant for conventional cytology as well as
considered HPV typing (16, 18 & 45) as a variant of HPV DNA HClI. Another potential addition to the
analysis would be the inclusion of subgroups that could have greater benefit from more efficient
screening strategies such as worst-off income groups and those living in rural areas.
The model was calibrated to cross-sectional data from a screened population assuming that each
member of the cohort experiences the same pattern of screening and treatment through her
lifetime. However, it is likely that older women were subject to different patterns than younger
women. This may explain that the model fit is better for younger women and older women. Also
although the probabilistic sensitivity analysis allows us to investigate the global impact of parameter
uncertainty in the model results, it assumes that parameters are independent not allowing the
exploration of correlation of parameters in the model.
8.4.3 Cervical cancer screening among HIV-infected women: an economic evaluation in a
middle-income country
In this analysis we compared the cost-effectiveness of a wide range of primary and secondary
screening strategies for HIV-infected women in terms of cost per years of life saved. Similar to the
previous analysis it lacks information on the quality of life related to the different states in the
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model, which would allow us to consider a more comprehensive measure of effectiveness.
Nonetheless, if we consider the minimal changes in quality of life due to cervical cancer pre-cancer
and cancer lesions observed in studies in high-income countries, we do not anticipate that our
results would changemuch by usingQALYsinstead of YLS.
As with the other two empirical analysis of the thesis, this evaluation did not include screening
strategies like direct visual inspection, visual inspection with acetic acid, visual inspection with
Lugol's iodine. Although they are not as relevant in Brazil, they may be relevant in lower income
countries. It would also be interesting to further stratified the screening strategies according
women's age as we did for the first empirical analysis, we could also have explored alternative
screening strategies according to different CD4cell count and HIVviral load levels.
Modelling the interaction between the two infections is a challenging task and could be the sole
topic a full PhDthesis. We developed a mathematical model (population-based) to simulate the HPV
infection as well as the HIV-mediated immunosupression among women in Brazil as in previous
analyses. However, in order to better understand the HIV and HPV co-infection, it would be
interesting to use an individual-based dynamic model, as it facilitates not only the incorporation of
variables on CD4 cell count, but also HIV viral load, HAART,and other behavioural factors. Having
more time and data available to explore the calibration of the co-infection model, it would be
beneficial to include more calibration targets such as cervical cancer incidence and mortality for HIV
infected women from a developing country. For the current analysis, this information could not be
found in the literature and the Brazilian cohort study that was used to calibrate the model had a
limited sample sizeto detect a great number of cervical cancer cases.
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8.4.4 Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic
individual-based approach
In the previous four studies looking at the cost-effectiveness of HPV vaccination in Brazil, only one of
the vaccines was evaluated, the bivalent one. In our study for the first time, we evaluated the cost-
effectiveness of the quadrivalent vaccine in Brazil. We have tried to model the quadrivalent vaccine
under the same modelling and economic assumptions as the bivalent studies so that the cost-
effectiveness results could be compared. However, we acknowledge that in order to better compare
the cost-effectiveness of the two vaccines it would be beneficial to use similar models and those
models should take into account the differences in cross-immunity to non-vaccine oncogenic HPV
types conferred by the two vaccines recently identified. Immunity against non-vaccine oncogenic
HPV type was reported as 23.4% for the quadrivalent vaccine and 47.7% for the bivalent vaccine [23,
58]. In the study by Coupe et al., they found that the inclusion of cross-protection had substantial
impact on the incremental cost-effectiveness ratio of the bivalent vaccine, but less impact on the
cost-effectiveness results of screening strategies for a vaccinated cohort [201].
In a similar fashion as performed by Van de Velde et al. [313], it would have been beneficial to
explore the impact of structural uncertainty in the cost-effectiveness prediction of the model. For
example, we could have compared a static vs dynamic models, as well as susceptible-infectious-
susceptible vs susceptible-infectious-recovered structures. Similar to most STI models we assumed
that sexual partnerships are instantaneous and transmission probability is per partnership, but could
have also considered pair formation and duration of partnerships. The model structure did not take
into account homosexual and bisexual partnerships, since there is a lack of data available to
populate the model. In respect to the framing assumptions, we have not modelled other benefits
and costs of other diseases associated with HPV such as anal, penile, vaginal, vulvar, head and neck
cancers as well as recurrent respiratory papillomatoses. The calibration exercise could also have
included more input parameters, therefore, increasing the necessity to use more efficient parameter
search strategies such as simulated annealing or Bayesian methods. Other important addition to the
178
analysis would be the inclusion of other high risk HPV types and other low risk types to further
explore different screening strategies for the vaccinated and the non-vaccinated cohorts. In theory,
given that the incidence of pre-cancer and cancer lesions will decrease due to the vaccine, a test
with greater sensitivity than cytology would be a better screening tool. It is important to point out
that we faced computational constraints, which are not unusual when dealing with a dynamic IBM,
which prevented us from increasing the size of the model and running more elaborate parameter
search algorithms. For the same reason, we did not perform a probabilistic sensitivity analysis as we
did in the previous screening analysis.
8.5 Areas of further research
Some areas that are worthy of further investigation were identified at four levels of uncertainty:
conceptual, methodological, structural and parametric. These levels are discussed in more details in
the following sections. Note that these levels are not independent from each other, and decisions
made at conceptual level, for example, are likely to have an impact at a structural and parametric
level.
8.5.1 Conceptual level
As pointed out in the previous section, there are uncertainties in the framing assumptions regarding
to what extent all costs and benefits of the HPV vaccine should be modelled. For example, we have
mentioned that other diseases associated with HPV could be taken into account such as anal, penile,
vaginal, vulvar, head and neck cancers alongside recurrent respiratory papillomatoses. We could also
consider the benefits and costs incurred by family members of these women, in both the short and
the long run. As we mentioned this neoplasm has a profound societal impact because it affects
Women in their 30s and 50s, a time when they are likely to be raising and supporting families.
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Therefore, if a mother had to quit working due to a HPV-related cancer and also to spend the family
savingsto get treatment, shewould be less likely to have the means to pay for a better education for
her children. Future studies could try to explore these possibilities in more detail.
At the framing stage of the analysis, most researchers tend to use databases such as MEDLINEand
EMBASEin order to better understand the biological processes being modelled. However, these
databases have a more medical focus and may potentially leave out important studies at a more
biological level. In fact even usinga broader search strategy, there are many questions regarding the
long term behaviour of these biological agents for which the literature has no answers yet. For
. example, although most economic evaluations of the vaccine analyzed a long time horizon (80-100
years), we do not know if in the long run the vaccine HPV-typeswill develop some sort of resistance
to the immunological mechanisms triggered by the vaccine or to what extent viral type replacement
will happen. Viral clade replacement is a well known phenomenon for viruses such as dengue and
influenza [338]. In the caseof HPV,it may be that the suppression of the vaccine HPVtypes will leave
a void that may be filled by other oncogenic HPV-typesnot covered by the vaccine. Therefore, there
may be a decrease in the pre-cancer and cancer lesions associatedwith the vaccine HPVtypes, but it
may be compensated by an increase in the lesions caused by types not included in the vaccine.
Although it is difficult to predict how this is going to affect the cost-effectiveness of the vaccine,
future studies could draw from expert elicitation methods to come up with possible scenarios to be
explored.
8.5.2 Methodological level
As discussedbefore, it would have been valuable to obtain QALYestimates for screening and cervical
cancer management in Brazil that could be used in future economic evaluations. Future studies
focusing on this could also compare different methods of valuing health benefits such as time trade-
off, standard gamble, person trade-off and others. These estimates could also be compared to
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others derived in other countries of different income-levels using the same method, in order to
investigate how transferable these estimates are from one country to another.
A clear obstacle not only for this analysis but for health decision making in Brazil is the absence of a
cost-effectiveness threshold that directly reflects the preferences of the Brazilian society. Hence, it is
important to address this matter in the near future. Given the importance of the issue of
affordability alongside value for money, we strongly believe that the Brazilian government should
perform or commission, if not yet done, a budget impact analysis of the HPVvaccine. These two
piecesof information would prove most useful during price negotiation with the manufacturers.
In the calibration review paper, we described in great detail the various possible calibration methods
that can be used in economic evaluation and also encouraged further research to investigate the
engineering and operational research literature for additional calibration methods. We also
supported that empirical research was required to assess the impact of different calibration
methods on economic evaluation results. This should be done for the different levels of the
calibration process. From a theoretical point of view for the three economic modelling assessments
of the thesis, it would have been interesting to compare the impact of different model calibration
methods on the analyses results, as performed by Jonathan Karnon and I using a breast cancer
model [210]. Additional investigation of the performance of different calibration methods for
different disease'smodels is also important to test the generalizability of these findings.
8.5.3 Structural level
As with all modelling studies, many assumptions are necessary to synthesise demographic,
epidemiological and biological data of a complex system. Although these assumptions are based on
the current scientific knowledge available in the literature, this knowledge may be incomplete and
may potentially change over time. The model structures used to represent the HPV/cervicaI cancer
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varied [192, 194, 196, 313]. Future studies should explore different model validation and calibration
strategies to gain understanding of the epidemiological and biological process related to this disease.
This would be particularly important to assess the impact of HIV on the natural history of
HPV/cervical cancer.
Given the high level of uncertainty regarding the HIVand HPVinteraction, it is necessaryto conduct
research to better understand the role of HIV infection in the risk persistence of HPV infection and
development of cervical cancer, and to clarify how this risk is modified by other factors (such as co-
infections with HSV and/or Chlamydia, HAART, and behavioural factors) in order to optimize
management strategies.
8.5.4 Parametric level
At the parametric level, since we have no reliable immune correlate of protection against HPV (Le.
no measurable indicator that a person is immune), it is difficult to determine the duration of HPV
type-specific acquired immunity [200]. From a modelling perspective, the duration of naturally
acquired immunity is an important parameter. This information will be particularly important to
model the epidemiological and economic impact of HPVvaccination in HIV-infected patients. The
first safetvand immunogenicity clinical trial of the HPV vaccination in pre-adolescent men and
women has recently been published and showed excellent results [339]. Efficacy trials will follow
soon. Diseasemodelling and calibration could be used to estimate these parameters [200, 340].
It is also important to point out that not only are there newer screening and vaccination
technologies under development such as a broader spectrum HPV vaccine, but also newer
technologies' to produce older technologies at a cheaper price such as HPV genotyping. These
strategies should be incorporated in future studies. Optimal delivery strategies combining
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prevention interventions for more than one disesaseshould also be explored in the future, this can
be particularly important to increasecompliance in resource-limited settings.
8.6 Implications for researchers and policy makers
Economic evaluation can help inform resource allocation in health. Most of these analyses are
heavily dependent on mathematical models. Model calibration poses not only as an approach to
estimate unobserved parameters for these models, but also as a way to evaluate the consistency of
modelling assumptions in general. This process may add more precision to the cost-effectiveness
results and consequently more credibility from decision makers using these analyses. This thesis
discusses in detail these calibration methods and proposes a practical seven-step approach for the
use of these methods by researchersperforming economic evaluation.
This thesis identified that HPVtriage for women age 30 or more, and repeat cytology for those age
25 to 29 is very cost-effective. This may be a good first step in the introduction of HPVtesting in the
cervical cancer screening programme of LMIC particularly Brazil. A further step may be to primarily
screen HIV-infected women with HPVtesting followed by cytology triage, since our results proved
that this strategy is also likely to be very cost-effective. Finally, of all prevention strategies
considered in this thesis, the HPVquadrivalent vaccine is the one that yielded the greatest health
benefits. The vaccination was deemed very cost-effective through a wide range of vaccination costs
and coverage rates, and even cost saving at a US$5cost per dose and 50% or 70% coverage rate.
This information should be considered when conducting price negotiations with the manufacturers
and when considering the budget impact of the vaccine.
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8.7 Conclusion
The overall aim of the thesis was to evaluate the cost-effectiveness of cervical cancer screening and
HPV vaccination strategies in Brazil. Whilst revising the previously published screening and
vaccination studies, it becamecJear the importance of model calibration methods and the lack of
standards in applying those methods in economic evaluation. Therefore, a review and guidance on
the use of calibration methods in economic evaluation was additionally provided. This review was
the first of its kind in the economic evaluation literature and it provides researchers with a practical
seven-step approach to calibrate models in a more structured way.
In order to achieve the overall aim of the thesis, three empirical cost-effectiveness analyses were
conducted. Two analyses focused on the screening of high risk groups, Le. women presenting
equivocal cytological results and women with HIV, and one focused on the quadrivalent vaccination
of the overall population. The first empirical analysis found that HPV triage for women above 30
years-old was the strategy with the highest probability of being very cost-effective. The second
empirical analysis found that to screen HIV-infected women annual HPVtesting followed by cytology
was likely to be very cost-effective. The last empirical analysis also demonstrated that adding the
quadrivalent vaccination of pre-adolescent girls to the current efforts to control cervical cancer in
Brazil was very cost-effective for most of the scenarios analyzed. The vaccine was even cost saving
for low coverage and cost of vaccination.
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10 Searchstrategies
Literature search strategy for studies on calibration of disease models used in economic evaluation
Database: MEDLINE
1. calibrat$ OR fitS OR validat$
2. diseas$ OR decision
3. exp Disease Models, Animal! or exp Models, Biological/
4.2AND3
5.1 AND4
6. limit 5 to English and humans
7. cost-effectS OR cost-util$ OR econom$.mp
8.6AND7
Database: EMBASE - similar search strategy as MEDLINE was used.
Literature search strategy for economic evaluation studies of the HPV vaccine
I;>atabase: MEDLINE
1. HPV OR human papillomavirus OR human papilloma virus OR cervix OR cervical.mp
2. vaccin$ OR immuni$.mp
3. cost-effectS OR cost-utus OR econom$.mp
4. 1and 2 and 3
Database: EMBAsE - similar search strategy as MEDLINE was used.
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Literature search strategy for economic evaluation studies of cervical screening
Database: MEDLINE
1. smear.mp
2. smear$.mp
3. HPV test.mp
4. HPV test$.mp
5. human papillomavirus test$.mp
6.liquid based cytology.mp
7.lbc.mp
B. HPV typ$.mp
9. human papillomavirus typing.mp
10. HPV typing.mp
11. Thinprep.mp
12. surepath.mp
13. autocyte.mp
14. Vaginal smears/
15. ((pap or papan$) and (smear$ or test$)).mp
16. cyto rich.mp
17. papnet.mp
lB. autopap.mp
19. care HPV test$.mp
20. Uterine Cervical Neoplasms/
21. Uterine Cervical Dysplasia/
22. Cervicallntraepithelial Neoplasia/
23. dyskariosis.mp
24. (cervi$ and screening).mp
25. (cervi$ and cytolog$).mp
26. (automated and cytology).mp
27. HPV genotype.mp
2B. HPV genotyping.mp
205
29. HPV mRNA test.mp
30. HPV viral load test.mp
31. HPV viral load detection.mp
32. HPV viral load count.mp
33. HPV integration.mp
34. p16 enzime linked immunosorbent assay.mp
35. p16 ELlSA.mp
36. P16 ELlSA.mp
37.p16
38. INK4a.mp
39. DARK.mp
40. RARB.mp
41. TWISTl.mp
42. TERC.mp
43. telomerase gene RNA component.mp
44. ~Iuor~sc~nc~ in situ hybridization assavs.mp
45. Fast HPV.mp
46. E6 strip.mp
47. Qiagen HPV test.mp
48. (economics or Economics).mp
49. (econom$ or Econom$).mp
50. costs or "Costs and Cost Analysis" /
51. 48 or 49 or 50
52. lor 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or
40or41or42or430r44or450r46or47
53. 20 or 21 or 22
54.52 and 53
55.54 and 51
Database: EMBASE - similar search strategy as MEDLINE was used.
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